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ABSTRACT 
 
A NOVEL NEEDLELESS LIQUID JET INJECTION DEVICE METHODOLOGY FOR IMPROVING 
CARDIAC GENE THERAPY: AN INVESTIGATION OF DELIVERY PARAMETERS AND THEIR 
ASSOCIATED HOST RESPONSES IN ISCHEMIC HEART FAILURE  
Anthony S. Fargnoli 
Charles R. Bridges 
Heart disease remains the leading cause of mortality and morbidity worldwide, 
with 22 million new patients diagnosed annually.  Essentially, all present therapies have 
significant cost burden to the healthcare system, yet fail to increase survival rates.  The 
heart transplant, which is the gold standard for patients suffering from disease, will never 
meet clinical demand due to the shortage of viable donors.  Therefore, the investigation 
of novel treatments is a significant unmet need in the health system with vast 
opportunity.  Since the decoding of the human genome, the rapid expansion of the 
biotechnology field has ushered in new tools for therapeutic development.  These new 
therapies can be tailored to act at the cellular level to address the root cause of disease 
progression or in other cases replace/repair those affected by disease.    
 One key employed strategy is the genetic reprogramming of cells to increase 
contractility via gene therapy, which has advanced to Phase IIb Clinical Trials for 
advanced heart failure patients.  It has been argued that the most significant barrier 
preventing FDA approval are resolving problems with safe, efficient myocardial delivery, 
whereby direct injection in the infarct and remote tissue areas is not clinically feasible.  
Briefly, widely accepted intracoronary (IC) infusion via catheterization is limited by poor 
transfer across intact endothelial barriers, while direct needle injection is essentially a 
dead end approach due to injury, inefficient transfer, and high incidence of the immune 
response.  Here, we aim to: (1) Improve direct cardiac gene delivery through the 
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development of a novel liquid jet device approach (2) Compare the new method against 
traditional IM injection with two different vector constructions and evaluate outcome (3) 
Evaluate the host response resulting from both modes of direct cardiac injection, then 
advance a drug/gene combination with controlled release nanoparticle formulations.  
 We plan to execute as follows.  Briefly, animals will be assigned to one of the 6 
resultant groups:  2 delivery methods x 2 AAV vector constructs = 4 treatment groups +2 
Saline delivery control groups.  Then each animal will be assessed for quantitative gene 
transfer, cardiac function and various immunohistochemistry assays to assess 
inflammation and adaptive immune responses.  Separately, a forward thinking drug/gene 
therapy concept will be advanced with controlled release polymer formulations. 
 The work presented in this dissertation represents the advancement in the field 
of cardiac gene delivery techniques toward improving outcomes in future pre-clinical and 
clinical studies.  The evaluation of synergistic relationships between route selection, 
vector configuration and their respective impact on the host response will improve 
delivery science. 
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CHAPTER 1 
 
Introduction:  Heart Disease and Emerging Gene Therapy Applications 
 
Adapted From:  Gene and Cell Therapy 4th Edition, Taylor and Francis Publishing Group, Chapter 
8:  Katz MG, Fargnoli AS, Williams RD, Bridges CR “Cell and Gene Therapies for Cardiovascular 
Disease”.  
1.1 Heart Disease Burden and Treatment Options 
 
An estimated 83.6 million American adults suffer from numerous cardiovascular 
diseases (CVD). Mortality data show that CVD accounted for 31.9% of all deaths in 
2010, or 1 in every 3 deaths in the United States. That is 4.4 times more than the deaths 
attributable to cancer. The total direct and indirect cost of CVD in the USA for 2010 is 
estimated to be $315.4 billion. By comparison, the estimated cost of all cancers and 
benign neoplasms was $201.5 billion [1]. These data clearly show that cardiovascular 
diseases are still the leading cause of mortality and morbidity in the US and developed 
countries.  In the United States, coronary artery disease is the underlying cause of CVD 
in 65-75% of cases [2].  Following the initial myocardial insult after a period of time, the 
unfortunate fate for the majority of chronic heart disease patients is full blown heart 
failure despite significant accumulated, yet ineffective clinical interventions.  Heart failure 
(HF) imposes a significant burden on the global healthcare system with annual costs 
alone exceeding $32 billion.  The incidence and death rate is appalling, with 22 million 
additional patients diagnosed per year with 50% mortality within 5 years.   In many of 
these patients, HF develops as a consequence of post infarction remodeling and 
associated progressive dilatation extending to remote areas distant from the original 
infarct [2].   
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Although cardiac transplantation is the gold standard for the treatment of end-
stage heart disease, up to 30% of patients unfortunately die waiting for a matched donor 
heart.  Even more disturbing, as many as 60,000 patients per year could benefit from 
such therapy [3,4].  The most frequently used technology at present for these patients is 
mechanical pump-based assist devices, which have been quite useful both as a bridge 
to transplantation [5,6], and as destination therapy using both left ventricular assist 
devices (LVAD) [7,8] and the total artificial heart [9].  Despite significant improvements 
mitigating some of the limitations of LVAD, most notably thromboembolic events, it 
appears that mechanical cardiac assist technology will face increasing scrutiny given its 
cost to benefit ratio.  Thus, given the shortcomings of the best available therapies, there 
is a significant unmet need for newer, more efficacious and more cost-effective therapies 
for severely afflicted patients. 
There are two major emerging alternative treatment paradigms to improve long 
term outcomes in both early and late stage heart disease, namely replacement (i.e. cell 
therapy) or genetic reprogramming of native cells with gene treatments.  The focus in 
late stage management is improving contractility, whereby the opportunity to arrest 
infarct expansion and global LV remodeling has past. Therefore, the transfer of 
therapeutic genes for the treatment has emerged as the more attractive strategy given 
its impact on directly enhancing contractility within the myocytes.  Extensive pre-clinical 
studies have provided solid proof of concept data indicating gene therapy’s clinical 
potential, whereby the expression of selected transgenes in the myocardium enhances 
contractility, restores global function, and in some cases completely reverses chronic 
HF.  Although promising, as this body of research will explore, a number of problems 
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must be addressed in order to achieve more successful outcomes and avoid the 
deleterious events the field has experienced in the early 2000’s. 
1.2 Cardiac Gene Therapy Applications Strategies 
 
Currently, there are primarily two strategies described for cardiovascular gene 
therapy manipulation (Figure 1.1).  
 
 
The most commonly applied strategy features overexpression of a target gene, 
which may involve either replacement of a missing or dysfunctional gene as in X-linked 
recessive disorders such as the heart failure associated with or Becker’s 
cardiomyopathy, an autosomal recessive gene defect such as those associated with 
alpha sarcoglycan deficiency in the limb girdle muscular dystrophies.  More commonly, 
heart failure may not have a defined genetic basis (ischemic cardiomyopathy) yet certain 
genes are consistently downregulated (e.g., SERCA2a). The second group of strategies 
Figure 1.1 Cardiac Gene Manipulation Strategies 
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relates to inactivation of dominant negative gene function involved in disease etiology or 
progression (other names: gene silencing or gene blockade) [10,11,12].  
1.2.1  Overexpression of target gene 
 
A gene’s physiological function y may be impaired or downregulated as a result 
of a mutation or a pathological process. Therefore, the restoration of function through 
exogenous delivery to replace the deficient gene seems quite logical. In this case, full-
length or partial cDNA encoding the deficient gene is delivered to the target tissues 
using a vector system capable of expressing the therapeutic protein [10]. Several steps 
in the gene overexpression process may be modulated, including the transcription, RNA 
splicing, translation, and posttranslational modification of a protein. 
1.2.2 Specific gene blockade 
 
1.2.2A  Antisense oligodeoxynucleotides (ODN) 
ODN are used as inhibitors of specific gene expression without any change in 
function of other genes. Single stranded ODN may be delivered either by direct 
administration (as a pharmacological agent) or by transfection with a vector encoding the 
ODN. The ODN binds to the target mRNA transcript and prevents translation. This 
mechanism of action is based on the presence of two forms of ODN: the RNase H-
dependent ODN, which induce the degradation of mRNA, and the steric-blocker ODH, 
which physically blocks the progression of mRNA translation. Concerning cardiac 
applications, the antisense ODH approach has been tested to prevent restenosis after 
balloon angioplasty [13]. Treatment with antisense ODN directed against VEGF 
receptors could prevent VEGF-mediated arteriogenesis [14]. Systemic delivery of an 
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antisense ODN induces silencing of miR-208a in the myocytes, thus improving cardiac 
function and survival in hypertensive-induced heart failure (HF) in rats [15]. 
1.2.2B  Decoy-based gene therapy 
Synthetic double-stranded (ds) DNA with high affinity may be introduced into 
target cells as a “decoy” or alternatively described as a cis-regulatory element, which 
binds to a sequence-specific DNA factor and changes gene transcription. Transfection of 
dsODN will result in the attenuation of the cis-trans interaction of cell surface receptors, 
and remove the trans-factor from the endogenous cis-element resulting in inhibition of 
gene expression [12]. dsODN containing binding sequences (decoy) for transcriptional 
factors involved in the activation of pathogenic genes. Transfection of the decoy ODN 
prevents the binding and trans-activation of the genes regulated by the target 
transcriptional factor [10].   
The decoy strategy is very attractive for several reasons: the synthesis of the 
sequence specific decoy is relatively simple and can be targeted to specific tissues, the 
knowledge of the exact molecular structure of the target transcription factor is 
unnecessary; it has been shown to be more effective than antisense technology [12]. 
Some restrictions of this method however are: short half-life, lower uptake efficiency and 
degradation by endocytosis and nucleases. Using mice and monkey models it was found 
that E2F decoy transfection prevented intimal hyperplasia in cardiac allografts [16]. In a 
report of Yamasaki et al, the successful in vivo transfer of NFkappaB decoy ODN to 
inhibit vascular stenosis in balloon-injured porcine coronary arteries was demonstrated 
[17].  
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1.2.2C  Short interfering RNA (siRNA)  
Gene silencing via siRNA technology is a novel strategy with great therapeutic 
potential. siRNA is a short dsRNA molecule that induces sequence specific 
posttranscriptional gene modification. This mechanism is called RNA interference 
(RNAi). Recently, this strategy was used for the treatment of HF and the results showed 
that the restoration of cardiac function was most likely through the reduction of 
hypertrophy [18].  Once transfected into a cell, the siRNA incorporates into the nuclease 
complex, where they then interrupt translation of targeted genes. Successful left 
ventricular intracavitary delivery of DNA/siRNA complexes by means of sonoporation 
was demonstrated in murine hearts [19]. The incorporation of siRNA into terminally 
differentiated adult rat cardiac myocytes using adenovirus has also been reported [20]. 
1.2.2D Ribozymes   
Another strategy used to inhibit the disease process at the transcriptional level is 
the use of ribozymes. Ribozyme gene therapy aims to turn off a mutated gene in a cell 
by targeting the mRNA transcripts copied from the gene. Therefore, protein synthesis by 
the target RNA may be specifically inhibited by ribozymes. This process involves three 
steps: (1) Delivery of RNA strands engineered to function as ribozymes (2) Specific 
binding of the ribozyme RNA to mRNA encoded by the mutated gene and (3) Cleavage 
of the target mRNA, preventing it from being translated into a protein. Several studies 
have used ribozymes to limit neointimal hyperplasia with smooth muscle cell proliferation 
in response to balloon angioplasty. Ribozymes against c-myb mRNA [21] and 
transforming growth factor [22] prevented development of restenosis. 
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1.3 Heart Failure Gene Targets 
 
Gene therapy targets generally aim to: increase contractility, attenuate adverse 
remodeling and inhibit apoptosis.  A schematic demonstrating the therapeutic aim and 
their associated specific targets is presented in (Figure 1.2). 
 
1.3.1 The calcium cycling proteins 
 
Ca2+cycling has been found to be critically dysregulated in chronic HF and, 
provides an important role in excitation-contraction coupling.  Depicted in (Figure 1.3) is 
the excitation contraction complex in the myocyte including all elements.   
Figure 1.2 Cardiac Gene Therapy Targets for Heart Failure 
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To understand the Ca2+ handling defects in heart failure, we need to briefly 
describe the processes occurring in cardiac excitation–contraction coupling. During the 
cardiac action potential, Ca2+ enters the cell through depolarization-activated Ca2+ 
channels as an inward Ca2+ current, which contributes to the action potential plateau. 
Ca2+ entry triggers Ca2+ release from the sarcoplasmic reticulum (SR). This allows Ca2+ 
to bind to the myofilament protein troponin C, which then switches on the contractile 
process.  For relaxation to occur there is a decline in intracellular Ca2+ concentration, 
allowing Ca2+ to dissociate from troponin. This requires Ca2+ transport out of the cytosol 
by pathways involving SR Ca2+ -ATPase, sarcolemmal Na+ / Ca2+ exchange, 
sarcolemmal Ca2+ -ATPase or mitochondrial Ca2+.   
1.3.1A  SERCA2a 
Deficient SR Ca2+ uptake during myocyte relaxation has been identified in failing 
hearts from both humans and animals, and is associated with a decrease in the 
expression and activity of sarcoplasmic reticulum calcium ATPase (SERCA2a).  This 
Figure 1.3 Calcium Handling Targets in Myocardium 
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protein is a Ca2+-ATP-dependent pump of the sarcoplasmic reticulum that has a critical 
role in Ca2+ regulation, known as SERCA2a. The overexpression of SERCA2a has been 
demonstrated to increase contractility and normalize calcium cycling in failing human 
cardiomyocytes [23]. A number of animal studies with a variety of models of HF has 
demonstrated that overexpression of SERCA2a has a positive inotropic effect, improves 
oxygen utilization, attenuates the progression of HF and prolongs survival. SERCA2a 
gene transfer was found to substantially decrease incidence of ventricular arrhythmias 
and reduce infarct size in a model of ischemia/reperfusion [24].  A lentiviral vector-
mediated SERCA2a intracoronary delivery after myocardial infarction in rats resulted in 
favorable molecular remodeling with improving systolic and diastolic function six months 
later [34]. An improvement in left ventricular diameter, fractional shortening, and Ejection 
Fraction was also demonstrated in a tachycardia-induced HF model [25].    
 A first-in-human clinical trial Calcium upregulation by percutaneous 
administration of gene therapy in cardiac disease’ (CUPID) involving gene transfer of 
SERCA2a cDNA via a rAAV1 vector in patients with advanced HF has been undertaken 
in a randomized, double-blind, placebo-controlled study; although the results were 
somewhat difficult to interpret due to the absence of a clear dose-response.  At 12 
months, SERCA2a treated patients in the highest dose cohort demonstrated a 
consistent trend in clinical symptomatic improvement and in functional capacity [26]. 
1.3.1B  S100A1   
In cardiomyocytes, S100A1 plays an important role in increasing SERCA2a 
activity. This effect is achieved through diminishing diastolic SR Ca2+ leak, augmenting 
the systolic open probability of the ryanodine receptors, leading to an overall gain in SR 
Ca2+ cycling. Also, S100A1 regulates SERCA2A-Phospholamban function, resulting in a 
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balanced enhancement of SR Ca2+ release and uptake. S100A1 is downregulated 
during the development of HF [27]. Thus, in theory, S100A1 may be a promising factor in 
the treatment of HF. In a rat model of HF, significant cardiac recovery was demonstrated 
after 8 weeks in AAV6/S100A1 treated animals [28]. A study in a postinfarction pig 
model after 14 weeks revealed improvement in dP/dt and ejection fraction, and also 
restoration of high-energy phosphate homeostasis in failing myocardium [29]. 
1.3.1C Phospholamban (PLN) 
PLN regulates the homeostasis of SR Ca2+ mediating slower cytosolic Ca2+ 
decay in cardiomyocytes, which translates into diastolic relaxation. Phosphorylation of 
PLN suppresses its inhibitory effect. AAV-mediated overexpression of a mutant 
(“pseudophosphorylated”) form of PLN improved LV function and mitigated adverse 
remodeling in post-MI rats [30].  Silencing of PLN expression after tachycardia-induced 
HF in sheep increased ejection fraction and decreased LV end-diastolic area [107].A 
study in a volume-overload HF proved that adenovirus encoding antisense PLN 
preserved LV contractility and normalized LV mechanoenergetics [31]. 
1.3.2 The β-adrenergic signaling cascade 
 
The β-adrenergic receptor (βAR) signaling system plays an important role in the 
control of cardiac function, mediating the inotropic, chronotropic and lusitropic responses 
to the sympathetic neurotransmitters [32,33].  Therefore it represents an attractive 
molecular target to improve heart function. Two important components of the βAR 
system include the β-receptors and the regulatory G protein-coupled receptor kinases 
(GRKs). Dysregulation of the βAR pathway, including downregulation, uncoupling of 
second-messenger systems, and upregulation of βAR kinase (βARK1, GRK2), has been 
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shown to be a hallmark of HF. βARs are regulated by GRK2, a member of a G protein-
coupled receptor kinase family that phosphorylates and inactivate these receptors [34]. 
βARKct, a competitive inhibitor of GRK2, has the potential to resolve βAR 
downregulation and desensitization associated with HF [34,35]. Thus, inhibiting the 
activity of GRK2 or lowering its expression appears to offer a novel means to enhance 
cardiac function. 
1.3.2A The βARKct Peptide   
In a rabbit model of HF induced by myocardial infarction it was first demonstrated 
that the βARKct transgene improved heart function and delayed development of HF [36]. 
Inhibition of myocardial βARK1 via Ad/βARKct delivery before creation of acute coronary 
ischemia, may represent a new strategy for cardiac protection [37]. Long-term βARKct 
expression in the rat is by reversed LV remodeling and a normalization of the 
neurohumoral status of chronic HF animals [38]. The high level of βARKct expression in 
pressure-overload heart hypertrophy can preserve adenyl cyclase activity and βAR 
density and also improve cardiac function and cell morphology [39]. Based on the above 
results and earlier results derived from transgenic animal models, it appears that delivery 
of βARKct could be beneficial in the setting of IHD and HF. 
1.3.3 Other Ischemic Heart disease targets  
 
Current gene therapy research efforts in IHD include: stimulation of 
angiogenesis; limitations of reperfusion injury through the use of antioxidant therapy and 
endothelial nitric oxide synthase; and cardioprotection by using anti-apoptotic proteins 
[40].  These are summarized in (Figure 1.4).  Nevertheless much of the previous 
research was devoted to the study of angiogenesis. 
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One major focus of gene therapy for ischemic heart disease is 
neovascularization of fibrous post-infarct or poorly-perfused (hibernating) myocardium. 
Therapeutic angiogenesis can be achieved by gene transfer of vascular endothelial 
growth factor (VEGF), hepatocyte growth factor, fibroblast growth factor, and hypoxia-
induced factor 1α.  VEGF has five isoforms which act on tyrosine kinase receptors, FLK-
1 and FT1. This protein factor has been shown to stimulate endothelial cell proliferation, 
migration and vascular permeability and to affects fibroblast and smooth muscle growth 
[40,41,42]. Preclinical gene therapy studies with VEGF in various large animal models of 
myocardial ischemia have demonstrated stimulation of angiogenesis and improvement 
in fractional shortening [43], reduction of infarct size and peri-infarct fibrosis [44].  In 
Figure 1.4 Other Targets for Ischemic Heart Disease 
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addition, it has been noted that there is an appearance of apoptosis-resistant 
cardiomyocytes in the border zone [45] and improvement of myocardial viability [46]. 
1.4 Therapeutic Vectors 
 
Choosing the right vector for cardiovascular applications is one of the most 
challenging aspects. The availability of vectors for gene transfer has improved 
significantly over time.  The ideal vector would have the following characteristics:   it 
must be cardiotrophic, result in long-term expression, minimize the risk of cellular 
immune response, have a large coding capacity and have high transduction efficiency 
[41].  The main challenges to the vector are as follows: (i) Escaping the neutralizing 
effects of specific antibodies and non-specific adsorption to other blood components (ii) 
overcoming the endothelial barrier and penetrating the vascular wall for diffusion through 
the extracellular matrix; and (iii) Uptake into the cell at the level of the plasma membrane 
and efficient trafficking to the nucleus and (iv) synthesis by the host of the complimentary 
DNA strand for single stranded delivery vectors followed by transcription and translation 
of the transgene [47]. A number of different vectors have been used to achieve 
myocardial gene transfer, modified or selected to enhance the probability of overcoming 
each of these challenges. All vectors can be classified into two main categories, the non-
viral and recombinant viral.  
1.4.1 Non-viral vectors 
 
Non-viral vectors are grouped as plasmid DNA, liposome-DNA complexes 
(lipoplexes), and polymer-DNA complexes (polyplexes).  Oligonucleotides are also 
considered non-viral vectors [48]. In 1990, Lin and associates injected plasmid DNA into 
the left ventricle and demonstrated that the lacZ gene could be introduced and 
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expressed in cardiac myocytes [49].  Although non-viral vectors have the major 
advantage of production in relatively large quantities at low cost while at the same time 
possess fewer toxic or immunological problems, their transfer efficiency is generally poor 
independent of delivery route [50,51].  Nevertheless, a large number of human cardiac 
clinical trials are based on plasmid-mediated gene transfer investigating angiogenesis in 
myocardial ischemia [52-54]. A major advantage of this approach is that it avoids many 
of the biosafety concerns associated with viral vectors.  However, the level of transgene 
expression and the efficiency of gene transfer (percent of target cells expressing the 
transgene) are low and expression is restricted to the zone of the injection site. DNA 
complexes are relatively more efficient [55].  
There is however a major discrepancy between the data obtained in vivo and in 
vitro.  In addition, these complexes are unstable and thus quickly removed by 
phagocytes when delivered, especially through intravascular delivery systems. An 
additional shortcoming of these vectors (e.g. oligonucleotides) is their short biological 
half-life due to intracellular degradation and non-specific binding [56].  The 
demonstration of plasmid gene transfer opened a new era of cardiovascular 
pharmacotherapy. Despite numerous efforts to enhance efficiency through modification, 
direct myocardial plasmid injection basically remains a proof of concept tool only [57]. 
1.4.2 Viral vectors  
 
Successful cardiac gene therapy applications demand both efficient myocardial 
transduction initially and long-term transgene expression. Many authors strongly believe 
that only viral vectors appear to meet these demands in terms of performance [58,59]. 
Compared to non-viral vectors, viruses have an evolutionary advantage in their 
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interactions with the cellular surface receptors, directly leading to more efficient 
intracellular trafficking of packaged DNA to the nucleus. Furthermore, their protein 
capsid protects the message from degradation in lysosomes [47,57,60,61]. Some viral 
vectors are able to integrate into the host genome, whereas others remain episomal. 
Integrating viruses result in persistent transgene expression while viruses in episomal 
form lead to long term expression in predominantly non-dividing tissues (e.g., adult 
myocardium) but only transient expression in rapidly dividing tissues (e.g., the 
hematopoietic system). It should be noted that for some disorders, short -term 
expression in a relatively small proportion of cells would be sufficient or even desirable 
(e.g., angiogenesis post myocardial infarction) whereas other pathologies might require 
long-term expression (e.g., autosomal recessive cardiomyopathy).  
1.4.2A Lentiviruses 
These vectors were initially developed for HIV therapy. Lentiviral vectors can 
infect non-dividing cells, cause long-term expression and do not typically induce an 
inflammatory or immune response. The major limitation is the risk for mutagenesis and 
oncogenesis [58]. The new generation of lentiviruses, containing a mRNA and a nuclear 
import sequence have been used for successful myocardial transduction, although 
expression is usually short-term [62,63]. Fleury et al. in a study with rat cardiomyocytes 
in vivo succeeded in obtaining persistent GFP transfer for up to 10 weeks [64]. In 
another study the transduction efficiency of lentiviral vector-mediated SERCA2 gene 
transfer was about 40% and the positive physiological effect persisted six months later 
[65]. 
1.4.2B  Adenoviruses 
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Adenoviral vectors have historically been the most frequently used transfer 
system in experimental and clinical studies. This is attributed to the vector’s known 
advantages such as: the ability to transduce non-dividing cells, ease of manufacture in 
very high titers, the possibility to achieve high levels of transgene expression and a large 
transgene cloning capacity. However, their use is limited clinically due to transient gene 
expression, and their inability to integrate the genome into the cellular chromosomal 
DNA. In addition, adenoviral vector particles are highly immunogenic and cause 
inflammatory and toxic reactions in the host.  This is due to the fact that the adenovirus 
stimulates both the innate and adaptive immune systems. Using a rat model, it was 
confirmed that adenovirus was several orders of magnitude more efficient in transducing 
myocytes than plasmid DNA expressing the same construct [66,67]. Later, it was shown 
that the direct intramyocardial injection of replication-deficient adenovirus can program 
gene expression in large animal in vivo. However, the authors noted a robust T cell-
mediated immune response against the vector and limited distribution of the reporter 
gene [68].   
Simultaneously, several groups confirmed the possibility to achieve significant 
cardiac gene expression after catheter-mediated delivery of adenovirus encoding 
phospholamban and the β2-adrenergic receptor [68,69]. Using adenovirus to deliver 
selected transgenes, enhanced cardiac performance several weeks after gene transfer 
has been demonstrated [70].  Despite sophisticated modifications in an attempt to 
attenuate the host immune response to the adenovirus, the risk is too high to advocate 
the use of this delivery vector for clinical cardiovascular applications. 
1.4.2C Adeno-associated viruses 
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Adeno-associated virus (AAV) is a small (20 nm), non-enveloped virus that 
belongs to the dependovirus genus of the parvovirus family. AAVs have a single-
stranded DNA genome. The viral genome is approximately 4.7 kb in length, and is 
composed of two major open-reading frames which encode Rep (replication) and Cap 
(capsid) proteins [71]. For an infection to occur, AAV requires co-infection with a helper 
virus such as adenovirus.  This allows the viral genome to replicate episomally, and 
leads to synthesis of the AAV proteins. AAV is one of the smallest viruses, with a capsid 
mean diameter of 22 nm. The first AAV2 infectious clone was created in 1982 by 
Samulski and colleagues [72]. Several years later, it was established that AAVs can 
express foreign genes in mammalian cells [73]. One of the major advantages of AAV 
vectors is that in multiple animal models and humans, it has been demonstrated that 
after reaching a steady state level, AAV expression may last for years with an absence 
of a significant immune response to the transgene [74]. Moreover, AAV vectors can be 
engineered to provide a wide range of cell type tropism with the ability to transduce both 
dividing and non-dividing cells. Due to their biological properties and advantages over 
other viral vector systems, AAV has gained great popularity in the last decade in many 
clinical trials. Seventy five clinical trials using AAV have been initiated over the past 15 
years [60] with ~10% indicated for cardiovascular diseases [75]. 
The process of AAV endocytosis and intracellular trafficking is complex and 
cannot be underscored in understanding problems with clinical outcomes.  Despite the 
availability and diversity of AAV vectors, several biological barriers appear to limit the 
effectiveness of AAV mediated gene therapy [76,77]. Understanding the fundamental 
basis of these barriers has led to the establishment of methods to improve the efficiency 
of rAAV-mediated gene delivery [61,77]. Clarification of the processes by which a virus 
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first enters and traffics through a cell helps to understand the life cycle of the virus and 
its ability to act inside the cardiac muscle. The transport activity of AAV is mainly 
determined by selective receptor-mediated vesicle transcytosis [78]. This intracellular 
route does not appear to alter the properties of the AAV. The entry of AAV vectors into 
the cell involves several steps illustrated in (Figure 1.5).  
 
 
(1) Binding to the membrane receptor/co-receptor, or attachment factors; (2) 
Endocytosis of the virus by the host cell occurs in distinct membrane compartments, 
called clathrin-coated pits, which can be internalized to form clathrin-coated vesicles. 
Clathrin-independent endocytosis involves the uptake in caveolae, membrane lipid rafts 
and microdomains; (3) Following endocytosis the AAV vectors are compartmentalized 
into early endosomes. This is the distribution station in the endocytic pathway; (4) Early 
endosomes then mature into late endosomes that are degraded by fusion with the 
lysosome later, secretory vesicles, and the material that will be recycled back to the 
Figure 1.5 Viral Vector Mediated Gene Transfer 
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plasma membrane; (5) Some separate viruses can escape lysosomal degradation via 
acidification of the endosome and it is a necessary prerequisite for the release of the 
AAV; (6) These  AAVs particles are then trafficked into the nucleus, where viral 
uncoating leads to single-stranded DNA release. The single stranded DNA is then 
converted to double stranded DNA, and finally to concatamers and or integrated into the 
host genome.                  
AAV transport can be blocked by neutralizing antibodies, temperature, and 
physical and chemical inhibitors through a time and dose-dependent process. In vivo 
studies have noted that several serotypes of AAV are able to cross vascular 
endothelium with different efficiencies [79]. It is known that AAV2 has a relatively poor 
tropism for vascular cells, although reasonable levels of transduction have been 
achieved in cardiac myocytes [80]. Local delivery AAV2 led to transduction of underlying 
vascular smooth muscle cells and sequestration of AAV in the extracellular matrix 
around endothelial cells thus preventing cell binding and entry. The potential of AAV6 
vector for cardiac gene therapy was achieved through the use of VEGF to increase 
vascular permeability [81]. 
1.5  Conclusions 
 
The growth in CVD gene therapy applications has been dramatic in recent times 
given successes in other disorders. However, physicians and translational scientists still 
must address key safety and efficacy problems associated with viral vector mediated 
gene transfer.  The adeno-associated virus platform to date offers the best means to 
achieve safe and long term gene expression as indicated now with over 3 years of safety 
data from the Phase I/IIb CUPID trials.  Despite this promise, the level of interest in 
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regenerative cell therapy applications will continue to grow unless the problems of 
efficient delivery and avoidance of undesirable immune responses can be achieved.  
Next generation viral and non-viral vector applications are being co-developed alongside 
smart device based delivery systems to increase cardiac specificity and limit off target 
effects.  The remaining chapters of this body of work are dedicated to advancing cardiac 
gene therapy through the development of a novel, cardiac specific delivery system.  This 
body of research essentially asserts that delivery strategy selection and execution drives 
outcome with any given high risk/reward gene therapeutic.  
References 
 
[1]  Go, A. S., D. Mozaffarian, V. L. Roger, et al., Heart disease and stroke statistics--
2013 update: a report from the American Heart Association. Circulation 2013. 1:e6-e245. 
[2]  St. John-Sutton M, Pfeffer MA, Moye L, Plappert T, Rouleau JL, Lamas G. Rouleau 
J, Parker JO, Arnold MO, Sussex B, Braunwald, E. Cardiovascular death and left 
ventricular remodeling two years after myocardial infarction: baseline predictors and 
impact of long-term use of captopril.  Circulation. 1997 Nov 18;96(10):3294-9. 
[3]   Goldstein DJ, Oz MC, Rose EA.  Implantable left ventricular assist devices. N Engl J  
Med. 1998;339:1522-1533. 
 
[4]  Frazier OH, Myers TJ.  Surgical therapy for severe heart failure.  Current Problems 
in Cardiology. 1998;23:721-768. 
 
[5]  Vitali E, Lanfranconi M, Ribera E, Bruschi G, Colombo T, Frigerio M, Russo C.  
Successful experience in bridging patients to heart transplantation with the micromed 
debakey ventricular assist device. Ann Thorac Surg. 2003;75:1200-1204. 
 
[6]  Delgado HD, Rao V, Ross JR, Verma S, Smedira N.  Mechanical circulatory 
assistance (State of Art) Circulation. 2002;106:2046-2050. 
 
[7]   Siegenthaler PM, Martin J, Loo A, Doenst T, Bothe W, Beyersdorf F.  Implantation 
of the permanent jarvik-2000 left ventricular assist device.  JACC. 2002; 39:1764-1772. 
 
[8]  Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, Long 
JW, Ascheim DD, Tierney AR, Levitan RG, Levitan RG, Watson JT, Ronan NS, Meier P.  
Long-Term Use of a Left Ventricular Assist Device for End-Stage Heart Failure. N Engl J 
Med. 2001; 345:1435-1443. 
 
21 
 
[9]  Dowling RD, Gray LA Jr, Etoch SW, Laks H, Marelli D, Samuels L, Entwistle J, 
Couper G, Vlahakes GJ, Frazier OH.  Initial experience with the abiocor implantable 
replacement heart system.  Journal of Thoracic & Cardiovascular Surgery. 
2004;127:131-141.  
 
[10]  Melo LG, Pachori AS, Gnecchi M, Dzau VJ Genetic therapies for cardiovascular 
diseases.  Trends Mol Med 2005; 11:240-250. 
 
[11]  Quarck R, Holvoet P Gene therapy approaches for cardiovascular diseases. Curr 
Gene Ther 2004;: 207-223. 
 
[12]  Morishita R. Perspective in progress of cardiovascular gene therapy.  J Pharmacol 
Sci 2004; 95:1-8. 
 
[13]  Quarck R, De Geest B, Stengel D, Mertens A, Lox M, Theilmeier G.  Adenovirus-
mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents 
injury-induced neointima formation and reduces spontaneous atherosclerosis in 
apolipoprotein E-deficient mice. Circulation 2001; 103:2495-2500. 
[14]  Marchand GS, Noiseux N, Tanguay J-F,  Sirois MG Blockade of in vivo VEGF-
mediated angiogenesis by antisense gene therapy: role of Flk-1 and Flt-1 receptors. Am 
J Physiol Heart Circ Physiol 2002; 282:H194-H204. 
[15]  Montgomery RL, Hullinger TG, Semus HM, Dickinson BA, Seto AG, Lynch JM, et 
al. Therapeutic inhibition of miR-208a improves cardiac function and survival during 
heart failure. Circulation  2011; 124:1537-1547. 
[16]  Kawauchi M, Suzuki J, Morishita R, Wada Y, Izawa A, Tomita N, et al. (2000) Gene 
therapy for attenuating cardiac allograft arteriopathy using ex vivo E2F decoy 
transfection by HVJ-AVE-liposome method in mice and nonhuman primates.  Circ Res  
87:1063-1068. 
[17]  Yamasaki K, Asai T, Shimizu M, Aoki M, Hashiya N, Sakonjo H.   Inhibition of 
NFkappaB activation using cis-element ‘decoy’ of NFkappaB binding site reduces 
neointimal formation in porcine balloon-injured coronary artery model.Gene Ther 2003;  
10:356-364. 
[18]  Suckau L, Fechner H, Chemaly E, Krohn S, Hadri L, Kockskämper J. Long-term 
cardiac-targeted RNA interference for the treatment of heart failure restores cardiac 
function and reduces pathological hypertrophy.  Circulation 2009; 119:1241-1252. 
[19]  Tsunoda S, Mazda O, Oda Y, Iida Y, Akabame S, Kishida T.  Sonoporation using 
microbubble BR14 promotes pDNA/siRNA transduction to murine heart.  Biochem 
Biophys Res Comm  2005; 336:118-127. 
[20]  Rinne A, Littwitz C, Kienitz M-C, Gmerek A, Bösche LI, Pott L.  Gene silencing in 
adult rat cardiac myocytes in vitro by adenovirus-mediated RNA interference.  J Muscle 
Res Cell Motil  2006; 27:413-421. 
22 
 
[21]  Macejak DG, Lin H, Webb S, Chase J, Jensen K, Jarvis TC. Adenovirus-mediated 
expression of a ribozyme to c-mybmRNA inhibits smooth muscle cell proliferation and 
neointima formation in vivo. 1999; J Virol 73:7745-7751. 
[22]  Yamamoto K, Morishita R, Tomita N, Shimozato T, Nakagami H, Kikuchi A.  
Ribozyme oligonucleotides against TGF-b inhibited neointimal formation after vascular 
injury in rat model: potential application of ribozyme strategy to treat cardiovascular 
disease Circulation  2000; 102:1308-1314. 
[23]  Davia K, Bernovich E, Ranu HK, del Monte F, Terracciano CM, MacLeod KT. 
SERCA2a overexpression decreases the incidence of aftercontractions in adult rabbit 
ventricular myocytes. 2001; J Mol Cell Cardiol 33:1005-1015. 
[24]  del Monte F, Lebeche D, Guerrero JL, Tsuji T, Doye AA, Gwathmey JK et al. 
Abrogation of ventricular arrhythmias in a model of ischemia and reperfusion by 
targeting myocardial calcium cycling. Proc Natl Acad Sci USA 2004; 101:5622–5627. 
[25]  Byrne MJ, Power JM, Preovolos A, Mariani JA, Hajjar RJ, Kaye DM. Recirculating 
cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental 
model of heart failure in large animals. Gene Ther 2008; 15:1550–155. 
[26]  Jessup M, Greenberg B, Mancini D, Cappola T, Pauly DF, Jaski B,et al. Calcium 
upregulation by percutaneous administration of gene therapy in cardiac disease 
(CUPID). Circulation 2011; 124:304-313. 
[27]  Most P, Remppis A, Pleger ST, Katus HA, Koch WJ.  S100A1: a novel inotropic 
regulator of cardiac performance. Transition from molecular physiology to 
pathophysiological relevance. Am J Physiol Regul Integr Comp Physiol 2007; 
293:R568–R577. 
[28]  Pleger ST, Most P, Boucher M, Soltys S, Chuprun JK, Pleger W,  et al. Stable 
myocardial-specific AAV-S100A1 gene therapy results in chronic functional heart failure 
rescue. Circulation 2011; 115:2506–2515. 
[29]  Pleger ST, Shan C, Klienzyk J, Bekeredjian R, Boekstegers P, Hinkel R et al. 
Cardiac AAV9-S100A1 Gene therapy rescues post-ischemic heart failure in a preclinical 
large animal model. Sci Transl Med 2011;3:92ra64. 
[30]  Iwanaga Y, Hoshijima M, Gu Y, Iwatate M, Dieterle T, Ikeda Y, et al.  Chronic 
phospholamban inhibition prevents progressive cardiac dysfunction and pathological 
remodeling after infarction in rats. J Clin Invest 2004; 113:727–736. 
[31]  Tsuji T, del Monte F, Yoshikawa Y, Abe T, Shimizu J, Nakajima-Takenaka C, et al.  
Rescue of Ca2+ overload-induced left ventricular dysfunction by targeted ablation of 
phospholamban. Am J Physiol Heart Circ Physiol 2009; 296:H310–H317. 
[32]  Rockman HA, Koch WJ, Lefkowitz RJ.  Seven-transmembrane-spanning receptors 
anheart function. Nature 2002; 415:206-212. 
[33]  Brodde OE.  Beta-adrenoreceptors in cardiac disease. Pharmacol Ther 1993; 
60:405–430. 
23 
 
[34]  Koch WJ, Rockman HA, Samama P, Hamilton RA, Bond RA, Milano CA, et al. 
Cardiac function in mice overexpressing the β-adrenergic receptor kinase or a βARK 
inhibitor. Science 1995; 268:1350–1353.  
[35]  Brinks H, Koch WJ.  βARKct: a therapeutic approach for improved adrenergic 
signaling and function in heart disease. J Cardiovasc Trans Res 2010; 3:499-506. 
[36].  White DC, Hata JA, Shah AS, Glower DD, Lefkowitz R, Koch WJ. Preservation of 
myocardial b-adrenergic receptor signaling delays the development of heart failure after 
myocardial infarction. Proc Natl Acad Sci USA 2000; 97:5428-5433. 
[37]. Tevaearai HT, Walton GB, Keys JR, Koch WJ, Eckhart AD, et al.  Acute ischemic 
cardiac dysfunction is attenuated via gene transfer of a peptide inhibitor of the b-
adrenergic receptor kinase (βARK1). J Gene Med 2005; 7:1172–1177. 
[38]. Rengo G, Lymperopoulos A, Zincarelli C, Donniacuo M, Soltys S, Rabinowitz JE et 
al.  Myocardial adeno-associated virus serotype 6-bARKct gene therapy improves 
cardiac function and normalizes the neurohormonal axis in chronic heart failure. 
Circulation  2009; 119:89-98. 
[39]. Tachibana H, Naga Prasad SV, Lefkowitz RJ, Koch WJ., Rockman HA. Level of b-
adrenergic receptor kinase 1 inhibition determines degree of cardiac dysfunction after 
chronic pressure-overload-induced heart failure. Circulation 2009; 111:591–597. 
[40].  Lavu M, Gundewar S, Lefer DJ.  Gene therapy for ischemic heart disease. J Mol 
Cell Cardiol 2011; 50:742-750. 
[41].  Gaffney MM, Hynes SO, Barry F, O’Brien T.  Cardiovascular gene therapy: current 
status and therapeutic potential.  Brit J Pharmacol 2007; 152:175-188. 
[42].  Isner JM. Myocardial gene therapy.  Nature 2002; 415:234-239. 
[43]. Josko J, Gwozdz B, Jedrzejowska-Szypulka H, Hendryk S.  Vascular endothelial 
growth factor (VEGF) and its effect on angiogenesis Med Sci Monit 2000; 6:1047-1052. 
[44]. Vera Javanel GL, Crottogini A, Cabeza Meckert P, Cuniberti L, Mele A, 
Papouchado M, et al.  Plasmid-mediated VEGF gene transfer induces cardiomyogenesis 
and reduces myocardial infarct size in sheep. Gene Ther 2006; 13:1133–1142.  
[45]. Lähteenvuo JE, Lähteenvuo MT, Kivelä A, Rosenlew C, Falkevall A, Klar J, et al. 
Vascular endothelial growth factor-B induces myocardium-specific angiogenesis and 
arteriogenesis via vascular endothelial growth factor receptor-1- and neuropilin receptor-
1- dependent mechanisms. Circulation 2009; 119:845–856. 
[46]. Ferrarini M, Arsic N, Recchia FA, Zentilin L, Zacchigna S, Xu X, et al.   Adeno-
associated virus-mediated transduction of VEGF 165 improves cardiac tissue viability 
and functional recovery after permanent coronary occlusion in conscious dogs. Circ Res 
2006; 98:954–961. 
[47].  Müller OJ, Ksienzyk J, Katus HA.  Gene-therapy delivery strategies in cardiology. 
Future Cardiol 2008; 4:135-150. 
24 
 
[48].  Felgner PL, Barenholz Y, Behr JP, Cheng SH, Cullis P, Huang L, et al.  
Nomenclature for synthetic gene delivery systems. Hum Gene Ther 1997; 8:511-512. 
[49].  Lin H, Parmacek MS, Morle G, Bolling S, Leiden JM.  Expression of recombinant 
genes in myocardium in vivo after direct injection of DNA. Circulation 1990; 82:2217-
2221. 
[50]. Acsadi G, Jiao SS, Jani A, Duke D, Williams P, Chong W, et al. Direct gene transfer 
and expression into rat heart in vivo.  New Biol 1991; 3:71-81. 
[51]. Nabel EG.  Gene therapy for cardiovascular disease.  Circulation 1995; 91:541-
548. 
[52].  Losordo DW, Vale PR, Symes JF, Dunnington CH, Esakof DD, Maysky M et al.  
Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial 
injection of phVEGF 165 as sole therapy for myocardial ischemia. Circulation 98:2800-
2804. 
[53].   Vale PR, Losordo DW, Milliken CE, McDonald MC, Gravelin LM, Curry CM et al.  
Randomized, single-blind, placebo-controlled pilot study of catheter-based myocardial 
gene transfer for therapeutic angiogenesis using left ventricular electromechanical 
mapping in patients with chronic myocardial ischemia. Circulation 2001; 103:2138-2143. 
[54]  Kastrup J, Jorgensen E, Rück A, Tägil K, Glogar D, Rusyllo W et al.  Direct 
intramyocardial plasmid VEGF-A165 gene therapy in patients with stable severe angina 
pectoris. A randomized double-blind placebo-controlled study:the Euroinject One trial. J 
Am Coll Cardiol 2005; 45:982-988. 
[55]  Qin L, Pahud DR, Ding Y, Bielinska AU, Kukowska-Latallo JF, Baker JR, et al.  
Efficient transfer of genes into murine cardiac grafts by Starburst polyamidoamine 
dendrimers.  Hum Gene Ther 1998; 9:553-560. 
[56]  Kizana E, Alexander IE.  Cardiac gene therapy: therapeutic potential and current 
progress.  Curr Gene Ther  2003; 3:418-451. 
[57].  Wasala NB, Shin J-H, Duan D.  The evolution of heart gene delivery vectors. J 
Gene Med 2011; 13:557-565. 
[58].  Vinge LE, Raake PW, Koch WJ.  Gene therapy in heart failure. Circ Res 2008; 
102:1458-1470. 
[59].  Hinkel R, Trenkwalder T, Kupatt C. Gene therapy for ischemic heart disease. 
Expert Opin Biol Ther 2011;11:723-737. 
[60].  Rapti K, Chaanine AH, Hajjar RJ. Targeted gene therapy for the treatment of heart 
failure.  Can J Cardiol 2011; 27:265-283. 
[61]  Ding W, Zhang L, Yan Z, Engelhardt JF.  Intracellular trafficking of adeno-
associated viral vectors.  2005; Gene Ther 12:873-880. 
25 
 
[62].  Zhao J, Pettigrew GJ, Thomas J, Vandenberg JI, Delriviere L, Bolton EM, et al. 
Lentiviral vectors for delivery of genes into neonatal and adult ventricular cardiac 
myocytes in vitro and in vivo. Basic Res Cardiol 2002; 97:348-358. 
[63].  Bonci D, Cittadini A, Latronico MV, Borello U, Aycock JK, Drusco A, et al.  
Advanced’ generation lentiviruses as efficient vectors for cardiomyocyte gene 
transduction in vitro and in vivo. Gene Ther 2003; 10:630-636. 
[64].  Fleury S, Simeoni E, Zuppinger C, Deglon N, von Segesser LK, Kappenberger L, 
Vassalli G.  Multiply attenuated, self-inactivating lentiviral vectors efficiency deliver and 
express genes for extended periods of time in adult rat cardiomyocytes in vivo.  
Circulation 2003; 197:2375-2382. 
[65].  Niwano K, Arai M, Koitabashi N, Watanabe A, Ikeda Y, Miyoshi H et al.  Lentiviral 
vector-mediated SERCA2 gene transfer protects against heart failure and left ventricular 
remodeling after myocardial infarction in rats. Mol Ther 2008; 16:1002–1004.  
[66].  Guzman RJ, Lemarchand P, Crystal RG, Epstein SE, Finkel T.  Efficient gene 
transfer into myocardium by direct injection of adenovirus vectors. Circ Res 1993; 
73:1202–1207. 
[67].  Kass-Eisler A, Falck-Pedersen E, Alvira M, Rivera J, Buttrick PM, Wittenberg BA, 
et al.  Quantitative determination of adenovirus-mediated gene delivery to rat cardiac 
myocytes in vitro and in vivo. Proc Natl Acad Sci USA 1993; 90:11498–11502. 
[68].  French BA, Mazur W, Geske RS, Bolli R.  Direct in vivo gene transfer into porcine 
myocardium using replication-deficient adenoviral vectors. Circulation 1994; 90:2414–
2424. 
[69].  Hajjar RJ, Schmidt U, Matsui T, Guerrero JL, Lee KH, Gwathmey JK, et al.  
Modulation of ventricular function through gene transfer in vivo. Proc Natl Acad Sci USA 
95:5251–5256. 
[70].  Maurice JP, Hata JA, Shah AS, White DC, McDonald PH, Dolber PC, et al. 
Enhancement of cardiac function after adenoviral-mediated in vivo intracoronary β2-
adrenergic receptor gene delivery. J Clin Invest 1999; 104:21–29. 
[71].  Berns KI, Giraud C.  Biology of adeno-associated virus. Curr Top Microbiol 
Immunol 1996; 218:1-23. 
[72].  Samulski RJ, Berns KI, Tan M, Muzyczka N.  Cloning of adeno-associated virus 
into pBR322: rescue of intact virus from the recombinant plasmid in human cells.  Proc 
Natl Acad Sci USA 1992; 79:2077-2081. 
[73].  Laughlin CA, Tratschin JD, Coon H, Carter BJ.  Cloning of infectious adeno-
associated virus genomes in bacterial plasmids. 1983; Gene 23:65-73. 
[74].  Rivera VM, Gao GP, Grant RL, Schnell MA, Zoltick PW, Rozamus LW et al.  Long-
term pharmacologically regulated expression of erythropoietin in primates following AAV-
mediated gene transfer.  Blood 2005; 105:1424-1430. 
26 
 
[75].  Coura Rdos S, Nardi NB.  The state of the art of adeno-associated virus-based 
vectors in gene therapy. Virol J 2007; 4:99. 
[76]. Ziello JE, Huang Y, Jovin IS.  Cellular endocytosis and gene delivery. Mol Med 
2010; 16:222-229. 
[77].  Coura RS, Nardi NB.  A role for adeno-associated viral vectors in gene therapy. 
Gen Mol Biol 2008; 31:1-11. 
[78].  Di Pasquale G, Chiorini JA.  AAV transcytosis through barrier epithelia and 
endothelium. Mol Ther  2006; 13:506-516. 
[79].  Wang Z, Zhu T, Qiao C, Zhou L, Wang B, Zhang J, et al.  Adeno-associated virus 
serotype 8 efficiently delivers genes to muscle and heart.  Nat Biotechnol  2005; 23:321-
328. 
[80].  Melo LG, Agraval R, Zhang L, Rezvani M, Mangi AA,  et al.  Gene therapy strategy 
for long-term myocardial protection using adeno-associated virus-mediated delivery of 
heme oxygenase gene. Circulation  2002; 105:602-607. 
[81]. Gregorovic P, Blankinship MJ, Allen JM, Crawford RW, Meuse L, Miller DG et al. 
Systemic delivery of genes to striated muscles using adeno-associated viral vectors.  
Nature Med 2004;10:828-834. 
 
 
 
 
 
27 
 
CHAPTER 2 
Cardiac Gene Therapy Delivery Systems: Present and Future Applications 
Adapted From:  Katz MG, Swain JD, Tomasulo CE, Sumaroka M, Fargnoli AS, Bridges CR.  
Current Strategies for Myocardial Gene Delivery. J Molecular Cell Cardiol. 2011 May: 50(5)766-
76. 
2.1  Introduction 
 
An important prerequisite for introducing cardiac gene therapy into clinical 
practice is the development of simple and efficient gene delivery techniques.  During the 
last two decades, we have witnessed the development of several experimental gene 
delivery strategies with potential therapeutic value for the transition from the preclinical 
phase to clinical trials. Yet, efforts at gene transfer will require solutions to several 
problems.  These problems include delivery of the vector to the target tissue, improved 
safety and efficacy, prevention of complications, creation of new delivery devices and 
techniques, and improved geographical specificity of gene delivery to areas of 
therapeutic interest while simultaneously minimizing systemic spillover.  
Although cardiac tissue-specific promoters may mitigate collateral organ gene 
expression, only a true cardiac specific gene delivery method can diminish the 
biodistribution of vector capsids to extra cardiac organs.  Extra cardiac exposure results 
in unsafe levels of exposure to antigen presenting cells.  Antigen presenting cells 
provide another mechanism to increase the potential for a T-cell mediated immune 
response to the vector capsid. Ideally, the most optimal gene-delivery system should be 
combined with an appropriate vector.  Recombinant AAV vectors have rapidly evolved 
as tools for cardiac gene therapy. For numerous target diseases, they offer advantages 
over other viral vector systems. Multiple AAV serotypes have been isolated in recent 
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years. Among all AAV serotypes, AAV2 vectors have been successfully used in several 
experimental approaches such as protection from ischemia/reperfusion injury, inotropic 
therapy and beneficial effects on neoangiogenesis.   Recent reports demonstrate that 
serotypse 6 and 9 facilitate relatively stable cardiac gene expression and are superior to 
others in the heart, likely due to enhanced cellular internalization and nuclear uncoating 
in cardiomyocytes. Successful solutions to these and other challenges will undoubtedly 
help to achieve transmural, homogeneous, high-density cardiac gene transfer [1, 2].  
There are many published methods to transduce myocardium; yet, most of these 
approaches have shown inefficient transduction and thus failed to demonstrate effective 
therapy when applied to disease involving the whole heart [3]. Existing methods of gene 
delivery can be classified by the site of injection, interventional approach and the 
physiology of the cardiac circulation (Figure 2.1) 
 
Figure 2.1  Diagram of Cardiac Gene Delivery Techniques by Route 
29 
 
 
In this chapter, we describe both the most common and innovative gene delivery 
methods and attempt to outline future developments in this dynamic field. 
2.2 Direct Cardiac Gene Delivery  
 
Direct gene delivery methods have been utilized for at least two decades and 
some authors continue to reference and utilize them in their preclinical cardiac gene 
therapy studies.  Numerous methods have also successfully been translated for use in 
clinical trials. The most relevant of them are usually classified as either an open 
technique, that is to include the surgical opening of the chest or a closed technique, i.e., 
transcutaneous or minimally invasive. A minimally invasive application is desirable and 
can also be achieved via a subdiaphragmatic or thoracoscopic approach.  (Figure 2.2) 
depicts the three major approaches and their results which are described in detail in the 
following subsections. 
   
 
Figure 2.2  Direct Myocardial Gene Delivery: Left, (A)  Pericardial; Center, (B) Catheter 
Based Endocardial; Right, (C) Intramyocardial Sites 
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2.2.1 Intrapericardial Injection 
 
The rationale underlying intrapericardial gene delivery is related to the advantage 
of the anatomical connection between the pericardium and the myocardium, and the 
accessibility of the pericardial sac for percutaneous vector delivery [4] (Figure 2.2A).  
Zhang et al. made a percutaneous puncture of the pericardium at the left costoxiphoid 
angle of the anterior chest with injection of Ad.CMV.lacZ. After three days, significant 
lacZ expression was observed in the epicardium, myocardium, and endocardium of 
neonatal mice. The authors concluded that intrapericardial injection is an efficient 
technique to achieve transmural gene expression. Unfortunately, these results appear to 
be age-specific and are far less efficient in adult (rather than neonatal) animals.  
Furthermore, the group later found that at two months the expression only persisted in 
atrial tissue and not in ventricles, the presumed target area to address the majority of 
cardiomyopathic diseases.  Additionally, this method was associated with high levels of 
hepatic transduction [5].   
Fromes et al. performed intrapericardial injections with a transdiaphragmatic 
approach, using adenovirus encoding β-galactosidase in rats. The staining observed 
was exclusively restricted to the pericardial cell layers; however, injecting a mixture of 
proteolytic enzymes with the virus led to an increase of transgene expression to 40% of 
the myocardium at day seven. As expected when using an adenoviral vector, the 
expression decreased to 0.5 % at day 28. The authors also found positive β-
galactosidase activity in distant organs [6].  March et al. used a hollow, helical-tipped 
penetrating catheter for vector delivery in the canine myocardium. The catheter was 
introduced percutaneously and advanced into the pericardial space through the apex of 
the right ventricle. All of the animals tolerated the procedure without incident, 
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demonstrating the feasibility of localized cardiac gene delivery via a catheter-based 
pericardial approach [7]. The administration of Ad2.CMV.LacZ into the pericardial sac 
produced extensive transfection of the visceral and parietal pericardium and doxycycline 
pretreatment increased this effect [8].  
2.2.2  Endocardial Injection    
 
The feasibility of fluoroscopy-guided, percutaneous endocardial vector injection 
was demonstrated by Gwon et al. in the porcine heart [9] (Figure 2.2B). Sanborn et al. 
used the same approach with a coaxial catheter for endocardial delivery of adenovirus 
encoding VEGF in the porcine myocardium. Regional VEGF expression was found to be 
significantly greater in targeted zones as compared with non-targeted zones [10]. 
Several authors believe that the electromechanical mapping-guided approach allows for 
better deployment of the tip of the catheter around areas of ischemia [11-13]. However, 
this system and the equipment needed to execute the procedure are quite complex and 
expensive.   
 In a porcine model, Grossman et al. compared endomyocardial and epicardial 
microsphere injection, finding that endomyocardial injection performed with the Stiletto 
system was associated with 43% microsphere retention, compared with 15% after 
epicardial injection. Reduction of injectate volume (10 µL) resulted in significantly 
improved retention compared to 100 µL injection, a typical volume used in clinical trials.   
These authors also found evidence of significant viral transfection in the liver and spleen 
after injection of adenovirus encoding β-galactosidase [14].  The study of Naimark et al. 
highlights the importance of enhancing the biocompatibility of the catheter for 
endocardial and epicardial gene delivery [15]. Despite the ease of implementation 
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advantage of catheter-based endocardial and epicardial injection, there is an increased 
potential for complications associated with ventricular perforation, cardiac tamponade, 
endocardial thrombosis and intramyocardial hematoma, especially in patients with 
chronic ischemia who have thinned and scarred myocardium [9].  
While there has been demonstration of the feasibility of percutaneous 
endocardial gene transfer and gene expression, many questions still exist regarding this 
approach [10]. For instance, in patients with ischemic cardiomyopathy, should 
vector/transgene administration be targeted to ischemic areas alone or to “border zone” 
to stimulate collateral flow? What quantity represents the ideal dose and how many 
injections are necessary, especially given that the patients have multiple areas of 
ischemia?  
2.2.3  Intramyocardial Injection 
 
The majority of successful preclinical studies have involved direct administration 
of vector. This technique allows for the application of a high concentration of vector 
directly at the target site.  Several groups have demonstrated the feasibility of delivering 
transgenes to the heart via direct intramyocardial injection of plasmid DNA [16-19] 
(Figure 2.2C). Although these studies have been encouraging because plasmid DNA 
may be expressed for up to six months by cardiomyocytes adjacent to the area of 
injection, estimates of the number of myocytes that can be transfected in vivo have been 
as low as 60 to 100 cells per injection [16]. This low efficiency has made it difficult to 
measure the physiological effects of gene expression in myocytes, making it unlikely that 
clinically significant effects will result [20]. The low transduction efficiency of plasmid 
DNA vectors leads to the search for improved gene transfer efficiency with direct 
33 
 
injection of an adenovirus vector. Hearts transfected with an adenovirus vector 
containing the β-galactosidase gene showed significantly increased β-galactosidase 
enzymatic activity compared with hearts injected with β-galactosidase plasmid. 
Unfortunately, the gene expression persisted for only one week after injection and it 
included acute inflammatory response, which the authors considered to be related to the 
injury produced by direct injection as well as a cellular immune response against the 
adenovirus itself [20].  
The studies of French et al. [21] demonstrated for the first time, in a porcine 
model, a number of important points relevant to this technique: 1) direct intramyocardial 
injection of replication-deficient adenovirus is 140,000 times more efficient than injection 
of an equal number of genome copies of recombinant plasmid DNA and can program 
recombinant gene expression in the cardiomyocytes of a large animal species; 2) the 
impact of this procedure on cardiac function appears to be negligible; 3) the amount of 
recombinant protein produced increases with the amount of virus; 4) the expression of 
recombinant genes following intramyocardial injection is similar in the left and right 
ventricles; 5) the percentage of cardiomyocytes expressing β-galactosidase in the 
needle track adjacent to the injection, but rarely are lacZ positive cells detected farther 
than 5 mm from the injection site [21].   
In a canine study using adenovirus encoding chloramphenicol acetyl transferase, 
peak gene expression was noted at two days and decreased by an order of magnitude 
14 days after direct single myocardial administration. In this study, there was not 
significant transduction of distant organs and no documented changes in global or 
regional LV function [22]. However, the feasibility of adenovirus-mediated gene transfer 
has been limited by the cellular immune response which causes myocardial 
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inflammation and results in transient recombinant gene expression [23].  
 Svensson et al. showed that stable β-galactosidase expression can be achieved 
without evidence of myocardial inflammation or myocyte necrosis after substituting rAAV 
for adenovirus vector-mediated gene transfer [24]. Furthermore, in an landmark study, 
Tomiyasu et al., succeeded in augmenting cardiac function in cardiomyopathic hamsters 
with heart failure by transfecting cardiac muscle with the β2-AR gene after direct 
intramuscular injection. Echocardiographic examination revealed that stroke volume and 
cardiac output were significantly elevated at two to four days after β2-AR gene transfer 
[25]. 
Rengo et al  studied myocardial gene transfer to post-myocardial infarct rats with 
intramyocardial direct injection. In order to stop beating of the heart (for 2.5 min), 
adenosine was injected and both ascending aorta and pulmonary artery were clamped. 
A volume of 4x1011 total particles of rAAV6-βARKct was injected in the LV free wall. The 
investigators found robust transgene expression in the LV at 12 weeks after delivery. A 
significant finding was that βARKct (gene of interest) significantly improved cardiac 
contractility and reversed LV remodeling in this heart failure model [26]. 
In summary, the direct gene delivery approach was the first among others that 
helped establish the therapeutic efficacy of cardiac gene therapy. Furthermore, the use 
of this method in some experimental models resulted in successful therapeutic 
myocardial angiogenesis, and focal treatment of cardiac arrhythmias through effects on 
cellular electrophysiology; thus, making this platform widely used. Finally, this approach 
has been successfully utilized in Phase І/ІІ clinical trials demonstrating its potential 
therapeutic relevance. 
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2.3. Transvascular Gene Delivery  
 
There are many potential therapeutic targets that are inaccessible directly in vivo 
and, hence, require the transvascular administration of gene delivery vectors. A few 
candidate therapeutic applications include essential hypertension and pulmonary 
hypertension. Effective therapy in these diseases will likely require a gene delivery 
method capable of globally transducing the myocardium and selected other tissues and 
organs [36-38]. This paradigm is particularly valid in heart failure gene therapy where 
most authors agree that gene transfer should be as diffuse and homogeneous as 
possible [39,40]. 
 
 
2.3.1. Selective Coronary Catheterization with Antegrade Intracoronary Delivery 
 
To date, one of the most preferred gene delivery methods involves catheter-
based, percutaneous infusion of vector into the coronary arteries (Figure 2.3A). The 
benefits of this technique include its minimal invasiveness, the possibility of transgene 
delivery to all four myocardial chambers, and the delivery of vector genomes using 
Figure 2.3  Catheter Based Antegrade Catheter Infusion Delivery Approaches: (A) Left, 
Selective (B) Right, Non-Selective 
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endovascular coronary catheterization—a procedure for which there is established 
clinical experience. Early reports using simple antegrade intracoronary delivery achieved 
very limited myocardial transduction efficiency [22,39,41,42].  The variability in 
transduction was due to a number of factors that included differences between animal 
species, biocompatibility of catheter and vector, different pharmacological agents used 
to permeabilize the vasculature, and vector-related variables such as vector serotype 
and titer [4].  
Using intracoronary perfusion in explanted hearts, Donahue et al. reported highly 
effective gene transfer to the heart and identified critical parameters influencing the 
efficiency of intracoronary gene transfer. These included exposure time, high coronary 
flow rate and perfusion pressure, the use of crystalloid solution as opposed to whole 
blood, virus concentration, and temperature [37]. Several authors believe that aside from 
these factors, a major deficiency in intracoronary gene transfer is the short residence 
time of vector within the coronary circulation [39,43,44].  Attempts to resolve this 
shortcoming have resulted in a number of strategies. Logeart et al showed that brief 
interruption of coronary flow is required to obtain significant myocyte transduction during 
single-pass delivery in the isolated rat heart model [42].   
In other experiments, this laboratory obtained similar results in vivo, when 
adenoviruses were delivered downstream of an occluded artery and when occlusion was 
maintained for 30 seconds following adenovirus injection [42]. This procedure raises 
questions as to the potential role of ischemia in enhancing gene transfer by increasing 
microvascular permeability. The authors also demonstrated that selective catheterization 
of the coronary venous sinus, which was transiently occluded and retroperfused with 
saline during their procedures, increased the pressure inside post-capillary venules, 
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which in turn improved gene transfer by increasing vector residence time in coronary 
vessels [39].  
Hayase et al. used the technique of antegrade intracoronary gene delivery with 
concomitant coronary venous blockade. The myocardium was preconditioned with one 
minute of occlusion of the left anterior descending and circumflex arteries. Quantitative 
β-galactosidase analysis showed that gene expression was improved after selective 
coronary venous blockade [40]. Donahue et al. found that decreasing perfusate Ca2+ 
concentration or pre-treating with serotonin or bradykinin significantly decreased the 
exposure time necessary to achieve widespread transfection [45].  To prolong viral 
exposure time, Ding et al. pharmacologically induced transient cardiac arrest, while 
occluding the aorta and obstructed venous return to the heart. Cardiac arrest of two 
minutes allowed for transfection of 18% of cells, whereas an extended time to five 
minutes resulted in a cardiac transfection of about 43% of cells [43].    
Increasing perfusion pressure and flow augments myocardial expression perhaps 
by increasing the fenestration width between capillary endothelial cells, permitting better 
viral transendothelial transfer and enhancing virus-myocyte interaction [46, 47]. Emani et 
al used an apparatus consisting of a constant flow infusion pump with pressure 
transducer and examined the effects of altering intracoronary flow rate, while obtaining a 
seal between the catheter and the coronary lumen. The results indicate that efficient 
cardiac transgene expression is dependent upon the infusion flow rate and requires an 
intraluminal seal. Excessive flow rate is associated with myocardial injury [48].  
2.3.2 Nonselective (indirect) Intracoronary Delivery 
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Hajjar et al observed that adenovirus infusion into the left ventricle during brief 
aortic clamping results in efficient adenoviral gene transfer, perhaps due to the resulting 
high perfusion pressure inside the coronary vessels (Figure 2.3B).  Later, to achieve 
diffuse cardiac gene transfer in vivo, the authors developed a catheter-based technique 
in rodents. In this approach, a catheter was inserted in the LV apex and advanced 
beyond the aortic valve. A high concentration of an adenoviral preparation was then 
injected through the catheter while the aorta and pulmonary artery were cross-clamped, 
distal to the catheter tip for a period of 10 to 40 seconds.   
This method achieves grossly homogeneous transduction of cardiac myocytes 
throughout the left and right ventricles. By cross-clamping both the pulmonary artery and 
the aorta, the left ventricular end-diastolic pressure does not increase because blood 
return to the left ventricle is minimal. This method relies on the creation of a 
transcoronary myocardial perfusion gradient for vector delivery. This allows perfusion of 
the virus at relatively low downstream pressure, and the endocardium can be efficiently 
transfected. It is noteworthy, according to the authors, that aortic occlusion during aortic 
valvuloplasty is well tolerated in ill patients for periods of time comparable to those 
required for gene transfer in animal models [36,49].  
Maurice et al used a similar technique in the leporine model, whereby a catheter 
was placed into the LV chamber through the apex of the heart. The adenovirus solution 
was injected while the aorta was cross-clamped for 40 seconds. After six days, the 
authors found global myocardial β-galactosidase expression in both ventricles. However, 
three weeks later, β2-AR over-expression was minimal [50]. This method shunts the 
virus down the coronary arteries, and global transgene expression is possible; yet, there 
is a risk of systemic ischemia and acute LV overload during the aortic cross-clamping, 
39 
 
and time must be limited [51]. This data was supported by Parsa et al., who showed in a 
rabbit model with cross-clamping of the aorta, a significant decrease in dP/dtmax, which 
they explained, indicates a negative effect on cardiac contractility after aortic occlusion 
with elevation of afterload [46].  Kaspar et al. also used aortic and pulmonary artery 
cross-clamping for indirect coronary delivery of AAV encoding GFP. Gene expression 
was evaluated at four time points up to one year after vector delivery, revealing 20-32% 
transmural gene expression in the left ventricle [52].  Eckhart et al. showed that in vivo 
myocardial gene delivery in rabbits using this LV/cross-clamp delivery method of either 
the β2AR transgene or a gene encoding βARKct can enhance cardiac function in normal 
hearts as well as failing hearts [53].  Variations of this method may include clamping of 
the aorta without pulmonary artery occlusion, occluding the distal rather than ascending 
aorta, and the use of hypothermia to prolong cross-clamp times [4].    
2.3.3. Selective Coronary Sinus or Coronary Venous Catheterization with 
Retrograde Delivery 
 
The feasibility and efficacy of percutaneous retrograde gene delivery by selective 
pressure-regulated retroinfusion of the coronary veins has been demonstrated by 
Boekstegers et al using a constructed apparatus, consisting of a pump unit, 
extracorporeal circuit, and retroinfusion catheter and suction device.  The authors 
demonstrated advantages of retrograde delivery compared to antegrade and confirmed 
the results from several groups that blocking the venous outflow and coronary ischemia 
can significantly increase viral transfection of the myocardium [44, 54]. These authors 
believe that selective coronary retroinfusion prolongs adhesion time of the vector and 
increases endothelial permeability.   
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This finding has led to an important advance in this field of delivery, although this 
method does not reduce transduction of extra cardiac organs like the liver and lung [55]. 
Also, Hou et al. showed that a single retrograde coronary venous administration resulted 
in efficient regional myocyte transfection of human Del-1 and GFP. The authors believe 
that the coronary venous approach offers minimal washout and allows for controlled 
dwell times for longer exposure [56]. Kaye at al developed the V-Focus delivery system 
for a minimally invasive percutaneous procedure, which was designed to isolate the 
coronary circulation from the systemic. This system includes percutaneous intervention 
catheters, extracorporeal pump-oxygenator circuit, infusion pump and monitors.  
According to the authors, this system achieves superior myocardial gene 
expression in contrast to intracoronary delivery and is associated with lower systemic 
expression [57, 58]. Although the authors represent this method as a “closed loop” 
recirculation, careful analysis of the authors’ reported quantitative PCR results indicates 
that the vector genome concentration was 26 times higher in the liver than in the heart 
and thus isolation of the heart was not achieved as claimed [59].  
In summary transvascular gene delivery provides the ability to obtain 
homogenous and efficient cardiac gene expression accomplished with rapid dilution of 
vector in circulating blood with significant extra cardiac expression. Surgical 
manipulations included temporary aortic/pulmonary clamping or coronary arterial/venous 
occlusion but both have significant clinical limitations and would require more 
translational research, preferably in large animals, prior to considering clinical 
application. 
2.3.4  Ex vivo Gene Delivery  
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Even though there is a shortage of donor organs, over 2,000 heart transplants 
are performed annually in the United States.  Ex vivo, myocardial gene delivery to the 
donor heart before reimplantation is an active area of investigation.  Such an approach is 
clinically relevant in the setting of clinical heart transplantation and in surgical treatment 
of heart failure. Strategies to improve cardiac allograft function could potentially increase 
the longevity of current allografts, modulate the host immune response for prevention of 
allograft rejection, treat ischemia-reperfusion injury and make available additional 
marginal organs for transplantation that are currently not utilized [64].   Multiple studies 
have demonstrated the ability to transfect cardiac allografts with intracoronary, 
intramuscular, and transported delivery of vectors prior to transplantation [60,65-67]. 
Because gene delivery is carried out in the donor heart, total body virus exposure is 
limited in the recipient, thus making it clinically favorable [68].  Using intracoronary 
perfusion in explanted hearts, Donahue et al. reported highly effective gene transfer to 
the heart [37].    
In the study of Griscelli et al., recombinant adenoviruses encoding β-
galactosidase were injected into the coronary vessels of the harvested non-beating 
hearts of piglets at a dose 1010-1011 pfu. The hearts were maintained in contact with 
the vector-containing solution for one hour at 40C and the coronary vascular bed was 
then washed out by injecting 100 ml of cardioplegia solution and the last virus titer in the 
coronary sinus effluent was three logs below that of the infused viral solution. Gene 
transfer to allografts was evaluated four days after heterotopic reimplantation. In four out 
of 11 animals, transgene expression was detected in all cardiac areas, PCR analysis 
revealed minimal collateral organ transfection [60], and gene expression was not 
enhanced by the exclusion of blood [47].  Shah et al. performed ex vivo perfusion of 
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cardiac allografts with adenovirus encoding transgenes that enhance β-AR signaling 
[69]. The group demonstrated that five days after heterotopic transplantation, left 
ventricular systolic and diastolic performance was significantly increased in transfected 
grafts compared with controls. Further, Svensson et al. showed that 15 minutes of 
perfusion with AAV.CMV.lacZ was sufficient to result in transduction of 40% of 
cardiomyocytes after four weeks [24]. 
2.3.5 CPB and Cardioplegic Arrest 
 
Another possible application of gene therapy is its use during operations with 
extracorporeal circulation or cardiopulmonary bypass (CPB), which has become a 
routine cardiac procedure. In fact, in 2009 more than one million cardiac procedures that 
depend upon CPB were performed worldwide. Potentially widespread clinical application 
would involve intracoronary (antegrade or retrograde) gene transfer in the setting of CPB 
and cardioplegic arrest. The ability to augment myocardial performance with gene 
transfer could potentially reduce the need for long-term inotropic or mechanical support 
in the post-bypass setting, avoiding the complications associated with these 
interventions [64].  
High-risk patients undergoing revascularization or valve replacement with 
coexisting severely reduced ventricular function and inherited forms of cardiomyopathy 
might particularly benefit from concomitant gene therapy.  Bridges et al. and Davidson et 
al. first hypothesized that cardiopulmonary bypass may facilitate cardiac-selective gene 
transfer using recombinant replication-deficient adenovirus [70,71]. The absence of a 
significant influence of cold temperatures on transgene expression in an in vivo model 
with CPB was described by Jones et al. [72]. They also demonstrated the presence of 
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crystalloid cardioplegia compared with blood cardioplegia within the coronary circulation 
had no effect on transgene expression and hypothesized that endothelial contact with 
cardioplegia and the associated relative ischemia likely increased endothelial 
permeability [73]. Ikeda et al. evaluated the feasibility of restoring δ-sarcoglycan 
deficiency in cardiomyopathic hamsters after injection of a cardioplegia solution 
containing an adenoviral vector encoding δ-sarcoglycan into the aortic root [74]. At one 
and three weeks after transfection, immunostaining showed extensive restoration of 
deficient membrane proteins with significantly less progression of LV dysfunction 
compared with controls.   Davidson et al. demonstrated the feasibility of myocardial gene 
delivery during CPB with cold, hyperkalemic cardioplegic arrest in the porcine model 
[71]. (Figure 2.4A).  
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Unlike previous studies that utilized a single-pass perfusion technique, Bridges et al. 
were the first to create an isolated “closed loop” recirculating model of vector-mediated 
cardiac gene delivery in the large animal heart using cardiopulmonary bypass with an 
antegrade delivery approach, allowing for vector recirculation for 20 minutes [70]. Later, 
they used CPB with high-pressure retrograde coronary sinus infusion with multiple-pass 
  
Figure 2.4  Advanced Cardiopulmonary Bypass Based Gene Delivery Systems: 
(A) Top, Single pass delivery (B) Bottom, Closed Loop Recirculation Delivery 
with MCARD 
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recirculation of vector through the heart and washed out of the cardiac circuit prior to 
weaning from CPB, which limited extracardiac gene expression (Figure 2.4B). They 
were able to show an increase of several orders of magnitude in cardiac marker gene 
activities compared with controls. Furthermore, there was minimal gene expression in 
the liver and other collateral organs [75].  These results validate this surgical technique 
as a potentially clinically translatable approach for cardiac gene therapy in carefully 
selected patients.   
In summary, despite the allure of ex-vivo and CPB-mediated gene delivery 
approaches, it should be noted that one cannot exclude possible attendant morbidity. 
Morbidity may be related to technique-associated complications as well as the additional 
CPB time required.  Finally, these methods have not been translated to clinical trials, 
and the only evidence we have that they are effective is founded on the basis of data 
derived from experimental studies. Therefore, it is difficult to judge objectively about the 
likely clinical efficacy of these gene delivery platforms. 
2.4 Cardiac Gene Delivery in Clinical Trials  
 
A significant proportion of patients with myocardial ischemia and congestive 
heart failure remain refractory to pharmacological therapies and unsuitable for 
percutaneous or surgical interventions. Trials involving gene therapy in patients with 
ischemic heart disease have been undertaken to stimulate angiogenesis. Rosengart et 
al reported a Phase І clinical trial involving 21 patients with clinically significant coronary 
artery disease that utilized adenovirus encoding human VEGF 121 cDNA with a goal to 
induce therapeutic angiogenesis. The vector construct was administered by direct 
myocardial injection into an area of reversible ischemia either as an adjunct to coronary 
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artery bypass grafting or as sole therapy via a mini-thoracotomy. In both groups, 
coronary angiography and stress sestamibi scans suggested improvement in angina 
class patients after therapy [80,32,33].  
 Percutaneous catheter-based myocardial gene transfer of naked plasmid DNA 
encoding phVEGF-2 was tested in human subjects by Vale et al. [81].  After the 
completion of electromechanical mapping, the injection catheter was introduced 
percutaneously via a femoral arteriotomy across the aortic valve into the LV and the 
needle was advanced 4 to 6 mm intramuscular to administer six injections of plasmid 
DNA into the ischemic myocardium. All patients experienced reduced angina, reduced 
nitroglycerin usage and improved myocardial perfusion by SPECT-sestamibi scanning. 
Also, results of single intracoronary administration of Ad5-FGF4 show evidence of 
favorable anti-ischemic effects in patients with stable angina pectoris [82]. In this study 
the transgene was infused over a period of 90 seconds through subselective catheters 
into all major patent coronary arteries that could be engaged. Nevertheless, it should be 
noted that these Phase I studies have not measured the amount of recombinant protein 
produced; hence, it has not been possible to make accurate, quantitative determinations 
of the relative efficiency of gene transfer, and a placebo-induced therapeutic effect 
cannot be excluded.  
Hajjar et al and Jaski et al performed the first-in-human Phase I/II clinical trial 
with single intracoronary infusion of AAV1.SERCA2a in advanced heart failure. Standard 
percutaneous catheter engagement technique with the coronary arteries was performed. 
This usually involves delivering two-thirds of the dose to the anterolateral and one-third 
to the posterolateral myocardium, based on the coronary anatomy. Of the nine patients, 
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several demonstrated symptomatic, functional and biomarker improvements from 
baseline to month six. The Phase II results largely showed similar results [83,84]. 
2.5 Conclusions 
Gene delivery technology and science has improved expeditiously as demanded by the 
growing pipeline of therapies for various cardiovascular diseases. Translational 
problems have surfaced through clinical implementation and are associated with dosing 
at sufficient levels to achieve therapeutic benefit while remaining within safety limits.  
The ideal method for a particular cardiac gene therapy application maximizes 
therapeutic expression with the least required dose and delivery efficiency at the 
cardiovascular tissue is paramount.  Despite significant advancements, there is still great 
room for improvement to increase both safety and efficacy through developing more 
advanced systems alongside the clinical science.  Minimally invasive catheter based 
systems remain at the forefront due to their ease of use in the clinic, but must address 
problems associated with compromised vessels.  As reviewed in this chapter, advanced 
catheterizations systems including pharmacologic agents to increase vector distribution 
from the primary infusion site have been implemented.  It is expected this trend will 
continue given that 80% or more of advanced patients present with moderate to severe 
coronary artery disease.  Higher risk surgical mediated delivery methods featuring 
cardiopulmonary bypass at present are the only known means to achieve the highest 
possible transduction through the vascular anatomy, but at the cost of complexity.  
Furthermore these systems would be only reserved for a limited number of patients 
undergoing cardiac surgery for a separate indication. 
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 Chapter 3 will describe the rationale for a unique contribution to the direct 
myocardial delivery repoitore, which is currently limited to standard IM injection.  Direct 
injection methodology are primarily reserved for local, peri-infarct area but could also be 
implemented for other therapies provided the risk/reward and clinical strategy are 
feasible.      
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CHAPTER 3 
 
Research Program Overview & Strategy 
3.1 Specific Aims and Hypotheses 
 
Despite a well characterized gene transfer vector in AAV, high levels of transfer 
in larger species have been problematic both due to scale (i.e. 100 times greater 
myocardial mass) and more restrictive anatomical barrier factors.  Transfer problems in 
general are not realized in murine models, since successful AAV mediated gene transfer 
can be achieved with a simple tail vein injection.  As summarized in detail in Chapter 2, 
cardiac gene delivery systems basically fall into two major categories:  
1.  Transvascular Based Infusion Methods (i.e. access and transfer of AAV through 
capillary network vessels into myocardium) 
2.  Direct Myocardial Injection Methods (i.e. AAV directed right into myocytes through 
mechanical means)  
By physician standards, either of these categories can be considered minimally 
invasive with recent advances in image guided catheterization.  Also as outlined in 
previous studies, each specific technique within its respective category has its own 
advantages and disadvantages.  Transvascular methods, particularly antegrade 
intracoronary infusion, are still the mode of choice given for AAV products since they are 
routinely utilized in the clinic by interventional cardiologists.  These following 
requirements however have not been met completely with current transvascular 
techniques:  
(1)  Limit or stop leakage of AAV in the system and demonstrate greater gene transfer in 
the heart versus collateral organs  
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(2) Provide a solution for patients pre-screened with antibodies to AAV 
(3) Allow for global myocardial gene transfer with the highest possible efficiency within 
safety limits (e.g. not damage delicate vessels).   
In response to the problems with other transvascular methods described in (1) (2) and 
(3), our lab has developed the most sophisticated transvascular gene delivery system, 
molecular cardiac surgery with recirculating delivery (MCARD). (Figure 3.1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MCARD was inspired from the need to address these demands from larger 
organisms: higher cardiac specific transduction efficiency and to reduce systemic 
exposure.  MCARD is a dual perfusion system featuring complete cardiac isolation in 
situ, which recirculates a high concentration of AAV (i.e. cardiac circuit is bloodless) with 
complete protection from the system circulation.  It offers the unique ability to deliver 
Figure 3.1  MCARD, Advanced Dual Perfusion Transvascular 
Delivery Featuring Complete Cardiac Isolation 
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AAV through the much more favorable dimensions of coronary venous system, while 
also not working against the beating heart (e.g. CPB arrests the heart).  When 
comparing the MCARD vs. standard intracoronary infusion delivery methods with the 
same vector dose, greater than 400 fold higher expression was found in the MCARD 
animals with no immune response [16,17].  Despite unprecedented transduction 
performance and the ability to minimize the risk for collateral expression, it is clear that 
the cost of invasiveness of this system relative to catheter based approaches will limit 
MCARD as an option for many patients unless substantial risk/benefit is demonstrated.  
This type of delivery method would most likely be indicated for Class III-IV heart failure 
patients receiving adjunctive therapy.   
On the other hand, the direct methods by and large are seemingly confined to 
needle based systems.  Due to the simple ease of use, needle injection into heart 
muscle was the first method performed at the large animal and human scale for gene 
therapy.  Once the heart is exposed via thoracotomy or accessed via catheterization, 
control and selection over the desired injection sites is attainable.   
Despite this advantage, it is well known now that several critical disadvantages 
with AAV needle injections have resulted in a clear bias in favor of vessel infusion 
techniques.  The problems of scale and immunogenicity have seemingly placed a dead 
end with using this approach for a clinical application.  With regard to scale, this is 
evidenced by the fact that 4-5 injections were found sufficient to achieve beneficial 
therapeutic expression levels in small animal models (heart weight = 3-6 g) versus 
greater than 200 to achieve a substantially reduced expression profile in larger species 
(heart weight = 350 – 600 g).  Limitations in volume injection per site, the number of 
available sites to inject, and adverse immune reactions have been documented by 
various investigators [18].  Furthermore there is an often overlooked problem of 
58 
 
inadvertent systemic leakage most likely attributable to myocardial wall perforation 
during the injection process.  
Given the limitations of the most advanced transvascular and needle injection 
methods, there is a need for a direct viral vector cardiac specific delivery system 
that would offer greater myocardial gene transfer per injection.  Understanding the 
immune consequences as a function of delivery and vector selection has not been 
explored in detail.  The scope of this work seeks to expand both the methodology 
and delivery science of direct myocardial injection.   
Global Hypothesis:  We hypothesize that liquid jet injection technology can offer an 
alternative delivery platform with superior cardiac specificity competitive with 
intracoronary infusion and superior to needle injection.  In addition, evaluating the role of 
delivery profiles in the context of the host response with regard to delivery and vector 
selection can improve outcome.  Specifically, this work will test four hypotheses that are 
described in detail below.  The overall goal of the work is to obtain a better 
understanding of how to address both the problem of scale and immunogenicity 
associated with direct intracardiac injections, especially within the ischemic disease 
setting since this is the intended clinical application.  
Specific Hypothesis #1:  The mechanical liquid jet device approach can be optimized 
for a cardiac gene therapy application to maximize cardiac gene transfer as measured 
per myocardial cross sectional area, while reducing unwanted systemic exposure as 
measured by collateral liver.  
Specific Aim 1:  Define and optimize engineering parameters for the liquid jet 
injection device for the cardiac application in an acute rodent model and ex vivo 
large animal setting to define a safe, yet effective operating transfer ranges.  
Optimization is defined as in vivo tolerance whereby significant cardiac damage is 
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avoided, yet sufficient myocardial transfer is achieved suitably.  This aim will be 
achieved with ex vivo testing, quantitative fluid mechanics evaluation of the jet, and 
limited non-survival animals. 
Specific Hypothesis #2:  The mechanical liquid jet device approach will result in 
increased myocardial retention, cardiac specificity (i.e. heart transfer to collateral organ 
exposure), and wider range delivery area versus IM injection, while in the range of the 
best intracoronary delivery approach in a rodent model. 
Specific Aim 2:  Perform a two phase therapeutic delivery study to the beating 
heart in an acute rodent model to evaluate the liquid jet approach against 
traditional methods in practice.  The methods to evaluate against are: A.  Standard 
IM Injection B.  Non-selective Intracavitary Infusion C.  Intracoronary Infusion 
featuring Occlusion.   The first phase of the study will evaluate immediate retention 
following 10 minutes of delivery in a non-survival model followed by a repetitive second 
phase study using AAV9.GFP marker therapy in the normal heart.  
Specific Hypothesis #3:  Liquid jet injection will achieve efficacious therapeutic AAV9 
mediated S100A1 gene therapy over standard IM injection, while minimizing collateral 
organ exposure and minimizing the immune host responses.  It is argued that a 
disperse, more homogenous expression pattern with the same magnitude range as IM 
delivery will yield greater efficacy.  
Specific Aim 3:  Perform a chronic ischemic infarction 10 week model study to 
evaluate delivery of a single dose 1.2 x 1011 Vgp of ssAAV9.S100A1 vector 
featuring a head to head format comparing liquid jet vs. IM injection.  Outcome 
assessment will be a comprehensive, compiled data set of: (1) AAV9.S100A1 genome 
copy detection (2) Quantitative proteomic S100A1 (3) CD38 Histological marker of 
Immune activation in cardiac tissue (4) Serological markers of global inflammation via 
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cytokine panel.  In this aim there will be 4 assigned groups: A.  IM Injection with Saline 
B.  Liquid Jet injection with Saline C.  IM injection ssAAV9.S100A1 and D.  Liquid Jet 
injection ssAAV9.S100A1     
Specific Hypothesis #4:  Altering therapeutic vector and delivery strategy can 
significantly alter outcome and in vivo performance.   
Specific Aim 4:  Two key testing parameters that may significantly alter host 
responses are offered: A.  Using self-complementary double stranded vector 
equivalent B.  Co-delivery of anti-inflammatory drugs to minimize host response 
during initial delivery phase.  The first part of this aim will be achieved by a simply 
repeat of the animal protocol in Aim#3, however this time with a more potent double 
stranded or self complementary scAAV9.S100A1 vector.   The second part explores a 
theoretical drug/gene combination approach with controlled release formulations in vitro. 
3.2 Overview of Research and Impact 
 
The motivation for advancing the topic of improving direct delivery of AAV 
mediated gene products is an important research discipline, especially since enrollment 
in cardiac gene therapy trials have been and are expected to increase in the near future.  
Despite significant advancements in the field overall, most of the attention in gene 
therapy is geared toward vector engineering and target identification but not delivery.  
Chapter 1 outlined all of the key therapeutic mechanisms, targets, and rationale for AAV 
mediated gene therapy, whereby S100A1 presents with significant potential to translate 
in future clinical trials.  Chapter 2 provides a thorough review and key insightful 
conclusions on state of the art cardiac gene transfer systems and concepts within the 
context of clinical applications.                                               
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This research seeks to provide a clear, yet comprehensive approach to 
designing, building and testing a new direct cardiac injection technique as well as 
identify key delivery variables with existing systems in its evaluation.  Chapter 4 
summarizes the rationale and technical development phase of the needleless liquid jet 
injection concept.  Chapter 5 is the heart of this work, which characterizes the refined 
concept in both an acute retention and AAV mediated marker gene expression model.  It 
is here where the technology is evaluated against existing methods with key insights 
offered for both future development of cardiac gene delivery applications.  Chapter 6 
presents a comparative head to head assessment of liquid jet injection against standard 
IM delivery in a chronic ischemic myocardial infarction model featuring the 
ssAAV9.S100A1 therapy.  The translational aspects of direct cardiac delivery are 
thoroughly evaluated in terms of outcome, whereby cardiac performance, transduction 
efficiencies and host response endpoints are paramount.   
From there, two novel therapeutic concepts are explored to improve direct 
cardiac delivery: (1) The use of self-complementary (scAAV9.S100A1) and (2) Co-
delivery of anti-inflammatory drugs with AAV products to increase efficacy.  Chapter 7 
provides a complete pilot study assessment with the same methodology in Chapter 6 to 
explore whether or not a different vector with S100A1 may result in an improved 
outcome.  Chapter 8 conceptualizes a forward thinking, theoretical concept of a 
controlled release drug/gene combination approach with a feasibility test in vitro.  Finally, 
Chapter 9 capstones key points for future cardiac gene therapy applications with respect 
to delivery science.  The work ultimately advances the body of knowledge with the aim to 
improve outcomes in cardiac gene therapy, specifically when using direct administration 
routes. 
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CHAPTER 4 
 
Needleless Liquid Jet Injection for Cardiac Gene Therapy:  
From Concept to Application 
 
4.1  Introduction 
 
The previous chapters provided a solid foundation describing the rationale for a 
new direct injection cardiac gene delivery method.  In this chapter, we briefly review the 
core science of ballistic delivery, its track record in similar applications, and the executed 
development path in this dissertation.  Needleless liquid jet injection is characterized as 
a ballistic delivery based approach.  The technology was originally developed in the 
early 1960’s and applied for these simple medical applications: mass routine 
vaccinations, administration of local anesthetics, tuberculin testing and dermatology 
treatments of minor skin lesions.  Closely related, the “gene gun” concept has a solid 
foundation in molecular biology.  In this chapter, the literature highlighting key results is 
briefly discussed in Section 4.1.1 below for the gene gun, while section 4.1.2 delves into 
the related, but fundamentally different liquid jet application.  Finally beta testing and 
modification of the concept for translation into the cardiac anatomy for a gene therapy 
application is detailed in sections 4.3 and 4.4, respectively.   
4.1.1  Gene Gun Ballistic Delivery Principles 
 
Particle bombardment (also called Gene gun or ballistic DNA transfer) utilizes 
heavy metal particles introduced with a high velocity pressurized inert gas into the target 
cell (Figure 4.1).  
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Naked DNA can deposit onto these particles, and after entering the cell they are 
gradually released. Acceleration can be achieved by a high-voltage electric spark or a 
helium pressure gun. For optimal gene expression the following parameters have been 
taken into account: (1) the properties, density and sizes of gold particles for 
bombardment; (2) the DNA doses, and (3) the discharge voltage for optimal gold 
particles penetration. Using a sub-microgram amount of DNA per bombardment, 1000 to 
10,000 copies of DNA can be delivered to each target cell [1,2]. 
The fundamental principal of the gene gun is the transfer of DNA-coated particles 
into the cell through the holes in the plasma membrane resulting from the initial injection. 
Some authors believe that it may be possible to employ a gene gun to transfect cells that 
are relatively resistant to other delivery systems [3]. In this method DNA or RNA adhere 
Figure 4.1 Gene gun delivery is demonstrated featuring gold 
particles coated with vector DNA being accelerated and dispersed 
at the target tissues 
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to metal particles (gold or tungsten) then the DNA-particle complex is accelerated and 
shot into the target tissue. Uncoated metal particles could also be delivered through a 
solution containing DNA surrounding the cell thus picking up the genetic material and 
proceeding into the living cell. 
Despite some interest in translation, the primary problem with the gene gun is the 
technical maintenance cost in addition to complexing vectors to relatively large metallic 
particles.  Given the stability and formulation advantages of modern viral vectors, 
ballistic delivery of active therapeutic is more cost effective through liquid jet delivery. 
4.1.2  Liquid Jet Delivery Principles 
 
A ballistic method jet injection is performed using a high-speed pressurized gas, 
usually CO2 but the driving gas can be changed per application. The injection is 
comprised of piercing center and surrounding microjets, whose effects create pores in 
cellular membranes to facilitate intracellular gene transfer (Figure 4.2).  
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The penetration power depends on three factors: the applied pressure of the gas, 
the dispersion factor of the jet as a function of the nozzle bore and the tissue‘s 
mechanical properties [4]. Levels of gene expression by jet injection were found to be 
50-fold higher than by conventional needle injection in one preliminary study [5]. The jet 
injection gene transfer is usually well tolerated without side effects provided that the 
settings are optimized. This method is described only for non-viral based techniques of 
gene transfer and uses a high pressure.  
Macromolecules of varying chemistries and properties can be delivered ranging 
from stable active compounds, DNA and to a lesser degree proteins.  Pressure used is 
typically less than 3-4 bars with resultant velocity profile of the droplets ranging from 100 
m•s-1 to 300 m•s-1. The velocity of the fluid in the jet injection contributes to the 
Figure 4.2 Liquid delivery is demonstrated featuring DNA vector 
suspended in a liquid formulation being accelerated and dispersed 
at the target tissues 
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distribution in the tissues, whereas the diameter of the jet and the injected volume limit 
the penetration depth [6]. The efficiency of this method depends on nozzle diameter 
(150-300 µm), velocity of the liquid jet and distance between the nozzle and surface of 
the tissue [7].  
The penetration of the injected molecules inside the cells subsequently results in 
direct uptake, maximizes bioavailability in the tissue environment for additional 
molecules, and worst case inadvertently reaches off target organs via systemic 
circulatory penetration. The high pressure of the jet creates a hole in the tissue surface; 
the depth of this hole is increased due to the accumulation of fluid.  The use of 
intramuscular jet injection of DNA combined with electroporation was demonstrated to 
be feasible in a mouse model [8].  We and others could not find publications on the 
applications of this method for cardiac gene therapy [9]. 
4.2  Device Description & Specifications 
 
The handheld needleless liquid jet (DERMOJetTM) was purchased from Robbins 
Instruments (Chatham, NJ).  The device itself was invented by Dr. A. Krantz in France 
with the medical device manufacturer Akra DermoJet (Pau, France).  The device (Figure 
4.3) is comprised of a stainless steel design with polycarbonate reservoir with 
dimensions: 8 ounces (weight), 6.5 inches (length), and 11/16th inches (Diameter) 
injector head.  The exit orifice is 0.0079" (32 gauge; 235µm) diameter in a jewel shape 
design.  The size transmission limit is crystalline particles up to 200 microns. 
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The device is actuated by an internal spring mechanism which drives a piston 
that subsequently accelerates a fixed volume fluid load.  Injection is executed by a 
loading lever mechanism which sets the spring lock element, while the push button 
trigger releases for the acceleration of drug through the orifice.  The ejection orifice 
features an internal jewel shaped configuration for a dispersive effect.  The ejection 
volume is fixed at 100µL at the ideal retention limit of most tissues.  Various mechanical 
components in the device are tunable, most notably the spring and orifice 
characteristics. 
4.3  Beta Testing 
4.3.1  Manual Injection 
 
My first experience testing the device after priming was to assess both the level 
of penetration and inflammatory response first hand.  At the manufacturer’s settings, I 
injected sterile saline into my palm approximately 0.5cm above the skin surface.  An 
immediate, sharp burst provided transfer beneath the dermal layer with a small pinhole 
entrance site marked by spot bleeding.  The inflammation and pain from the injection 
peaked at 24 hours, and diminished after 48 hours.  It was determined that if left at this 
Figure 4.3 The DermoJet Needleless Liquid Jet Device 
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current setting transfer would not be ideal since the piercing jet did not provide adequate 
distribution but only a deep penetrating bolus in a locale.  Subsequent manual tests at 
greater distances revealed much less piercing, but it was interesting to note significant 
fluid retention under the surface of the skin with seemingly no pain from the injection was 
observed.  This transfer distance whereby retention was achieved at the lowest level 
was about 24 inches from the nozzle. 
4.3.2  Explanted Rodent Hearts 
 
Methylene blue dye was loaded into the device and fired directly on the surface 
of explanted rodent myocardium samples, which are generally 1-2 cm thick transmurally 
across the left ventricle.  A clear “jet track” line was noted, with less than 1mm 
distribution from it.  It was noted that retracting the device at 2 inch increments resulted 
in more surface coverage and in some cases complete penetration.  At greater distances 
this effect was erratic and a “spray” behavior was noted indicating only superficial layer 
penetration.  Given that the cardiac gene therapy application requires both maximal 
transfer without damage and consistency, several modifications to the device were 
needed for application.     
4.4  Device Modifications for the Cardiac Gene Therapy Application 
 
Following the very early experiments described previously, it was readily 
determined that optimizing both the pressure and distance settings would permit ideal 
transfer within safety limits.  Very early acute model rats suffered severe cardiac 
bleeding events and or arrest with distances less than 8 inches at the manufacturer 
settings.  Safety limits were defined as tolerance of at least 6 consecutive 100µL 
injections without significant EKG changes or morbidity.   
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4.4.1  Pressure and Velocity Optimization 
 
The original experiments indicated that the device as is would not be suitable for 
any cardiac application since the potent jet was piercing with high force and 
simultaneously providing limited distribution.  Advancing to distances greater than 24 
inches from the target organ were required to remotely obtain anything of value in terms 
of dye transfer, thus it was imperative to modify the settings.  Since the device was 
actuated by a spring, we worked with the manufacturer to cut the constant down by 80% 
of the original length.  The original jet velocity was measured and confirmed by the 
factory at just over 330 m/s out of the nozzle.  The modified device yielded roughly 110 
m/s exit velocity with a 100-200kPa driving pressure range.  As a means to control the 
distance between the exit nozzle and the target, the device was mounted to an arm 
apparatus as shown in (Figure 4.4). 
 
    
Figure 4.4 Mounted Device to Control and Optimize Delivery 
Distance 
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CHAPTER 5 
 
Needleless Liquid Jet Injection: Validation Studies in Normal Hearts 
 
Adapted From: Fargnoli AS, Katz MG, Williams RD, Margulies KB, Bridges CR.  A Needleless 
Liquid Jet Injection Delivery Method for Cardiac Gene Therapy: A Comparative Evaluation of the 
Novel Approach Versus Standard Routes Demonstrates Enhanced Therapeutic Retention and 
Extensive Cardiac Specific Gene Expression.  Submitted to Human Gene Therapy Jun 10th 2014. 
5.1  Introduction: 
 
Heart failure (HF) remains a significant burden to the global healthcare system 
with annual costs exceeding $32 billion [1].  Besides the limited number of donor organs 
available for transplantation, current medical and device therapies have not significantly 
reduced disease burden.  Through careful scientific investigation and clinical 
development, gene therapy has emerged as a potential strategy to directly treat myocyte 
dysfunction at the molecular level.  A number of genes have been identified to impact 
these critical disease pathways - which if expressed robustly in the myocardium - 
enhance contractility, promote survival, and in some cases completely reverse chronic 
HF [2-4].  Adding to this momentum, novel microRNA and angiogenesis targets 
promoting genetically induced regeneration are accelerating through various 
developmental stages [5,6].  Therefore, the recent basic scientific progress has 
bolstered an already thriving pipeline of viral mediated gene therapeutics and it is 
expected that new clinical trials will be forthcoming.   
A pivotal milestone for the cardiovascular gene therapy field was the successful 
launch of the Calcium Up-regulation by Percutaneous Administration of Gene Therapy in 
Cardiac Disease (CUPID) trial featuring adeno-associated viral vector (AAV) encoding 
the contractility enhancing sarcoplasmic endoreticulum ATPase (SERCA2a) gene [7].  
This key trial has provided reason for cautious encouragement as favorable results were 
achieved in the high dose group versus placebo [7,8]. Despite these encouraging results 
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in the high dose group, achieving efficacy with lower doses remains a concern given that 
no improvement was found in patients receiving less than the maximum 1 x 1013 
DNAase resistant viral particles (vp) [8].  Delivery efficiency is the main concern, 
whereby higher doses are needed to achieve sufficient expression levels, which 
inherently increases the risk for adverse events.  Therefore, more efficient delivery 
systems would most likely improve clinical outcomes.        
 The administration route currently in clinical trials is antegrade intracoronary 
infusion, given its safe and effective implementation in clinical practice [9].  From a 
therapeutic AAV transfer perspective however, standard infusion approaches are 
critically limited by these factors: (1) Prohibitive physical barriers (e.g. pre-capillary 
sphincters and endothelial barriers) preventing viral vector diffusion into the interstitial 
compartment [10] (2)  Plaques and inflammatory elements in primary vessels, which are 
common in HF patients with advanced coronary disease (3) neutralizing antibodies and 
blood components which limit viral particle bioavailability [11] (4) Inadvertent systemic 
exposure via general circulation and finally (5) Exclusion of many patients seropositive 
for AAV.  Sophisticated modifications to percutaneous catheter infusion (e.g. single or 
concomitant retrograde/antegrade balloon occlusion systems [12] and even surgical 
closed loop recirculation systems [13]) have been advanced recently to increase 
efficiency at the cost of complexity.  Some of these systems may be implemented in 
future trials, however most would either exclude high risk patients or impose additional 
safety concerns.           
 An alternative to infusion methods in an effort improve efficiency in terms of 
cardiac specificity is direct myocardial delivery.  Direct injection methods circumvent the 
blood and anatomical barriers by directly administering product into the myocardium, 
which additionally offers the advantage of precise site selection.  For this reason direct 
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intramuscular (IM) injections were attempted with adenovirus in the very first series of 
angiogenesis trials [14], but yielded poor results.  Cited problems with this route are 
limited distribution per site and inflammatory responses [15,16].  There has been little 
work to date to improve direct myocardial delivery applications despites these concerns 
and limitations.        
In this study we present a novel approach to improve direct cardiac gene delivery 
using a needleless liquid jet methodology.  Similar ballistic delivery methods were 
utilized in very early DNA transfection studies via gene gun [17,18], but to date none 
have attempted delivery of AAV therapeutics as a potential clinical strategy.  The liquid 
jet application is essentially a device concept that accelerates and disperses the 
therapeutic at a targeted myocardial site.  The core hypothesis offered is that this 
approach with optimized settings could result in: increased therapeutic retention in the 
initial delivery phase, achieve significantly more total myocardial expression per dose , 
and in addition yield a more homogenous profile around the injection site.  Overall, this 
would increase efficiency in terms of transduced muscle per delivery site unit and 
decrease the likelihood of an immune response.   
This proof of principle study optimizes the needleless liquid jet strategy for 
cardiac applications and evaluates the method in a series of rodent experiments. In each 
set of experiments, the liquid jet method is compared with three existing methods:  
Intramuscular injection (IM), Single pass LV intracavitary infusion (LVIC) infusion, and 
LV intracavitary infusion with aortic and pulmonary artery occlusion (LVIC-OCCL).  In the 
first series of experiments we evaluate each methodology’s immediate myocardial 
retention profile in an acute model.  In the second series we utilize a highly cardiotrophic 
AAV9.EGFP marker gene construct to simulate a more realistic long term gene 
expression scenario.  Finally, a preview of the needleless liquid jet method’s translational 
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potential in the large animal setting is performed with post-harvest specimens.  Key 
translational aspects for direct injection and infusion approaches are then discussed for 
future directions to improve cardiac gene delivery technologies.       
5.2  Materials and Methods: 
 
Animal Care and Handling 
40 rats were procured from Charles River Laboratories and handled in accordance with 
IACUC guidelines at the Cannon Research Center at Carolinas Healthcare System.  
Normal Sprague Dawley rats (males, weight 300 g) were obtained for all experiments. 
Needleless Liquid Jet Injection Device Optimization & Specifications 
A DermoJetTM liquid jet device (Robbins Instruments, Chatham NJ) was acquired and 
modified for cardiac delivery applications.  The spring actuator length was reduced by 
80% to 1.9 cm, which resulted in a significant driving power reduction.  A super speed 
camera (Zeiss International, Thornwood NY) at the University of Pennsylvania Complex 
Fluids Laboratory was used in a custom analysis suite to quantify jet fluid exit velocity 
and to compute estimated driving pressure.  The nozzle jet velocity was measured at 
110 m/s based on a 30,000 images per second capture rate.  The driving pressure 
ranged from 150 – 250 kilopascals (kPa).  Prior to the modification, the factory setting 
results were 330 m/s velocity at greater than 550 kPa.   
The next key parameter to optimize for a surgical application was the injector head 
distance normal to the target cardiac plane.  To execute, the pen configuration injector 
was mounted to a stainless steel arm apparatus secured to a solid base.  For alignment 
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with the cardiac targeted surface plane, an optical system consisting of a field laser and 
digital level were utilized in conjunction to ensure accuracy between injections. 
The safe liquid jet delivery distance range was determined by performing a limited 
number of acute studies with methylene blue dye injection.  Safety criteria were defined 
as tolerance of 6 consecutive projected needleless injections without visible bleeding 
and EGC changes.  Confirmation of hits was validated via marks by surface retention of 
dye.  The optimal distance range was determined between 8-10 inches (i.e. nozzle tip to 
heart surface).  This range was found effective where sufficient dye was retained 
transmurally, but no incidence of major cardiac damage was observed.  
Rhodamin B Dye Preparation for Acute Studies 
Rhodamin B Dye (Sigma Aldrich, St. Louis MO) was prepared in (50 µg/mL) working 
aliquot concentration.  Rhodamin B dye was selected based on easy formulation and 
high performance in muscle tissue types for the acute retention purpose.   
AAV9.EGFP Viral Vector Production for Survival Studies 
All Recombinant AAV9.EGFP was sourced from the University of Pennsylvania Vector 
Core (Philadelphia, PA).  Briefly, vector production, harvest, purification and testing were 
done from cell lysates by the Penn Vector Core. The recombinant vector used in this 
study contains an AAV serotype-9 viral capsid and a single strand: ~4.5-kb DNA 
containing the EGFP marker gene driven by a cytomegalovirus immediate-early 
promoter/enhancer, a hybrid intron, and a bovine growth hormone polyadenylation 
signal.  Manufacturing process details can be found 
(http://www.med.upenn.edu/gtp/vectorcore/).  Following production, viral preps were 
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pooled from individual lots and aliquoted in sterile vials each containing a dose of 2 x 
1011 vp in 500µL volume. 
Acute Model Protocol:  Retention of Rhodamin Dye 
The endpoint selected for retention in the cardiac cross sections was % myocardial area 
positive for Rhodamin B dye level shortly after cardiac delivery.  Since global, 
homogenous distribution is the ideal outcome for contractility genes, this measure 
essentially determines what areas of myocardium are accessed per route.  
All rats were anesthetized with ketamine IM, intubated and placed on a Harvard 
Apparatus ventilator and maintained with isoflourane 1-3%.  A left thoracotomy was 
performed and the pericardium excised to expose the beating heart.  Each animal was 
then assigned to 1 of 4 acute delivery groups (n=6 each) [IM Injection, Needleless Liquid 
Jet, LVIC-OCCL, LVIC)] to receive a single 500µL fixed dose Rhodamin B Dye.  A 10 
minute waiting period commenced after delivery.  The heart was then harvested and 
sectioned immediately following. 
Delivery Route Descriptions 
(Figure 5.1) provides a conceptualized illustration of all 4 cardiac delivery approaches of 
IM Injection, Needleless Liquid Jet injection, Left ventricular single pass infusion (LVIC) 
and Left ventricular infusion with concomitant occlusion of the aorta and pulmonary 
vessels (LVIC-OCCL) applied in the model studies.   
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The technical delivery details for execution were as follows: 
IM Injection 
A 1 mL 30 gauge syringe was loaded with the 500µL of volume.  Injection sites on the 
left ventricular apex, anterior wall, and lateral wall were marked with a surgical pen.  Two 
injections were performed in the mid-ventricular plane for each of the anterior and lateral 
walls, with a single injection in the apex for 5 total injections.  Injections were spaced 
about 5 mm.  
Needleless Liquid Jet Injection 
Figure 5.1.  Cardiac Gene Delivery Methods (A) IM Injection (B) Liquid Jet 
Injection Concept (C) Intra left ventricular cavitary Infusion [LVIC] (D) LVIC-
OCCL Infusion featuring dual occlusion of aortic and pulmonary vessels 
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500µL delivery volume was loaded into the chamber with a residual capacity of at least 
200µL additional to ensure the 5th shot maintained the same kinetics as per DermoJetTM 
manufacturer instructions.   A digital level and laser was used to ensure adequate 
degree and plane alignment with the middle left ventricular plane.  Five separate shots, 
each containing 100µL, were fired perpendicular to the LV surface.  Hits were confirmed 
by detection of pinhole piercing on the epicardial surface with surrounding coloration 
changes.  
LVIC-OCCL Infusion 
Silk suture was placed in two locations, the proximal aortic arch and the left pulmonary 
artery.  Following, a 16 gauge needle introducer was used to catheterize the left ventricle 
from the apex. A catheter was secured in place with a syringe containing the 500µL of 
therapeutic.  Just prior to infusion, concomitant occlusion of both snares with slow 
infusion was conducted over a 10 second period.  The occluding sutures were then 
released after the 10 second period. 
LVIC Infusion 
A 16 gauge needle introducer was used to catheterize the left ventricle from the apex. A 
catheter was secured in place with a syringe containing the 500µL of therapeutic.  Slow 
infusion in the left ventricle over 10 seconds was performed without interruption. 
Survival Model Protocol: Expression Profile Following Delivery of AAV9.EGFP 
All rats were anesthetized with ketamine IM, intubated and placed on a Harvard 
Apparatus ventilator and maintained with isoflourane 1-3%.  A left thoracotomy was 
performed and the pericardium excised to expose the beating heart under aseptic 
79 
 
conditions.  Each animal was then assigned to 1 of 4 delivery groups (n=4 each) 
following the same delivery protocol for [IM Injection, Needleless Liquid Jet, LVIC-OCCL, 
LVIC)] groups.  The therapeutic was a single 500µL fixed dose 2 x 1011 (vp) of single 
stranded adeno-associated virus encoding green fluorescent protein (ssAAV9.EGFP).  
Following delivery, the incision was closed and each animal was recovered and 
monitored to 6 weeks.  At the 6 week peak expression endpoint, the harvest 
commenced. 
Tissue Harvest and Cross Section Preparation 
For each Rhodamin Dye animal, middle and basal left ventricular cardiac sections and a 
single liver cross section was acquired.  Similarly, for each AAV9.EGFP therapy animal, 
the left ventricle was sectioned in 2 plane regions: Middle and Basal regions to assess 
the degree of AAV mediated EGFP dispersion per route.  A single liver section was also 
acquired.  All cross sections were snap frozen in OCT.  Ten micron sections were cut on 
a cryostat and mounted on glass slides for further analysis.  
Immunohistochemistry Staining for EGFP Detection 
Tissue from rats receiving the ssAAV9.EGFP was stained with a rabbit polyclonal Anti-
GFP antibody (Abcam ab-290). Bound antibody was detected with an ImmPRESS anti-
Rabbit kit (Vector Labs MP-7401) and visualized with ImmPACT VIP chromagen (SK-
4605). Cells were counter stained with methyl green.   
Cross Section Image Capture  
Images of the entire cross section were obtained using an Olympus BX40 microscope 
with a DP72 camera and CellSens software with fixed acquisition settings at 4 x 
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magnification.  Multiple images at 4x were stitched to reconstruct a complete 2D cross 
section for heart and liver per animal per region.  Slides of unstained cross section tissue 
from rats receiving Rhodamin B were imaged under 540nm fluorescence.  Basic light 
microscopy was used with the same approach as described above for the EGFP 
sections, however without fluorescence as positive GFP detection was indicated by 
brown-purple stain hues.   
Imaging Analysis Protocol 
Following acquisition, all myocardial and liver cross section images were standardized 
with a custom Java programmed macro in ImageJ software to apply uniform brightness, 
contrast and sharpness settings.  Quality control checks of pixel density, resolution, and 
image size were done prior to analysis. All images were saved into Grayscale 16 bit 
format and blinded for analysis. 
Cardiac Cross Section Analysis 
Each cross section was loaded into ImageJ.  For the Rhodamin B fluorescent images 
only, each cross section was first subtracted from saline control templates to minimize 
the background effect.  The Iterative self-organizing data analysis technique (ISODATA) 
algorithm was utilized to determine the threshold for positive therapeutic (Rhodamin B or 
EGFP positive pixels).  Briefly, the algorithm mathematically derives the statistically 
validated threshold based on the normal distribution sampling of all pixel intensity values 
and arrives at an optimal detection value [19]. 
Following ISODATA identification, the 16 bit Grayscale images were converted into 
binary, whereby all pixel values above the computed threshold were scored positive.  
Two myocardial contours were drawn, one for the outer epicardial border and another for 
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the inner endocardial surface.  The percentage positive therapeutic area was defined as 
follows for the cross sectional myocardium: 
% Score =  # Postive Therapeutic Pixels# Pixels in Outer Area − # Pixels in Inner Area × 100 
Liver Cross Section Analysis 
The cross sectional images were handled the same as described above, however 
scoring was focused on therapeutic intensities in the liver to gauge systemic uptake.  
First, as in above the percentage positive liver area was determined.  Second, the 
grayscale Integrated density was determined by multiplying the gray value (1-255) for 
each pixel: 
� Gray Value x Pixel UnitTotal (+) Pixels
1
 
The final exposure score was computed as the mean gray value of all positive pixels 
determined from the algorithm (Integrated Density/Total Positive Pixels) X % affected 
area. 
Both the Rhodamin and EGFP populations were evaluated in two separate left 
ventricular planes, middle and basal respectively.  For simplicity, an overall score 
combining both planes was used to characterize the Rhodamin model.  Similarly, an 
overall score was compiled for the EGFP groups by combining both LV sections for a 
total cardiac score, but presently separately to assess total myocardial coverage. 
Needleless Liquid Jet Evaluation in Explanted Ovine Myocardium 
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To obtain a basic translational perspective on the optimized device, a basic methylene 
blue injection experiment was executed with post-harvest ovine left ventricle.  15 liquid 
jet injections each containing 100µL were fired from the device setup at a 4 inch distance 
to account for the greater thickness.  Qualitative epicardial and endocardial wall 
penetration as well as coverage were observed. 
Data Analysis and Statistics 
All data are reported as mean ± SEM, per delivery group in each respective study.  
Single way ANOVA was used to determine difference across all 4 delivery groups.  T-
testing with Bonferroni correction was used for comparison between multiple groups. 
 
5.3  Results: 
 
Rhodamin B Dye Acute Model Analysis 
(Figure 5.2) illustrates the typical distribution profile per method from the Rhodamin B 
retention analysis.  The images demonstrate both the degree of myocardial coverage 
and regional cross section peak intensities (e.g. mild red to hot yellow) as a function of 
delivery route.  These results were consistent between subjects per group; supporting 
the claim that delivery route had a major influence on retention profile.   
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IM injection resulted in highly focal, heterogeneous cardiac delivery with a moderate 
degree of systemic exposure.  By comparison, the liquid jet group demonstrated a more 
disperse, yet homogeneous pattern with higher intensities along the epicardial surface, 
but none has high as in the IM sections.   
Conversely, the infusion groups demonstrated that increased retention is driven by 
induced pressure and residence time as there was a dramatic difference between the 
LVIC-OCCL and LVIC groups. 
Quantitatively, the Liquid Jet [52±6] % (+) myocardial area group performed in a similar 
range with the LVIC-OCCL group [58±5] % (+).  Both the Liquid Jet and LVIC-OCCL 
methods resulted higher distribution levels (p<0.01) compared with the IM [31±8] % (+)  
and LVIC [35±5] % (+)  (Figure 5.3A).  All groups presented with varying degrees of 
Figure 5.2.  Acute Study Results Per Group (Left to Right) IM Injection, Liquid 
Jet Delivery, LVIC-OCCL and LVIC Infusion.  Rhodamin B dye retention 
demonstrated in myocardial cross sections (top) and systemic exposure in the 
liver sections (bottom) 
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systemic liver exposure, (Figure 5.3B) IM [37±7] arbitrary Rhodamin Units (AU), Liquid 
Jet [26±5] (AU), LVIC-OCCL [45±7] AU and LVIC [46±7] AU.  The Liquid Jet group was 
the most cardiac specific. 
When comparing direct (i.e. combined IM/Liquid Jet) versus infusion (i.e. combined 
LVIC/LVIC-OCCL), higher systemic liver exposure (Figure 5.3C) [46±5] AU as 
compared with direct injection methods [31±4] AU was found p<0.05.    
 
   
 
Figure 5.3.  Acute Model Results: (A) Liquid Jet and LVIC-OCCL demonstrate 
significantly greater retention versus both IM and LVIC groups p<0.05 (B)  All 
groups result in systemic exposure (C) Direct methods, IM and Liquid Jet 
combined demonstrate lower overall exposure versus Infusion methods or LVIC-
OCCL and LVIC combined 
85 
 
AAV9 Mediated EGFP Expression Analysis at 6 Weeks Post Delivery 
Despite the profound size (Rhodamin dye 20-50Da; AAV 4 x 106Da), , diffusive 
properties and functional differences between dye and AAV, it was found that the overall 
distribution patterns for each delivery group nearly matched those results found in the 
acute study.   
A key number of findings were determined, specifically with respect to the EGFP 
distribution throughout the LV anatomy, indicative of methodology characteristics.  
(Figure 5.4) depicts representative whole left ventricular cross sections per group (i.e. 
higher basal and lower middle LV plane regions), whereby GFP detection is indicated 
with (brown/purple) stain while white/blue regions are devoid of any detectable 
expression.  The results are summarized by group as follows: 
IM Injection Group 
The GFP distribution was localized around the primary injection sites, but in comparison 
to dye results the size and bioactivity of AAV permitted greater myocardial coverage in 
the middle region.  The middle left ventricular region score was significantly higher 
[46±2] % (+)   than the basal region [13±12] % (+)   p<0.05.  This difference was most 
likely attributable to the consistent application of AAV into the middle left ventricular 
zone. Based on this difference, it is likely that not much product diffuses into regional 
distances beyond the site of injection.  The GFP systemic liver exposure score was 
relatively high at [71±10] AU.     
Liquid Jet Injection Group 
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The needleless jet offered a robust, yet homogenous pattern of GFP expression with 
nearly equal levels in the basal and middle left ventricular sections indicating the jet 
profile’s dispersive effects per shot.  The scores were [54±8] % (+)   in the middle and 
basal [56±9] % (+) regions.  The intensity was generally greatest in the epicardial 
regions of site impact, although significant expression was found in the remote posterior 
wall regions indicating complete myocardial penetration.  Moreover, the systemic liver 
score was low at [27±3] AU.    
LVIC-OCCL Infusion 
This route offered the highest degree of expression in terms of both intensity and 
distribution of cross sectional GFP coverage.  The score in the middle left ventricular 
was the highest at [71±6] % (+).  The basal region also scored high [50±14] % (+) and 
presented with a homogenous pattern.  These model results recapitulate the importance 
of driving local pressure and residence time to maximize delivery through the coronary 
anatomy. 
LVIC 
The difference between expression levels between the anatomical regions was the most 
dramatic here, with the middle region scoring [41±6] % (+)   while the basal region [5±3] 
% (+), p<0.05.  These results suggest that very little retention in remote areas is 
achieved without increased pressure and residence time.   
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Figure 5.4.  Left Ventricular Cross Section GFP Expression Distribution Per 
Delivery Method.  Top to Bottom, IM Injection, Liquid Jet, LVIC-OCCL and LVIC 
AAV9 groups.  Expression profiles presented in the Middle and Basal LV 
sections (left to right) per group with composite % area transfected with GFP. 
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Overall when combining both the middle and basal regions, AAV mediated GFP delivery 
in the heart was more effective with the Liquid Jet [54±5] % (+) and LVIC-OCCL [60±8] 
% (+) methods, both p<0.05 as compared with IM [30±9] % (+)   and LVIC [23±9] % (+) 
(Figure 5.5A).  The Liquid Jet group was the most cardiac specific resulting in a lower 
liver score versus the other 3 groups, p<0.05 (Figure 5.5B). 
 
 
 
Ex Vivo Ovine Myocardial Liquid Jet Injections 
The selected epicardial injection distance for the proposed clinical equivalent was 
determined at 4 inches.  This strike distance was found optimal since maximum 
myocardial coverage and retention transmurally, but not through the endocardium 
Figure 5.5.  AAV9.GFP Survival Model Study Results.  (A) Liquid Jet and LVIC-
OCCL groups demonstrating greater overall expression versus IM and LVIC 
groups, p<0.05. (B) Liquid jet group presented with a much lower GFP liver 
exposure score compared with the other groups, p<0.05 
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surface (i.e. complete LV wall retention).  The figure below depicts primary impact sites 
shown on the epicardial surface (Figure 5.6A) and transmural retention shown from the 
reverse endocardial surface (Figure 5.6B).  As expected the greater scale size factor 
imposes concerns for direct delivery. 
 
 
 
5.4  Discussion: 
 
Achieving sufficient myocardial expression through any selected vector, dose 
and delivery route configuration is balanced by the clinical implementation risks [20,21]. 
As demonstrated in this study, the choice of delivery method alone can significantly 
impact the type of cardiac distribution and collateral organ expression profiles realized 
over time.  The ideal cardiac gene delivery method would facilitate sufficient transduction 
levels in as much myocardium possible effectively achieving global rescue with the 
Figure 5.6.  Ex Vivo Ovine Methylene Blue Results for translational potential of 
needleless liquid jet injection (A) Injection points located on the epicardial surface 
demonstrate the jet’s local, yet dispersive profile along the adjacent surface contours 
and (B) robust transmural delivery retained per injection site within the endocardial 
surface. 
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minimum required dose.  The resultant expression profile would also have to be 
sustainable over time and not induce host responses.  Fundamentally this study 
demonstrates that route efficiency is paramount in achieving maximum myocardial 
expression, but also offers insight into distribution profiles.  The initial delivery is largely 
influenced by physical transport principles (i.e. pressure, residence time, dispersion 
trafficking, mechanical resistance) that are independent of AAV characteristics and 
therefore must be considered with any given delivery strategy.  AAV serotype and capsid 
engineering must also be considered within these limits in obtaining desired expression 
patterns. 
Two unresolved problems with direct delivery wherein the needleless liquid jet 
approach may be beneficial are to improve initial therapeutic retention and diminish 
subsequent host responses associated with highly focal expression.  With regard to the 
first problem, other studies have confirmed that a significant portion of the IM injection 
volume is either lost into the systemic circulation or back through the injection site itself 
[22-24]. This finding likely explains the variable results achieved between patients, since 
the beating heart represents a challenging dynamic target featuring accentuated 
changes in the structural wall thickness during injection [25].  Our results in this study 
demonstrated that the IM method consistently had a higher degree of systemic delivery 
as exemplified  in the liver versus the liquid jet method.  Our application of liquid jet 
technology demonstrates that a tunable pressure/dispersion profile can promote 
maximally retained therapeutic per unit volume across a wider surface area within a 
range of given thickness.  With a more sophisticated instrumentation setup, it would be 
possible to actively adjust driving parameters with real time system feedback and or 
image guidance.  
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The second and more challenging problem to resolve for direct delivery methods 
is the risk for adaptive immune responses.  Large animal studies utilizing IM injection 
have reported high incidence of myocarditis and T cell mediated immune responses [26].  
In addition to the inflammation generated from multiple needle sticks, comprehensive 
studies have raised key concerns regarding the highly localized gene expression profile 
in muscle [26,27]. It has been postulated that both inflammation resulting from injury at 
the time of delivery as well as the highly focal expression profile are interrelated in 
triggering subsequent immune responses long after the initial delivery period [28].  Both 
innate and adaptive immune responses are major concerns especially since advanced 
heart failure patients present with moderate to severe degrees of chronic inflammation 
and fibrosis [29].  This study did not evaluate levels of induced inflammation, but it is 
hypothesized that the jet’s impact should be less inflammatory versus repeated needle 
sticks in the same area.  Expounding upon this point, other reports confirm that 
pharmacodynamic effects with IM injections saturate to a biological limit [30,31], 
whereby expression levels beyond the therapeutic threshold provide no clinical benefit 
and actually increase risks.  
Although intriguing, the liquid jet injection approach would need extensive 
modification to be positioned in the clinic as a standalone intervention.  Certainly our 
results are very limited to effectively targeting 1 gram of transmural myocardial mass in 
the rodent.  In on our development course, we have identified optimized settings for a 
thickness level (e.g. transmural rodent cross section at 0.5cm).  The settings in this 
particular application are most likely not optimal for larger animals..  Our basic explanted 
heart dye application demonstrated this point and underscored the problem of scale.  
Given that 1 g of mass was covered with 5 injections, it is very likely that >250-500 sites 
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would be needed to achieve the same level of coverage in a human left ventricle.  This is 
certainly not feasible with the existing setup.  Future model studies will be needed to 
determine if further optimization is possible to reduce the number of sites as well as 
establish safety limits with a more sophisticated prototype.  
Infusion approaches will remain on the forefront in trials but must address the 
problem of increasing driving pressure and navigating anatomical/disease barriers while 
remaining within safe limits. In the future there could be a gradual shift to direct methods, 
since >50% of the general population has pre-existing immunity to one or more AAV 
serotypes, preventing enrollment [32].  Therefore, improved direct delivery methods 
would most likely be a better choice for these patients.  It is conceivable that future 
applications could include modifying the various driving parameters with a single injector 
for angiogenesis products that require local delivery and a multiple injector array 
adapted to supporting instrumentation for global delivery for heart failure applications. 
Either approach could be further developed as an adjunctive or primary minimally 
invasive surgical procedure, or along with microinjection devices  with minimally invasive 
endocardial delivery applications.       
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CHAPTER 6 
 
A Comparative Evaluation of Direct Injection Methodology:  Liquid Jet Injection 
Increases the Efficacy of Therapeutic S100A1 Expression in Limiting Ischemic 
Myocardial Infarction 
 
6.1  Introduction 
 
Chapters 4 & 5 established the core bioengineering concepts and physical limits 
for needleless liquid jet injection delivery of AAV therapeutics to the myocardium.  Given 
that the injections were well tolerated with excellent results in normal subjects, the 
research focus then shifted to determine if whether or not the delivery profile could 
rescue from ischemic myocardial infarction.  The therapeutic selected for the study was 
serotype 9 single stranded AAV S100A1 (ssAAV9.S100A1), which has been established 
as a potent therapeutic in driving contractility and restoring cardiac function.  As 
discussed in previous chapters, AAV is the primary vector of choice in clinical trials 
where long term therapeutic expression is desired. Therefore it was logical to evaluate 
the direct injection methodology in an ischemic infarction setting with a gene that could 
rescue from acute MI and restore contractility.  This chapter describes a very thorough 
evaluation of direct delivery methods and their outcomes with a potent transgene 
encoded with a high quality vector.  A key focus is placed on the quantitative aspects of 
gene therapy, which are seldom explored in detail including genome copy number, 
therapeutic induced protein levels, and finally a careful look into the immunological 
aspects of direct delivery of AAV to the myocardium. 
6.2  The S100A1 Target: Molecular Actions & Previous Studies 
 
6.2.1  The multi-potent effects of S100A1 
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The lead candidate in clinical trials at present is the AAV1.SERCA2a therapeutic, 
which seeks to restore calcium handling through long term SERCA2a expression to 
drive calcium handling in the sarcoplasmic reticulum in failing myocytes.  As described in 
Chapter 1, SERCA2a is further along the regulatory pathway; however the S100A1 
target has certainly provided very intriguing results to date and is well positioned for 
clinical trials.  The S100A1 target is multi-faceted in aim, improving not only calcium 
handling, but also shown to accentuate function in these areas: anti-apoptotic 
mechanisms, mitochondrial energetics, structural protein binding enhancements and is 
also hypothesized to have a role in directing regeneration [1].              
S100A1 is a member of the S100 protein family, which represents the largest 
group among EF-had Ca2+ binding proteins prevalent in vertebrates [2,3].  In addition to 
vigorous effects on calcium handling, these S100 proteins have a variety of key 
biological functions including but not limited to: cell proliferation, differentiation, survival, 
motility, cytoskeletal dynamics, nitrous oxide homeostasis [4-6].  S100A1 expression is 
the highest in the myocardium, with moderate levels found in the skeletal muscle, 
kidneys and nervous tissues.  Within myocardium, S100A1’s presence is only in 
myocytes and not fibroblasts or endothelial cells, suggesting a prime role in contractility.  
It has a role in both diastolic and systolic function through influencing both SERCA2a 
and secondary calcium gating ryanodine receptor 2 (RyR2) as shown in (Figure 6.1) [7-
10].     
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From detailed pre-clinical studies, it is evident that S100A1 has multiple binding 
sites within the cytoplasmic domain featuring separate effector mechanisms in both 
energetics and structural integrity of myocytes.  With regard to energetics, S100A1 in 
cardiac mitochondria enhances the effects of the enzyme mitochondrial ATP synthase, 
which is the most important enzyme for ATP production.  In addition to synergistic 
activity with the synthase, S100A1 also works on the adenosine nucleotide translocator, 
mediating exchange of ADP and ATP between the mitochondrial matrix and the 
cytoplasm, thus increasing the availability of ATP for use [11-13].  Thirdly, S100A1’s 
effects on myocyte viability via structural integrity have been documented through 
activity on microfilaments.  S100A1 has been detected and found to play a significant 
role in the sarcomere unit.  Periodically, it appears at the Z and the M line as well as 
within the I and A bands [14-16].  The key function is within the I band, whereby S100A1 
interacts with a very large integral structure protein titin.  Titin has a key role in cardiac 
mechanics, specifically with the preservation of passive tension in myocytes [16].    
Figure 6.1  Multi-target effects of S100A1 Protein 
99 
 
6.2.2  Previous Results from Animal Studies  
  
The first attempts with S100A1 overexpression were with an adenovirus vector in 
a rodent heart failure model via coronary infusion at 12 weeks.  The study reported 
reversal of post ischemic deterioration and preservation cardiac function [17].  Serial 
studies in swine led by Dr. Patrick Most revealed S100A1’s clinical potential both with 
AAV6 and AAV9 serotypes, demonstrating high expression levels and rescue from post 
MI [18,19].  Summarizing, it is anticipated that S100A1 gene therapy for ischemic 
cardiomyopathy will gain significant traction moving toward a Phase I trial in the next 1-3 
years.   
6.3  Methods & Materials  
 
Protocol Summary 
32 rats received a baseline echo and infarct creation via left anterior descending 
artery (LAD) ligation and were divided into 4 separate groups (n=8 ea.): 2 Control 
consisting of,  Needle injection (IM) and  Liquid Jet Injection (LJ), both receiving equal 
amount of saline and 2 Experimental consisting of,  IM and LJ each receiving 1.2x1011 
vg of ssAAV9.S100A1.  IM injections were performed with three separate 100uL in the 
left ventricle with a 30G needle, while the LJ device fired three separate 100 µL 
injections projected at the exposed left ventricle from 25 cm above the thoracotomy.  
Following 10 weeks, the rats were evaluated with echocardiography for LV function, 
Masson’s Trichrome staining for infarct area, QPCR for AAV9.S100A1 genome 
detection, and IHC staining for S100A1 protein.  In addition to function and therapeutic 
endpoints, host response assessment was conducted on 10 week blood and cardiac 
tissue specimens via cytokine panel and the CD38 immune marker. 
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6.3.1  Echocardiography Procedures 
 
All rats were subjected to baseline and follow up 10 week post myocardial 
infarction echocardiography as follows.  Rats were induced and maintained with 1-5% 
isoflourance and placed supine on a surgical table.  The VisualSonics Vevo5000 
Echocardiography small animal unit was utilized to capture all images.  Briefly, 1.7 – 2.2 
cm depth, 15-20MHz frequency, 60-70% Gain, and other visual parameters were 
adjusted for optimal view.  Long axis and M-mode views to assess ventricular wall 
motion score were obtained for each animal.  3 individual data sets were acquired and 
averaged for 1 overall score set reported for each animal.  This ensured minimal 
variability per run, an example is shown in (Figure 6.2). 
 
 
 
 
Figure 6.2  Echocardiography of Left Ventricular Function 
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6.3.2 Surgical Procedures & AAV Delivery 
 
An SP02, Harvard Apparatus Ventilator, and ECG devices were calibrated prior to 
surgery. Following induction and intubation, all rodents were placed in the left decubitus 
position and prepared for a mini left thoracotomy while under complete monitoring of 
heart rate, ECG, SPO2 and respiratory parameters.  The heart was exposed and the left 
anterior descending artery was identified.  The mid line of the artery was marked with a 
surgical pen, then 7.0 prolene sutures were used to ligate the artery.  Infarct creation 
was confirmed by both discoloration and ECG changes.  Following infarction, each 
animal received 3 separate 100µL injections of either saline or ssAAV9.S100A1 
therapeutic by either IM injection or the Liquid Jet.  All animals were recovered and 
monitored until the 10 week endpoint.  The heart was harvested, with myocardial cross 
sections and individual samples prepared for assay testing. 
6.3.3  Quantitative Real Time Poly Chain Reaction (QPCR) of ssAAV9.S1001 
Genome  
All servicing was performed blinded by the Molecular Profiling Core at the 
Cannon Research Center.  Three separate cardiac zones were harvested from each 
animal: Anterior Wall, Borderzone, and the Lateral Wall.  The liver organ was selected 
as the primary endpoint target to quantify systemic exposure and was also collected for 
each animal.  Once samples were transferred to the facility a routine protocol with 
robotic instrumentation was used for processing.  Briefly, whole DNA was isolated from 3 
left ventricular and 1 collateral organ liver specimens using the Chemagen MSM1 kits to 
set up the QPCR assays for viral AAV9.CMV.S100A1 DNA.  To examine the expression 
of S100A1, customized kits designed by Abiomed Systems generated the S100A1 
primers and then laboratory equipment was prepared to execute the experiment. The 
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level of ovine GAPDH DNA was used to calculate normalized expression with the ΔΔCt 
method to obtain QPCR values.  Absolute genomic copies of S100A1 DNA were 
quantified with the standard normal curve built from serial dilutions.  Data was reported 
as number of viral genome copies (GC) per 100 ng of whole DNA.  Data analysis was 
performed for each delivery group combining data from all 3 cardiac zones, with the liver 
scored separately.  All samples reported out of range, either undetectable at the limit of 
transfer or those >100,000 GC per 100 ng DNA were removed from the analysis. 
6.3.4 Histology Protocols:  Quantitative S100A1 Protein Analysis in Myocardial 
Cross Sections via Immunohistochemistry with Confocal Microscopy & Masson’s 
Trichrome Staining for Infarction Area 
 
6.3.4.1  Quantitative S100A1 therapeutic protein levels in myocardium 
Samples of Rat Heart Tissue 
Sections were prepared from formalin fixed and paraffin embedded heart tissue blocks.  
All Immunofluorescence staining, image processing, and quantification were performed 
by the CaresBio Resources Inc. (Shelton, CT) service provider in a blinded manner.  
Immunofluorescence (IF) 
Immunofluorescence staining was performed on tissue samples. Briefly, slides 
were subjected to heat induced antigen retrieval in citrate buffer (pH 6.0) and or in 
proteinase. Slides were incubated for 1 hour/ overnight with primary antibodies  CD38, 
S100A1), after blocking with nonspecific antigenicity blocker. Corresponding fluorescent 
conjugated secondary antibodies were applied for 1 hour at room temperature. 4, 6 - 
Diamidino-2-phenylindole (DAPI) were included with the secondary antibodies to 
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visualize nuclei. The staining, imaging and image analysis were performed by CaresBio 
Laboratory, LLC (Shelton, CT, USA). 
Image Acquisition and Analysis 
Briefly, slides were scanned using a customized, computer-controlled 
microscope (with xy-stage and z controller) a Zeiss LSM780 confocal microscope (Carl 
Zeiss GMBh, Jena, Germany) with ×40 and X20 objective.  Every case had 32 images 
including 16 images per section. Images were analyzed using an image analysis 
software based on MATLAB (R2011b, MathWorks), developed by CaresBio Laboratory. 
The final result is the average of 32 images per case what was compared with average 
baseline to calculate times of increase. Image analysis algorithms were applied to the 
images generated from microscopic slides of tissues stained with secondary antibody 
and isotype controls to generate the background score. Control/Baseline was used to 
generate the algorithm to differentiate between the signals and signal to noise ratio. The 
same algorithm has been applied to all the images. This provided the option for 
separation of single stained only areas-and double/triple-stained areas from secondary 
only and or- isotype only stained areas by means of subject specific thresholding. A 
good separation of single- and double-stained pixels from secondary antibody only and 
or isotype control (background) stained pixels was achieved. Automatic background 
subtraction was performed. Significant differences in relative areas stained and mean 
specific intensity for the stains between control and treatment groups in rat tissue were 
calculated. 
Quantitative analysis of the IHC cross sections stained for S100A1 was 
performed with confocal microscopy detection and normalization to untreated controls to 
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remove the effect of endogenous levels.  A 32 array grid, featuring 8 randomn but 
separate zones defined in the anterior, lateral, posterior and septal wall regions were 
obtained for analysis at 20x magnification.  (Figure 6.3) best characterizes the method, 
whereby the yellow squares represent individual regions of interests zoomed out at 4x 
magnification.  A composite overall expression score normalized to control (i.e. 1.0 
background endogenous S100A1) was computed for each animal.   
 
 
 
 
6.3.4.2  Masson’s Trichrome Staining for Infarct Size Characterization  
Formalin fixed paraffin embedded tissues were sectioned at 4 microns on a Leica 
RM2125 microtome, picked up on Plus slides and air dried overnight. Slides were then 
baked in a 60 degree oven for 20 minutes to remove excess paraffin before being 
deparaffinized and with xylene and rehydrated with several changes of graded alcohol to 
Figure 6.3  Quantitative Proteomic S100A1 Methodology Featuring IHC & 
Confocal Microscopy; 32 individual zones (YELLOW) throughout the 
myocardium were analyzed 
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distilled water. H&E sections were stained with Mayer’s hematoxylin for 20 minutes, 
rinsed with running tap water and stained with Eosin Y for 5 seconds followed by several 
rinses in 95% alcohol. Masson’s Trichrome slides were stained with Weigert’s Iron 
Hematoxylin for 10 minutes followed by a rinse in tap water. The rest of the staining was 
done with a Masson’s Trichrome kit purchased from Polyscientific (Bay Shore, NY cat# 
k037 ).  The slides were then dehydrated with several changes of graded alcohol and 
cleared with xylene before being coverslipped with Permount. 
6.3.5  Host Response to S100A1 Gene Therapy 
 
The IM route has documented evidence of inducing both inflammatory and 
adaptive immune responses that can dramatically reduce efficacy and lead to poor 
outcomes.  As described in the previous chapters a significant aim of the dissertation 
presented was to investigate these both in the myocardial tissue and global response via 
blood testing.  The analysis was divided into two subparts, cardiac tissue and whole 
blood. 
Cardiac Tissue Immunohistochemistry for CD38 Expression 
The CD38 protein is a marker of cell immune activation, specifically described at 
the crossroad of innate and immune activation [18].  The same preparation of tissue and 
quantitative methodologies described in section 6.3.4 were utilized, except with an anti-
CD38 antibody obtained from AbCam Scientific.   
Whole Blood Cytokine Panel 
This analysis was utilized to obtain a clear picture of the host’s global 
inflammatory profile at 10 weeks post myocardial infarction and gene delivery.  Analyte 
concentrations were measured and quantitated using a Bio-Plex Suspension Array 
System (Bio-Rad, Hercules, CA, USA). A Bio-plex multiplex premixed rat cytokine, 
chemokine and growth factor panel was used. Analytes including EPO, G-CSF, GLP-1, 
106 
 
GM-CSF, GRO KC, IFN-ɣ, IL-1 α, IL-1ß, , MCP-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-10, IL-
12p70, IL-13, IL-17A, IL-18, M-CSF, MIP-3α, RANTES, TNF-α, and VEGF were 
examined. These assays use color-coded bead sets, each of which is conjugated with 
analyte-specific antibodies and designed in a capture sandwich immunoassay format. 
The samples were diluted using with the supplied diluent as directed. The antibody-
coupled beads were mixed and incubated with diluted plasma samples, or with the 
standards. Thereafter, unbound proteins were removed by washing in the Bio-Plex Pro 
wash station (Bio-Rad) and a biotinylated detection antibody was added to the beads. 
Each captured analyte was detected by the addition of a reporter molecule, streptavidin-
phycoerythrin. The contents of each well were drawn into the Bio-plex array reader (Bio-
Rad) where precision fluidics align the beads and lasers excite them in order to 
quantitate the captured analytes. Analyte concentrations were automatically calculated 
with Bio-Plex Manager software by using a standard curve derived from the recombinant 
standard provided with the assays.  A key focus was placed on these markers which 
were more relevant for the particular analysis of innate and adaptive immune response 
following gene therapy: IFN-ɣ, IL-1α, IL-4, IL-6, IL-10, IL-17,  RANTES, TNF-α. 
6.4  Results 
6.4.1  Operative & Delivery Results 
 
The overall survival rate from induction to 10 weeks endpoint was 93%.  A limited 
number of animals (n=3) were lost during infarct creation and replaced such that each 
group tallied at least (n=8).  The IM injections were tolerated without major incidence, but 
minor bleeding events were noted and managed appropriately.  The liquid jet injections 
were also tolerated without any major incidence, although some minor bleeding and 
discoloration in the impacted area was noted as in previous studies with this method. 
6.4.2  Echocardiography Measures of Cardiac Performance 
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(Table 6.1) below summarizes all major data obtained to determine left ventricular 
function in addition to global left ventricular remodeling parameters associated with the 
progression following ischemic myocardial infarction.   
 
 
Single way ANOVA revealed no significant difference in any data point at baseline.  
However, as expected the effects of both the infarction and potential therapeutic action 
of S100A1 led to a number of differences observed at the terminal 10 week post MI 
point.  First confirming model behavior, all 4 groups exhibited an increase in LV 
Table 6.1  Echocardiography and Outcome Data for ssAAV9.S100A1 
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remodeling points, all * p<0.05 for: End Diastolic and End Systolic Indices, Ejection 
Fraction, 2D Epicardial Area and a decline in LV wall thickness suggestive that the 
ischemic MI induced these changes.  These are consistent results and provide solid 
evidence that the infarction promoted the typical dysfunction and compensatory changes 
following the initial myocardial insult at time zero.  Second, as compared in order with 
the [IM Saline] ; [Liquid Jet Saline] and [Liquid Jet-S100A1] groups, the IM-S100A1 had 
a more progressive remodeling course suggestive of more severe LV dysfunction with 
End Systolic Volume Index at [1.0±0.2 µL/cm2] vs. [0.7±0.2 µL/cm2] ; [0.7±0.1 µL/cm2] 
and [0.5±0.1 µL/cm2] respectively and greater End Diastolic Index at [1.7±0.2 µL/cm2] vs. 
[1.2±0.2 µL/cm2] ; [1.3±0.1 µL/cm2] and [1.3±0.2 µL/cm2] respectively.  These data points 
did not pass the single way ANOVA, however two key points did, Ejection Fraction and 
Global Myocardial LV thickness. 
The Liquid Jet-S100A1 preserved the most baseline function at [60±3]% and was 
greater p<0.01 than the other 3 groups in terms of overall performance; IM Saline 
[47±3]%, Liquid Jet [46±3]% and IM-S100A1 [43±4]%.  There was a much greater 
degree of structural integrity in the treated Liquid Jet S100A1 group with a greater 
overall wall thickness p<0.05 [1.5±0.1 mm] versus all 3 other groups.   
The infarct sizing characterization yielded very striking results.  In support of the 
functional data, The IM-S100A1 exhibited extremely profound deterioration in the left 
ventricular cross sections.  The infarct size in this group revealed a much greater 
affected zone [40±4] %, p<0.05 area versus the IM Saline [33±6]%, Liquid Jet Saline 
[20±6]% and Liquid Jet S100A1 [17±5]%.  (Figure 6.4) depicts the extreme, featuring a 
typical IM S100A1 (A) compared with a typical Liquid jet S100A1 (B). 
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The Liquid jet S100A1 group overall had the lowest scar size, which was not expected 
but intriguing.  Overall, there was a clear difference between the delivery groups with the 
same therapeutic dosing/gene strategy thus confirming the method was the difference in 
outcome both in terms of function and LV integrity. 
6.4.2  Quantitative PCR Detection of AAV9.S100A1 Therapeutic DNA 
 
The analysis was divided into two major anatomical zones.  The first was the 
Cardiac zone comprised of 3 harvested sites per animal (Anterior Wall, Borderzone, 
Lateral Wall) to determine the degree of therapeutic transfer (i.e. 8 animals by group x 3 
specimens = 24 Cardiac).  The second collateral liver (i.e. 8 animals by group x 1 liver 
specimen = 8 Liver). 
The IM S100A1 group demonstrated robust detection in all 32 cardiac and liver 
specimens, however 10 were greater than 100,000.  This suggests that there was very 
high focal expression in the myocardium and a high degree of systemic exposure in the 
liver as found in the Chapter 5 marker study.  After the removal of these outliers, the 
Figure 6.4  Masson’s Trichrome Staining for Infarct scar at 10 Weeks: (A) Typical 
IM gene therapy animal with large (blue) infarct zone while the Liquid Jet therapy 
group (B) demonstrated much lower scar and thicker myocardium 
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overall cardiac zone score for the IM group was [13128±2774] GC per 100 ng DNA, 
while the systemic liver score was significantly higher p<0.05 at [65051±15836] GC per 
100 ng DNA.     
The Liquid Jet S100A1 group on the other hand demonstrated an overall lower 
score in terms of focal expression as 14/32 specimens did not have detection, however 
those that did scored in the range (n=10), but lower than the IM group at [10147±3572] 
GC per 100 ng DNA.  The collateral liver analysis revealed minimal detection [40±40], 
with two samples with readings near zero.  (Figure 6.5) summarizes the data by delivery 
method.  For assay validity, non-therapy controls were run and yielded undetectable 
readings (data not shown).   
 
 
 
These results confirm what was found in the Chapter 5 marker study: (1) IM 
delivery results in highly focal levels of viral mediated expression (2) Inadvertent infusion 
Figure 6.5  Quantitative PCR Results:  IM-S100A1 Group (Red) Demonstrated 
significantly higher detection in the Liver, while the Liquid Jet-S100A1 group 
(Green) was more cardiac specific with higher detection in the heart. 
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and or in combination with poor myocardial retention occurred resulting in lower cardiac 
specificity.  The greater cardiac specificity of the liquid jet is most likely attributable to the 
tuning of the jet properties, whereby microjet penetration is sufficient enough to 
perforate, but remain in the myocardium with reduced volume entry into the left 
ventricular cavity.  Although not confirmed with additional biodistribution testing, there is 
most likely collateral residual expression in the thoracic and adjacent lung tissues with 
the liquid jet’s dispersion and impact effects. 
6.4.3 Quantitative Myocardial S100A1 Proteomic Levels & Confocal Microscopy 
 
The overall proteomic S100A1 detection assay utilizing advanced confocal 
microscopy applications featuring immunofluorescent detection yielded more detailed 
findings beyond viral mediated detection.  Two key findings were overall fold higher 
expression and a difference in distribution per method. 
In terms of overall S100A1 expression as measured by normalization to saline 
controls [1.0±.05], both the IM [5.0±0.1] and Liquid Jet [4.3±0.1] gene therapy groups 
yielded dramatically higher fold S100A1 in S100A1 Fluorescence Intensity Fold Ratios.  
As expected, AAV9 mediated viral vector transfer of S100A1 raised baseline levels and 
or restored depleted S100A1 reserves lost in ischemic MI.  Another key finding inline 
with QPCR data was that the IM had roughly 1 fold greater overall S100A1 gene 
expression (Figure 6.6).   
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Due to the variability inherent with both delivery and the ischemic model, a logical 
fixed 32 zone sequences was utilized to determine overall expression, but the overall 
score does not address the problem of heterogeneous expression as found previously 
with the IM group.  
In an effort to characterize the degree of S100A1 expression per zone, the 
standard deviations derived per animal resulting from the 32 individual zones were 
analyzed.  It was found, as expected, that the Liquid Jet had a more homogenous 
S100A1 as measured by a lower variability score in the S100A1 expression profile 
[13.5±1.5] versus the IM group [20.1±0.5], p<0.05. (Figure 6.7) 
Figure 6.6  Quantitative Proteomic Analysis:  Both IM-S100A1 and Liquid Jet 
S100A1 groups yielded significantly higher fold overall S100A1 in the 
myocardial cross sections at 10 Weeks.  IM scored higher as compared with 
Liquid Jet, all p<0.05. 
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The confocal microscopy images verified these findings with vibrant images indicating 
the degree and distribution pattern of S100A1 expression typically found by route 
(Figure 6.8).  These are depicted in the figure below. 
 
 
 
 
Figure 6.7  S100A1 Expression Variability.  IM Injection results in a higher 
degree of variation in the myocardium following after analyzing the standard 
deviation in the 32 zones per animal. 
Figure 6.8  Confocal Microscopy Images:  Cross sectional myocardial S100A1 
expression (maroon) with labeled nuclei (blue) by route: (A) IM Injection (B) 
Liquid Jet Delivery.  Liquid Jet has a less intense, more disperse pattern of 
expression as compared with IM. 
114 
 
6.4.4  Host Responses to Direct ssAAV9.S100A1 Expression 
 
Given the dramatic difference in outcome between the delivery groups, as 
asserted in this dissertation as well as compelling evidence suggests that highly focal 
cardiac expression may contribute to triggering maladaptive immune responses.  The 
host response was approached from both a local tissue inflammatory CD38 marker in 
part A, and a complete physiologic cytokine panel B.  Part A seeked to determine local 
risk profile for an adaptive T cell mediated immune response via CD38 activation, while 
B sought to determine if the immune system was activated via evidence of elevated 
cytokines.   
6.3.4A  The CD38 Inflammatory Marker 
Given the difference in both LV performance and cardiac structure, it was 
anticipated that the IM-S100A1 group suffered from the compounded effects of 
myocardial infarction in addition to a host response.  Both groups experienced a 
significant level of CD38 expression throughout the myocardial cross section against 
Control specimens [1.0±0.03].  The IM-S100A1group [7.2±0.8] was nearly twice as high 
as the Liquid Jet-S100A1 group [3.8±0.2] in CD38 Fluorescence Intensity Fold Ratio 
(Figure 6.9).   
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6.3.4B  The Whole Blood Global Pro-Inflammatory Cyotkine Panel 
The cytokine results are clearly summarized in (Table 2) with a number of key findings.   
 
  
The IM-S100A1 group exhibited a significantly higher amount of a variety of key 
circulating pro-inflammatory cytokines involved in innate and adaptive immune 
responses.  These were IL-α, CCL5 (RANTES), TNFα, and IFNγ.  Higher trends were 
also noted with IL-4, IL-6 and IL-12.   
           
CYTOKINE:
  
Controls IM - S100A1 Liquid Jet - S100A1
IL-1α 113±29 319±127* 197±21
CCL5 (RANTES) 156±22 262±55* 211±29
TNFα 124±26 256±50* 189±94
IFNγ 79±15 242±77* 54±11
IL-4 37±8 67±22 28±4
IL-6 46±11 136±65 109±95
IL-12 54±14 105±49 39±13
* p<0.05; AAV.S100A1 Delivery Group vs. Saline Controls
BLOOD LEVELS [picograms/mL]
Figure 6.9 Pro-Inflammatory CD38 Marker Expression reveals significant fold 
higher presence in b th the Liquid jet and IM groups *p<0.05.  The magnitude 
was nearly 2 fold higher in the IM group †p<0.05 suggesting a higher degree of 
immune activation. 
 Table 6.2  Pro-Inflammatory Blood Cytokine Data at 10 Weeks Post MI 
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Thus, both inflammatory signals were found in the cardiac zones and the 
peripheral blood system indicating the AAV mediated gene therapy via direct injection 
induces a number of responses.  It is clear that these responses, inline with the poor 
outcome data, were more profound in the IM group. 
6.5 Discussion 
 
The results from this study solidify key points identified in the Chapter 5 marker 
study.  Major novel contributions include revealing some key risk factors for direct AAV 
mediated gene therapy post myocardial infarction.  First, all of the major principles of 
liquid jet injection were re-affirmed in this study with a bona fide AAV9.S100A1 
transgene vector platform, namely: 
• Liquid jet can achieve a disperse, long term gene expression profile in the disease 
setting of acute myocardial infarction 
• S100A1 is a robust transgene that promotes long term rescue of myocytes in the 
ischemic MI setting. 
• A homogenous expression profile similar to infusion approaches is possible 
• Liquid Jet Injection more cardiac specific than IM since optimized settings control the 
degree of penetration into higher risk areas (i.e. left ventricular cavity) 
• Synergistically, a cardiac specific, homogenous gene expression profile and minimal 
collateral organ expression is at much less risk for host responses 
Reflecting these key points above in the context of this rodent study, Liquid Jet 
injection results achieved a disperse, cardiac specific S100A1 profile compared with the 
heterogeneous profile of the IM route.  The conclusion that delivery with 
ssAAV9.S100A1 therapy is more efficacious with the liquid jet route is more than justified 
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given the compiled data sets.  The difference in ventricular function, geometry, and 
disease burden were dramatically different between the treatment groups.  The IM 
S100A1 group suffered deleterious effects in the left ventricle leading to poor outcome, 
most likely attributable to an adaptive immune response that exacerbated left ventricular 
remodeling, despite seemingly adequate levels of S100A1 overexpression.  In particular 
the infarct size measurements were striking, whereby nearly double affected zone was 
found between groups.  The non-homogenous expression profile as found in the 
proteomic analysis in combination with much higher levels of systemic exposure via 
QPCR data are more than likely the causes.   
In essence, there were 3 main stimuli events in this model that factored into the 
clinical outcome and host responses found at 10 weeks: A. Induced Myocardial 
Infarction B.  Injury from Delivery C.  AAV mediated S100A1 expression and D. 
Inflammatory risk factors.  The interaction of all 4 of these determined the outcome per 
group.  A goal of this dissertation was to determine the relationships.  With respect to 
infarction it is understood that there is inherent variability in any given ischemic model, 
however it is very unlikely that variation alone in this category factored in the outcome 
based on robust numbers in each group.                           
With respect to injury, it was beyond the means of this particular study to determine 
the level of injury at the cellular level per route, especially in the context of acute MI. 
However despite this key limitation, a few points can be introduced for future discussion.  
It has been challenged by this dissertation that one of the advantages of Liquid Jet 
injection is that it is safer than the IM route.  This was visually evident in the surgeries, 
whereby less bleeding was noted with the jet injections which only left visible welts on 
the epicardial surface.  As asserted previously, any given delivery method results in a 
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level of injury, but the degree of injury is paramount to consider in the actual delivery 
application.                    
Numerous studies have made the case that host inflammation resulting from delivery 
itself can result in aggressive adaptive immune responses against AAV mediated 
transgenes [19].  While the immunological possibilities are complex, it is logical to 
conclude there is a synergistic role of delivery in an already inflammatory post MI 
environment.  Although not supported with additional data, it was very intriguing to find 
that the Liquid Jet Groups (treated and untreated) had smaller infarct zones overall.  
This observation would counter an argument that the system is more deleterious alone 
versus IM injection.      
Additional insight for future studies with S100A1 or AAV mediated products is the 
degree of overexpression.  The CD38 inflammatory expression data indicates that 
greater expression levels increase the risk for maladaptive immune responses.  In this 
case study, it appears that delivery route, more than the vector/transgene with direct 
injection contributed to the poor outcome in the IM group, but these factors may have  
different relative significance with other vector/transgene systems.  In general, numerous 
gene therapy studies selecting the IM route have confirmed that very little successful 
transfer and or reactions occur in damaged muscle [20].  Similar problems, but to a 
lesser extent, have been found in Hemophilia trials, whereby infusion of the same AAV 
dose in the liver was much more efficacious than IM delivery [21,22].  Thus, the case for 
liquid jet injection for cardiac gene therapy applications with AAV product is solidified.   
Expanding on the discussion of adequate expression levels, optimal gene therapy 
treatment would utilize the minimum amount of vector such to achieve therapeutic 
expression in the myocardium.  From the standpoint of adequate expression levels, it 
was interesting to note that despite very high S100A1 expression as measured by both 
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QPCR and proteomic analysis, the IM S100A1 was spiraling down the path of chronic 
heart failure.  The Liquid jet group on the other hand despite a fold lower, was 
efficacious.  It is asserted by this dissertation that the difference can be found with the 
host response, in that once the responses drive beyond a threshold to complete 
systemic activation the therapy itself becomes toxic.                                
Summarizing, these results communicate an important concept that there is most 
likely a delicate balance between successful therapy (i.e. tolerance) with AAV mediated 
products versus complete immune activation.  The conclusions in this study assert that 
outcome can most definitely be mitigated with route, vector and dose selection.  The 
next two Chapters 7 and 8 are dedicated to exploring additional options in navigating this 
balance.  Chapter 7 repeats the study design as presented in this chapter, except with a 
double stranded AAV9 vector. 
References 
 
[1]  Rohde D, Rittheroff J, Voelkers M, Katus HA, Parker TG, Most PJ.  S100A1: A 
multifaced therapeutic target in cardiovascular disease.  J. of Cardiovasc. Trans. Res. 
(2010) 3:525-537 
 
[2]  Donato R. Functional roles of S100 proteins, calcium-binding proteins of the EF-
hand type. Biochim Biophys Acta 1999; 1450: 191–231. 
 
[3] Marenholz I, Heizmann CW, Fritz G. S100 proteins in mouse and man: from evolution 
to function and pathology (including an update of the nomenclature). Biochem Biophys 
Res Commun 2004; 322: 1111–1122. 
 
[4] Zimmer DB, Wright Sadosky P, Weber DJ. Molecular mechanisms of S100-target 
protein interactions. Microsc Res Tech 2003; 60: 552–559. 
 
[5] Goch G, Vdovenko S, Kozlowska H, Bierzynski A. Affinity of S100A1 protein for 
calcium increases dramatically upon glutathionylation. FEBS J 2005; 272: 2557–2565. 
 
[6] Wright NT, Cannon BR, Zimmer DB, Weber DJ. S100A1: structure, function, and 
therapeutic potential. Curr Chem Biol 2009; 3: 138–145. 
 
[7] Kiewitz R, Acklin C, Schafer BW, Maco B, Uhrik B, Wuytack F et al. Ca2+ -dependent 
120 
 
interaction of S100A1 with the sarcoplasmic reticulum Ca2+ -ATPase2a and 
phospholamban in the human heart. Biochem Biophys Res Commun 2003; 306: 550–
557. 
 
[8] Kettlewell S, Most P, Currie S, Koch WJ, Smith GL. S100A1 increases the gain of 
excitation-contraction coupling in isolated rabbit ventricular cardiomyocytes. J Mol Cell 
Cardiol 2005; 39: 900–910. 
 
[9]  Most P, Boerries M, Eicher C, Schweda C, Volkers M, Wedel T et al. Distinct 
subcellular location of the Ca2+-binding protein S100A1 differentially modulates Ca2+-
cycling in ventricular rat cardiomyocytes. J Cell Sci 2005; 118: 421–431. 
 
[10]  Most P, Remppis A, Pleger ST, Loffler E, Ehlermann P, Bernotat J et al. 
Transgenic overexpression of the Ca2+-binding protein S100A1 in the heart leads 
to increased in vivo myocardial contractile performance. J Biol Chem 2003; 278: 
33809–33817. 
 
[11] Boerries M, Most P, Gledhill JR, Walker JE, Katus HA, Koch WJ et al. Ca2+ -
dependent interaction of S100A1 with F1-ATPase leads to an increased ATP content in 
cardiomyocytes. Mol Cell Biol 2007; 27: 4365–4373. 
 
[12] Leyva JA, Bianchet MA, Amzel LM. Understanding ATP synthesis: structure and 
mechanism of the F1-ATPase (Review). Mol Membr Biol 2003; 20: 27–33. 
 
[13]  Balaban RS. Cardiac energy metabolism homeostasis: role of cytosolic calcium. J 
Mol Cell Cardiol 2002; 34: 1259–1271. 
 
[14]  Yamasaki R, Berri M, Wu Y, Trombitas K, McNabb M, Kellermayer MS et al. Titin-
actin interaction in mouse myocardium: passive tension modulation and its regulation by 
calcium/S100A1. Biophys J 2001; 81: 2297–2313. 
 
[15]  Fukushima H, Chung CS, Granzier H. Titin-isoform dependence of titin-actin 
interaction and its regulation by S100A1/Ca2+ in skinned myocardium. J Biomed 
Biotechnol 2010; 2010: 727239. 
 
[16] Maco B, Mandinova A, Durrenberger MB, Schafer BW, Uhrik B, Heizmann CW. 
Ultrastructural distribution of the S100A1 Ca2+-binding protein in the human heart. 
Physiol Res 2001; 50: 567–574. 
 
[17].  Most P, Pleger ST, Volkers M, Heidt B, Boerries M, Weichenhan D et al. Cardiac 
adenoviral S100A1 gene delivery rescues failing myocardium. J Clin Invest 2004; 114: 
1550–1563. 
 
[18].  Partidá-Sánchez S, Rivero-Nava L, Shi G, Lund FE (2007). "CD38: an ecto-
enzyme at the crossroads of innate and adaptive immune responses". Adv. Exp. Med. 
Biol. Advances in Experimental Medicine and Biology 590: 171–83. -34814-8_12.  
 
[19.] Mays LE, Wilson JM: The complex and evolving story of T cell activation to AAV 
vector-encoded transgene products. Mol Ther 2011, 19(1):16–27. Epub 2010 Nov 30.  
121 
 
  
[20].  Snyder RO, Spratt SK, Lagarde C, Bohl D, Kaspar B, Sloan B, et al: Efficientand 
stable adeno-associated virus-mediated transduction in the skeletal muscle of adult 
immunocompetent mice. Hum Gene Ther 1997, 8:1891–1900. 
 
[21]. Wang L, Cao O, Swalm B, Dobrzynski E, Mingozzi F, Herzog RW: Major role of 
local immune responses in antibody formation to factor IX in AAV gene transfer. Gene 
Ther 2005, 12:1453–1464. 
 
[22]. Cao O, Hoffman BE, Moghimi B, Nayak S, Cooper M, Zhou S, et al: Impact of the 
underlying mutation and the route of vector administration on immune responses to 
factor IX in gene therapy for hemophilia B. Mol Ther 2009, 17:1733–1742. 
 
[23]. Mingozzi F, Maus MV, Hui DJ, Sabatino DE, Murphy SL, Rasko JE, et al: CD8(+) T-
cell responses to adeno-associated virus capsid in humans. Nat Med 2007, 13:419–422. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
122 
 
CHAPTER 7 
 
Alternative Strategies for Enhancing Direct Myocardial Gene Delivery in Ischemic 
Myocardial Infarction: A Case Study Featuring Self Complementary Vector 
7.1  Introduction 
 
The previous chapter revealed some key findings with the use of 
ssAAV9.S100A1 therapy through two different direct routes of administration.  Despite 
the strong compelling case for Liquid Jet Injection as the superior route and the 
confirmation of multiple host responses in the IM group, there was no conclusion on 
whether or not it was the intensity of the expression profile, vector capsid interactions, or 
high systemic exposure that caused the aggressive host responses in the IM group.  
Given that both groups had a high expression profile in terms of cross sectional area and 
intensity, it would appear less likely that S100A1 was the problem given the discrepancy 
in outcome at 10 weeks.  As described in previous chapters, AAV infection imposes risks 
to the system that have been acknowledged in the field for decades, but more recent 
studies have elucidated the means [1].   
In particular with AAV in muscle, a diagram model of the host response is 
presented below in (Figure 7.1).  Numerous studies have unraveled more detailed 
information on the risks of AAV mediated gene therapy in terms of host response. In 
order to improve clinical outcomes, one major goal the field is focusing upon is 
correlating the upfront risks of delivery with systemic priming, whereby ultimately the 
immune system tips into therapeutic tolerance or mounts a response.  It is believed that 
understanding these interactions throughout the process of therapy can mitigate the 
risks. 
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AAV is less immunogenic than adenovirus because it avoids directly interacting 
with and transducing antigen presenting cells.  However, in the presence of inflammation 
or when systemic exposure penetrates a threshold, these key cells can be activated 
against both AAV and transgene antigens and or signals derived from the cells that 
contain them [2]. 
In our case study example presented in Chapter 6, it is very likely the IM S100A1 
group with single stranded vector suffered a deleterious TH1 adaptive immune response 
since the risk factors were present, recapitulating: (1) High levels of IFNγ, TNFα in the 
blood (2) CD38 markers all present in higher proportion versus the other 3 groups (3) 
Inflammation from both infarct and delivery events were present at time zero and 
beyond.  Not shown in the diagram is the contribution of early inflammation, dubbed 
Signal 0, which has a role in determining whether or not Signal 2 occurs. 
Given that ischemic myocardial infarction and subsequent therapeutic target areas are 
very high risk, this Chapter describes an alternative vector strategy, the self-
Figure 7.1  Host Response model depicting the difference between tolerance 
and immunity.  Multiple signaling events contribute to adaptive immune 
response through antigen recognition (Signal 1), Co-stimulation (Signal 2) and 
the production of systemic inflammatory markers (Signal 3). 
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complementary AAV9 vector or double stranded DNA vector which has several 
advantages over the single stranded version.   
One of the key advantages of S100A1 besides its potent effects is its transgene 
cassette size at only 330 base pairs (bp).  The cloning capacity of AAV cassette is only 
4,440 bp total, however much of the space is designated for the inverted terminal 
repeats, promoter and other elements, thus limiting transgene packaging to around 3100 
base pairs.  Therefore other transgenes over a certain size such as SERCA2a could 
never be packaged into a double stranded vector.  The double stranded vector has two 
key advantages that might increase performance in higher risk myocardium.          
The first advantage is leveraging the key molecular biological advantage double has 
over single stranded versions that is skipping the DNA template conversion step.   
Described briefly here since vector engineering is beyond the scope of this 
research, all AAV viruses package single stranded DNA sequence cassettes that must 
first convert to double stranded DNA.  This step precedes which precedes therapeutic 
expression and if conversion fails so does the therapy.  Self-complementary vector was 
developed to address the key rate limiting step of single stranded DNA to double 
stranded after the virus successfully transfects a cell.  This process of template 
synthesis was which was once thought highly efficient, however key studies and 
applications in clinical scenarios prove otherwise [3,4].  Furthermore, even after 
successful template synthesis conversion, studies have reported instability events 
whereby the newly converted strand is degraded rapidly in vivo, negating any 
therapeutic potential of the original transfection [5].   
The second hypothesized advantage, although controversial and one point this 
research seeks to determine is whether or not double stranded vector with the same 
dose/transgene should be less inflammatory.  Single stranded DNA infections have a 
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long established research track record with vaccinations, or induced immune responses 
[6].  The following logic is that within inflammatory environments and or high 
concentrations of product (i.e. vaccination delivery), this would increase the risk of an 
adaptive response.   
Supported by a solid body of evidence, the double stranded vectors because of 
these cited reasons leads to both faster and higher levels of gene expression in muscle 
[7].  One study in rodent hearts reported 10 to 15 fold higher copy number vector 
transfer along with a more robust  marker gene expression profile [8].  This study cited 
the concept of a saturation point, whereby maximum possible copy number increased 
with local injection but reached an upper limit in terms of actual cellular transduction  
Therefore, this Chapter 7 was dedicated to exploring the concept of using the 
same gene therapeutic intervention, however constructed with a self-complementary 
vector.  The central hypothesis challenged is twofold: 
(1) That for one or both routes of direct injection, self-complementary vector would offer 
increased expression levels and similar or better outcome at 10 weeks post MI 
(2) Due to eliminating the conversion step risk factor, the therapy overall would be less 
inflammatory 
7.2  Methods & Materials  
 
7.2.1  Protocol Summary 
20 rats received a baseline echo and infarct creation via left anterior descending 
artery (LAD) ligation and were divided into 2 separate groups (n=10 ea.):  2 
Experimental consisting of, IM and LJ each receiving 1.2x1011 vg of scAAV9.S100A1.  
IM injections were performed with three separate 100uL in the left ventricle with a 30G 
needle, while the LJ device fired three separate 100 uL injections projected at the 
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exposed left ventricle from 25 cm above the thoracotomy.  Following 10 weeks, the rats 
were evaluated with echocardiography for LV function, Masson’s Trichrome staining for 
infarct area, QPCR for AAV9.S100A1 genome detection, and IHC staining for S100A1 
protein.  In addition to function and therapeutic endpoints, host response assessment 
was conducted on 10 week blood and cardiac tissue specimens via cytokine panel and 
the CD38 immune marker. 
Essentially this study is a repeat of the previous Chapter 6, however featuring 
delivery of only scAAV9.S100A1 vector.  All echocardiography, surgical, animal 
handling, and tissue harvest/analysis were as is the previous. 
7.2.2  Grouping & Data Analysis 
Previous data from the 2 control groups [IM Saline, Liquid Jet Saline] and 2 
ssAAV9.S100A1 treatment groups [IM S100A1, Liquid Jet S100A1] were used to assess 
various endpoints in comparison to the results presented in Chapter 5.  Specifically, the 
control groups were not repeated and used for reference to evaluate: LV mechanics, 
S100A1 and CD38 proteomic expression normalization, and cytokine panels.  The 
genome copy detection via QPCR is however completely original.  
7.3  Results 
7.3.1  Operative & Delivery Results  
 
One animal in each the IM group and Liquid Jet group was excluded due to 
complications with either the MI or delivery, thus grouping IM scS100A1 (n=9) and Liquid 
Jet scS100A1 (n=9) for the analysis.  Delivery parameters were executed as in the 
previous study without major incidence.   
7.3.2  Echocardiography Results 
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The key hemodynamic data from this follow up study are presented in (Table 7.1). 
 
 
There was no difference between the groups at baseline.  At 10 weeks however, 
the most striking results were found in the IM SCS100A1 group, whereby   dramatic LV 
functional improvement  was found as compared to the single stranded data as found in 
Chapter 5 Table 1.  This group unlike the analogous with the single stranded, preserved 
significant baseline function at [60±2]% and was found superior to both IM Saline [47±3] 
and Liquid Jet Saline [46±3]%.  This group also demonstrated the lowest degree of 
global geometric LV remodeling changes with: (1) Lower 2D Epicardial Area [1.1±0.1] 
         
Data Point: IM - Sa. Liquid Jet-Sa.IM - SC S100A1 Liquid Jet - SC S100A1
Weight [g] 409±21 406±32 373±14 336±24
Heart Rate [bpm] 355±12 346±9 343±13 318±13
End Diastoic Volume Index 0.6±0.1 0.7±0.1 0.5±0.1 0.7±0.1
End Systolic Volume Index 0.2±0.03 0.2±0.05 0.1±0.02 0.2±0.02
Ejection Fraction [%] 71±2 68±2 72±1 70±1
Epicardial 2D Area [cm2] 0.7±0.1 0.8±0.1 0.6±0.1 0.8±0.1
LV Wall Thickness [mm] 1.5±0.06 1.4±0.05 1.4±0.04 1.5±0.06
Data Point: IM - Sa. Liquid Jet-Sa.IM - SC S100A1 Liquid Jet - SC S100A1
Weight [g] 587±16* 610±22* 581±13* 573±8*
Heart Rate [bpm] 306±31 317±9* 314±15* 309±13    
[mL/cm2 ] 1.2±0.2* 1.3±0.1* 0.8±0.1* 1.3±0.2*    
[mL/cm2 ] 0.7±0.2* 0.7±0.1* 0.3±0.1* 0.8±0.2*
Ejection Fraction [%] 47±3* 46±3* 60±2* † 57±4* †
Epicardial 2D Area [cm2] 1.4±0.1* 1.5±0.1* 1.1±0.1* † § 1.5±0.1*
LV Wall Thickness [mm] 1.2±0.1* 1.2±0.1* 1.4±0.04* † 1.5±0.1 †
Infarct Size [% LV Area] 33±6 20±6 30±13 32±9
* p<0.05; Baseline to 10 Weeks
† p <0.01; vs. Control Saline Groups
§ p<0.01; vs All Other Groups
BASELINE 
10 WEEKS POST MI
Table 7.1  Echocardiography and Outcome Data: scAAV9 Pilot Study 
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cm2 p<0.05, versus all other groups IM Saline [1.4±0.1] cm2, Liquid Jet Saline [1.4±0.1] 
cm2, and the Liquid Jet SCS100A1 group [1.5±0.1] cm2.  (2) Trending lower End diastolic 
and End systolic dimensions.  It is important to note however that this particular group 
also started with lower indices, but the point is the difference in direction from the single 
stranded group which dramatically worsened in the direction of chronic heart failure. 
On the other hand, the Liquid Jet SCS100A1 group basically confirmed similar results 
found in the previous study, with a significantly retention of LV functionl [EF+57±4%], 
p<0.05 versus IM Saline and Liquid Jet Saline. 
Structure wise, both treatment groups featured severe MI zones with IM 
SCS100A1 [30±13]% and the Liquid Jet SCS100A1 [32±9]% LV affected area.  Despite 
these affected zones however, both treatment groups had greater average LV wall 
thickness (IM SCS100A1 [1.4±0.04] mm; Liquid Jet SCS100A1 [1.5±0.1] than both IM 
Saline [1.2±0.1] and Liquid Jet Saline [1.2±0.1], suggestive of rescue. 
Summarizing, both the IM and Liquid Jet herapy groups in this pilot study evaluating 
scAAV9.S100A1 were efficacious within study limits. 
7.3.3  Quantitative PCR Detection of scAAV9.S100A1 DNA 
 
The same methodology for analysis were that were used in Chapter 5 were also 
applied here.  The fold expression with the self-complementary vector was much higher 
compared with the single stranded results in Chapter 5 (Figure 7.2).  In comparison to 
the single stranded vector results, there are a number of key points that can be drawn.  
First, the large change in the magnitude of copy number in both groups was profound, 
more so in the IM group as expected with the focal expression profile.  The IM 
SCS100A1 group presented with [304276±36753] GC per 100 ng DNA in the cardiac 
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regions, but also had a  distinctly higher presence in the liver that superseded all group 
specimens tested at [665279±39818] GC per 100 ng DNA, p<0.01. 
 
 
 
 
By comparison, the Liquid Jet (i.e. compared with IM SCS100A1) cardiac regions 
had nearly 10 times less copy number, with [36753±5844] GC per 100 ng DNA.  
However unlike the previous single stranded set, a sizeable amount was found in the 
Liver at [39818±3246] GC per 100ng DNA. 
Fold detection wise, the IM group experienced a roughly 23 fold increase in the 
cardiac zones comparing double to single stranded vector transduction.  The Liquid jet 
likewise was 3.6 fold higher in the cardiac but ever more so in the liver at nearly 1000 
fold.  Recall there was minimal detection in the liver with the single stranded vector with 
this route previously. 
Figure 7.2  QPCR analysis revealed significantly higher transfer levels in both 
the cardiac regions and collateral liver.  The IM Group demonstrated 
significantly higher expression * p<0.05 for both regions, with the liver 
superseding † p<0.01 other tissues.  
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Summarizing, double stranded vector in terms of transduction performed higher than the 
reported target of 10-15 times fold in comparison to single stranded vector, but 
particularly with the IM group the cardiac specificity is an issue.   
7.3.4 Quantitative Cross Sectional S100A1 Proteomic Expression 
 
Given the accentuated increase in copy number it was expected protein amount 
would also increase with the self-complementary vector.  This was true for both the IM 
and Liquid Jet groups.  The IM SCS100A1 group scored very high levels of 
overexpressed S100A1 protein [8.8±0.3] S100A1 Fluorescent Units, in fact significantly 
p<0.05 higher than the other 3 delivery/vector combinations (Figure 7.3).   
 
 
 
 
Figure 7.3  The second iteration of S100A1 proteomic analysis revealed 
significantly higher overexpression in all treatment groups * p<0.05.  
Comparatively, both Self Complementary vector treatment groups scored 
higher † p<0.05 than corresponding Single stranded groups.  The IM-SC group 
scored much higher overall than all others § p<0.05. 
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The Liquid Jet SCS100A1 group reached [6.1±0.3] levels, higher than both single 
stranded IM [5.0±0.1] and Liquid Jet [4.3±0.1].  
Confocal microscopy images revealed what was found in the analysis at 20 times 
magnification.  (Figure 7.4) demonstrates the typical intensity in S100A1 expression 
found when comparing single versus self-complementary vector results.   
 
 
 
7.3.5  Host Response to scAAV9.S100A1 Therapy 
 
In line with both an increase in copy number and S100A1 protein detection, 
CD38 marker also increased.  As found in Chapter 5, the Liquid Jet SCS100A1 [8.0±0.3] 
CD38 Fluorescent Intensity Units was significantly p<0.05 lower than the IM SCS100A1 
which scored the highest at [10.7±0.5].  (Figure 7.5) plots the results. 
Figure 7.4  Representative image comparing single stranded versus self-
complementary S100A1 expression (A) IM single stranded Group (B) IM self-
complementary Group demonstrates higher S100A1 expression 
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Blood Cytokine Panel Results 
(Table 7.2) summarizes the cytokine analysis determining the global immune effects of 
self-complementary vector driven overexpression.   
 
 
           
CYTOKINE:
  
Controls IM - S100A1 Liquid Jet - S100A1
IL-1α 113±29 282±94* 353±157*
CCL5 (RANTES) 156±22 257±34* 325±86*
TNFα 124±26 158±54 183±51
IFNγ 79±15 100±30 133±72
IL-4 37±8 65±17 42±9
IL-6 46±11 80±37 92±62
IL-12 54±14 137±44* 209±88*
* p<0.05; AAV.S100A1 Delivery Group vs. Saline Controls
BLOOD LEVELS [picograms/mL]
Figure 7.5  CD38 Expression trends higher inline with overall viral mediated 
S100A1 expression.  As found previously, overexpression of S100A1 
increases immune signaling * p<0.05.  The IM group as compared with Liquid 
Jet was significantly higher † p<0.05.   
Table 7.2  Pro-Inflammatory Blood Cytokine Data at 10 Weeks Post MI: scAAV9.S100A1 
133 
 
Elevated profiles of IL-1α and CCL5 (RANTES) were found in both the IM and 
Liquid Jet groups.  There was however no major increase in TNFα or IFNγ as found in 
the IM single stranded group that experienced an increase in all 4.  Another unique  
finding was that the double stranded results yielded an increase in IL-12, which was not 
found previously.  Based on these results, overall, it appears the double stranded vector, 
despite much higher fold S100A1 expression, is less inflammatory for IM Injection.  For 
Liquid Jet Injection on the other hand, it appears more inflammatory but does not result 
in poor outcome at 10 weeks.   
In terms of outcome based on cardiac mechanics and host response, a penultimate 
outcome overview is described in (Table 7.3). 
 
 
7.4 Discussion 
 
The two major limitations of this study are the single dose of 1.2 x 1011 viral 
particles and the lone 10 week follow up timepoint.  We will review the compiled data 
within the context of these two limitations.  Despite these constraints, the compiled 
     p    y  p
THERAPEUTIC PROFILE
Function EF% Integrity LV WT LV Scar % S100A1 Fold Expression Myocardium CD38 Blood Cytokines
Liquid Jet S100A1 60±3% 1.5±0.1 17±5% 4.3±0.1 3.8±0.2 None
IM S100A1 43±4% 1.1±0.1 40±4% 5.0±0.1 7.2±0.8 IL-1α, CCL5, IFNγ, TNFα, IL-12 
Liquid Jet SC-S100A1 57±4% 1.5±0.1 32±9% 6.1±0.3 8.0±0.3 IL-1α, CCL5, IL-12
IM SC-S100A1 60±2% 1.4±0.04 30±13% 8.8±0.3 10.7±0.5 IL-1a, CCL5, IL-12
CARIAC FUNCTION PROFILE HOST RESPONSE PROFILE
GROUP
Table 7.3 Compiled Outcome Results: ssAAV9 vs. scAAV9 Per Group 
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studies do offer some very interesting concepts that can be explored for future direct 
myocardial delivery studies featuring AAV mediated overexpression for ischemic MI.  
Several key topics for discussion will be: the pharmacodynamic effects of viral mediated 
S100A1 therapy by vector/route selection, saturation limits with the IM route regardless 
of dose, and factors that elevate host response risk profiles.                                                  
As argued by this dissertation, the ideal  direct delivery mediated gene treatment 
paradigm for ischemic MI would do the following: (1) Transfect a sufficient % of 
myocardium to rescue failing myocardium and simultaneously reduce disease burdened 
cells in affected fibrosis area (2) Tip the host response in favor of tolerance rather than a 
deleterious adaptive immune response (3) Minimize collateral overexpression in non-
target organs with an optimized direct route of administration. (4) As a function of (1), (2) 
and (3) selection of the correct vector/dose that would achieve the objective within safety 
limits.  Essentially we argue that a solution is not likely an optimized vector construct or 
the perfect device arrangement, but a systematic approach exploring the interactions 
between them. 
One key element of a systematic approach includes an understanding of the 
pharmacodynamics of AAV mediated cardiac gene therapy.  This has become a 
significant area of interest, with a number of studies designed to elucidate the ideal copy 
number required for an efficacious delivery profile or exploring relationships between 
exposure and downstream expression levels [9].  In this study as in previous studies 
[10], self-complementary vector at the same dose level and route results in dramatic 
differences in:  therapeutic viral DNA transfer, mRNA expression levels, and 
subsequently therapeutic protein production.  For IM delivery, our results demonstrated 
a 23 fold difference with the same dose.  For Liquid Jet, less dramatic, but still significant 
elevated at roughly 4 fold.  Thus, it is a reasonable conclusion that the same therapeutic 
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benefit in our study could have been achieved with a lower dose of self-complementary 
AAV given that only a 4 fold overall increase in S100A1 expression was found to be 
efficacious in the ssAAV9.S100A1 Liquid Jet S100A1.  Therefore, future dose response 
studies including both vectors would reveal more important findings on kinetics.  
These observations on the performance differences between the vector 
constructs leads our discussion into two key directions with regard to dose/vector 
selection when targeting failing myocardium. First, after breaching an inherent biological 
capacity threshold, additional copy numbers may not provide benefit in terms of 
additional therapeutic protein production and should be considered carefully.  Secondly, 
direct routes (i.e. whether IM, needleless microinjections) a cardiac muscle region via 
saturation limit prior to inducing host response risks.  This upper limit is analogous to 
those that are sought with routine vaccinations, whereby a successful cardiac gene 
therapy administration is the antithesis.   
Expanding on the first point above, it was found that the overall fold protein 
S100A1 ratio in the IM Groups (i.e. increase from 5.0 to 8.3 fold) did not correlate with 
the 23 fold increase in DNA copy number, the basis for expression.  This suggests 
internally either the cells can only generate so much S100A1 protein from mRNA or 
additional regulators exist.  From a clinical perspective, this indicates an important 
concept on a per gram myocyte basis scaled up to larger organisms.  Therefore, it is 
plausible that there is a suitable effective range of vector which in effect reaches the 
biological upper limit, but does not provide benefit beyond that with increased copy 
number.  This range may depend on the health of the area, since diseased muscle areas 
are more difficult to transfect [11], but ultimately an upper limit is reached readily with 
direct injection methods since there are minimal barriers to circumvent as opposed to 
transvascular delivery [12].  This study demonstrates that at least 2,000 – 10,000 copies 
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per 100 ng DNA of encoded S100A1 DNA in rodent myocardium seemed to be sufficient 
in rescuing from acute myocardial infarction with raising basal expression levels 4 fold.   
Expanding upon the second major point, we and others assert that the same therapy  
providing benefit beyond the window can dramatically increase the risk of host 
responses.  In our case studies this concept may have been realized even though two 
groups were efficacious, but immunologically activated.                  
This concept was exemplified in this study with two very different vector 
transduction efficiencies at the same dose level.  The group with the highest cardiac 
specificity was the single stranded Liquid Jet, the only group (Table 7.3) with both a 
positive cardiac and host tolerance outcome measures.  This group featured the lowest 
overall fold S100A1 protein level by comparison with the other 3, but also had the least 
host response as measured by CD38 and the systemic cytokines.  It is very likely that 
very minimal off target exposure in the liver reduced these risks given that delivery, 
vector and dose variables were controlled.    However it is important to note when 
switching to self-complementary vector this level in the Liquid Jet group increased nearly 
1000 fold.  Although striking and not in proportion with the IM group changes, this is 
likely explained by the difference in single stranded genome conversion between in the 
liver.  In other AAV mediated gene studies it was found that liver cells have much more 
difficulty with single strand synthesis likely explaining the results in our studies [5-7].  
Therefore, collateral exposure is a function of both delivery and vector selection and 
must be considered in risk assessment.  
The most striking outcome discrepancy in the compiled results is clearly with the IM  
route when comparing single versus self-complementary vector.  It appears one 
plausible conclusion is that the difference in outcome when comparing transduction and 
protein levels with IM are: (1) the single strand to double strand conversion step is very 
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inflammatory with a robust, heterogeneous IM expression profile and (2)  Self 
complementary vector has a significant time advantage in establishing vital expression in 
the early post MI period.                    
As described previously, strong evidence supports the claim that the single 
stranded genome conversion process in vivo after the viral nuclear docking step is not 
without risk and can trigger immune activation.  The difference between the IM and liquid 
jet expression profiles established in Chapter 5 is spatial myocardial distribution.  It is 
reasonable to assert that the highly heterogeneous, overexpressed regions in muscle 
containing unconverted viral origin single stranded DNA triggered the difference.  The 
liquid jet methodology essentially disperses this risk under a theorized immunological 
threshold.  The second intriguing explanation may be timing, whereby self-
complementary has a key advantage in the early stage of acute MI.  This is due to the 
fact that self-complementary vector as designed delivers fully capable therapeutic DNA 
that immediately generates S100A1 protein.  Therefore, is very likely that in addition to 
being less inflammatory, the scAAV9 vector generated efficacious levels much faster.       
Due to the 10 week timepoint limitation, no conclusion can be made as to whether or not 
any of the 2 efficacious groups with elevated risk profiles (Liquid Jet SCS100A1 or the 
IM SCS100A1) would be remain so over time.   
There are many studies that demonstrate efficacy for periods up to 3 months, 
then show rapid losses of both therapeutic expression and outcome measures due to 
aggressive immune responses.  For this reason, a number of gene therapy trials have 
actively acknowledged the risks of systemic exposure and inflammation by incorporating 
immunosuppression in an effort to keep the host under the critical threshold of immune 
activation [13].   
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Summarizing, outcome is a function of the efficacious target expression balanced 
by the risk of delivering the sufficient vector payload to reach a stable range, yet not 
breach tolerance.  Host response problems are clearly identifiable when doses are 
dramatically increased beyond a range such that therapeutic outcome has saturated or 
systemic exposure becomes too high.   
This study illustrated these concepts and support further temporal experiments 
with additional vector configurations, whether self-complementary or those with different 
promoters/transgenes etc.  Chapter 8 explores a means to reduce the host response 
risks upfront with a combination drug/gene therapy concept.  It is anticipated that the first 
critical post AAV delivery window has a major role in determining therapeutic benefit.    
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CHAPTER 8 
A drug/gene combination strategy to enhance direct myocardial AAV delivery 
Adapted from: Fargnoli AS, Mu A, Katz MG, Williams RD, Margulies KB, Weiner DB, Yang S, 
Bridges CR.  Anti-inflammatory Loaded Poly-Lactic Glycolic Acid Nanoparticle Formulations to 
Enhance Myocardial Gene Transfer: An In-Vitro Assessment of a Drug/Gene Combination 
Therapeutic Approach for Direct Injection.  J Transl Med. 2014 Jun 16; 12(1):171   
8.1 Introduction 
 
Acquired heart disease from myocardial infarction (i.e. heart attack) remains the 
leading cause of mortality and morbidity worldwide, with 22 million new patients 
diagnosed annually.  Essentially, all approved pharmacologic and device systems 
impose significant cost burden to the health system, yet fail to increase survival rates. [1-
3] Cardiac transplantation, which is the gold standard for patients, will never meet the 
clinical demand due to the chronic shortage of viable donors [4,5].  Therefore, new 
therapeutic approaches to manage the disease burden represent a significant unmet 
need.  Recently, sophisticated molecular profiling tools combined with a deeper 
knowledge base derived from disease models have ushered in a new era of 
biopharmaceutical development for heart disease. This has resulted in the development 
of a more potent class of therapies designed to act at the myocyte level, whereby 
therapeutic action is achieved primarily through DNA, RNA and or microRNA genetic 
reprogramming. [6]  
Various gene therapy concepts have been applied successfully in animal models 
demonstrating increased contractility, repaired myocardium, and or regenerated new 
vessels to reduce myocardial infarction reoccurrence. [7-10]  Independent of the 
targeted gene mechanism, the most common means to achieve these aims are with 
either bioengineered viral or non-viral vector biologics, since the uptake and success 
rates of naked molecular therapies is very poor in vivo. [11,12]  The most effective gene 
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products today have shown remarkable promise, but at the same time have also 
presented more risks and complicated translational issues, especially when compared 
with traditional pharmaceutical compounds.       
Despite the availability of effective transgene-vector systems, one major rate 
limiting problem is with achieving safe and efficient myocardial gene transfer in the clinic. 
[13,14]  Due to size scale and more complex membrane barriers, these issues do not 
emerge in smaller animal studies yet are a major challenge in larger organisms. [15,16] 
Although the preferred route of administration in clinical trials, it remains controversial 
whether or not minimally invasive catheter infusion approaches can yield sufficient 
therapeutic expression levels that significantly improve outcomes in the clinic. [17] 
Another major problem with these systems is restricting therapeutic expression to the 
heart and minimizing off target effects.  In fact, published large animal data has 
demonstrated a greater than 2000 fold higher presence in collateral organs versus the 
heart [18-20]. Alternatively, direct myocardial delivery methods can largely restrict 
therapeutics to the heart if safely administered.   
Direct myocardial delivery methods (e.g. needle injection, sonoporation) can offer 
greater cardiac specificity of gene therapeutics compared to percutaneous infusion 
approaches.  The key unresolved problem is with the limited distribution of gene 
therapeutic per delivery site requiring many injections. [21] Increasing the number of 
injections has the adverse effect of triggering inflammation in the myocardium, thus 
limiting the availability of additional injection sites and jeopardizing the retained therapy.  
The immune response to gene therapy products, especially notorious with the viral 
mediated products, is complex but several key studies have demonstrated a clearer 
relationship between inflammation and the increased risk of an adaptive immune 
response. [22,23]  Therefore it is postulated the use of an anti-inflammatory drug co-
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delivered with the gene therapy product could: (1) Address the inflammation to minimize 
the adaptive immune response and promote therapeutic tolerance (2) increase 
trafficking and uptake in a more favorable microenvironment and (3) potentially permit 
more injection sites. 
This concept of a direct injection drug/gene approach has yet to be translated 
into the heart, whereby problems exist with increasing uptake and extending the half-life 
of anti-inflammatory drugs at the site of injection beyond the peak acute inflammatory 
window of 48 hours.  In addition to the timing issue, the anti-inflammatory load must not 
interfere with vector trafficking or the subsequent gene expression efficiency.  Numerous 
studies have explored of advanced non-viral vectors to increase in vivo performance by 
means of transfection alone. [24,25]  However, none have attempted to use anti-
inflammatories at the injection site co-delivered with a higher risk, but optimal gene 
transfer vector to provide a more promising clinical strategy.   
This study summarizes the development and parameter testing of a reliable 
nanoscale anti-inflammatory formulation production process for co-delivery with gene 
products.  The development phase features aspirin and prednisolone, two widely utilized 
anti-inflammatories and incorporates them into two common FDA approved poly lactic 
glycolic acid (PLGA) polymers. [26] Complete nanoparticle characterization, process 
tolerance limits and an in vitro feasibility assessment in harvested myocytes are offered 
to evaluate the concept of a drug/gene combination therapy.    
8.2  Methods and Materials: 
 
Poly-Lactic Glycolic Acid Nanoparticle Production Process 
Pre-Processing Steps: 
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A water oil water (w/o/w) double emulsion process outlined in (Figure 8.1) was 
executed to generate aspirin (99% pure, Sigma Aldrich USA) and prednisolone (99% 
pure, Sigma Aldrich USA) loaded poly- lactic glycolic acid (PLGA) nanoparticles (NPs).   
 
 
 
First, initial drug load water phase stocks of 1-3 mg/mL aspirin and 0.1-0.4 
mg/mL prednisolone were created by dissolving in 1% poly vinyl alcohol (PVA) solution.  
In the case of prednisolone due to its poor water solubility, a 10% Ethanol (w/w%) was 
added.  These doses were selected based on body weight and pharmacokinetic data for 
the rodent species.  The second step or oil phase was generated in a separate vial, with 
PLGA, input mass range (20-120 mg) of one of either types (50:50, 65:35 i.e. % of lactic: 
glycolic acid chains) dissolved in 2.5 mL of Dichloromethane.  For the in vitro study only, 
production runs were carried out as described in the methods above except 100 g of 
Rhodamin B dye powder was added to the first drug water phase. 
Process Steps: 
The first emulsion was created by adding 1 mL of aspirin or prednisolone drug 
PVA 1% solution dropwise to the oil phase polymer in a 5 mL glass vial under probe 
Figure 8.1.  The water oil water double emulsion nanoparticle production 
process work flow sequence to generate high quality anti-inflammatory 
formulations 
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sonication.  After 3 minutes, this resultant emulsion was then added dropwise to a larger 
outer water phase containing 15 mL of PVA 1% to create the double emulsion.  The 
double emulsion was then placed in a fume hood and stirred gently for at least 24 hours 
to facilitate solvent evaporation and particle formation.  Separation was achieved with via 
ultra-centrifugation at 30,000g for 35 min at 10C.  The resultant particle pellets were 
washed to remove residual drug/polymer, then freeze dried overnight.  Four nanoparticle 
compositions were generated with the reaction: PLGA (50:50 Aspirin), PLGA (65:35 
Aspirin), PLGA (50:50 Prednisolone) and PLGA (65:35 Prednisolone). 
Post-Processing: 
All yields were weighed then stored in sterile cryovial containers at -20C.   
Scanning Electron Microscopy (SEM) Analysis & Characterization 
Approximately 5 mg of each freeze dried NP sample was prepared for SEM with 
gold sputter coating, and then imaged on a JEOL SEM unit at 1.00 kV between 10-
20,000 x.  Multiple images were taken from separate locations on the field with focus in 
the range of 1 um to 500 nm.   
Stability Testing 
24 Hour Formulation Stability Test 
Saline stability re-constituted particles tests were also conducted.  Ten mg of 
freeze dried nanoparticles were dissolved and probe sonicated in sterile 0.9% saline 
water and allowed to settle over a 24 hour period.  Repeat droplets were first dried and 
sputter coated for loading into the SEM. 
Zeta Potential Colloidal Stability Measurements 
A sample of each particle composition was prepared in water and added to 
testing cuvettes per manufacturer instructions of the Zetasizer Nano ZS instrument 
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(Malvern Instruments, UK).  Triplicate runs were averaged to represent a single data 
point for multiple samples from the same production lot.   
Controlled Release & Loading Efficiency Analysis 
A UV-vis spectrophotometer (NanoDrop, National Instruments) was used to 
generate two separate standard curves for serial dilutions of known drug concentrations.  
The wavelength consistent with aspirin detection was 275 nm and 235 nm for 
prednisolone.       
Drug loading efficiency calculations 
To compute loading efficiency, the amount of either aspirin or prednisolone 
encapsulated in the nanoparticle formulations was determined by measuring the residual 
amount in the supernatant following centrifugation relative to the initial load in the water 
phase.  Percentage was derived as the mass amount of drug remaining in the 
supernatant following separation. 
Controlled Release Analysis 
High quality yields were selected based on the most potent drug formulation of 5 
wt.% PLGA aspirin and 1.5% PLGA prednisolone were manufactured per process 
specifications.  Each particle formulation was prepared for controlled release studies as 
follows:  (1) 20 mg of particle was dissolved into 10 mL of 42C (2)  Samples for 
spectrophotometry analysis were removed with a syringe 450nm filter at 12 hours, 1, 2, 
3, 4, 5 days (3) The sample volume was replaced and the process repeated for each 
interval up until the final point (4)  Triplicate UV-vis spectrophotometry measurements 
against the standard curve for each drug were performed on each sample to determine 
the percentage released for each run. 
In Vitro Testing Protocol 
Neo-natal Rat Cardiac-myocyte harvesting 
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Day 0 to 3 neonatal pups are used and the pups were euthanatized by 
decapitation and the heart was immediately removed with forceps.  The atria and great 
vessels were removed and the left ventricular tissue was minced and subjected to a 
trypsin-based disaggregation procedure in a 6 well plate with ethanol cleaned scissor, 
rinsed with HBSS with1% P/S/G, and place in a 50ml conical tube containing 10ml of 
Trypsin solution for shaking (200rpm) at 37C for 15 min.   Cells were then centrifuged at 
660rpm at 4c for 5 minutes.  The supernatant was discarded and the cells were re-
suspended in 20 ml of media and pre-plate for 1-3 hours in the incubator.  Harvested 
cells were collected with centrifuge spin at 660rpm for 5 min at room temperature.  Cell 
pellets for experiments were then placed in the culture media and counted using 0.4% 
Trypsin blue.   
Plasmid GFP DNA & Tagged Nanoparticle Preparation 
A 10 mg master aliquot of eGFP plasmid DNA was obtained from Invitrogen and 
handled according to manufacturer’s instructions.  Under sterile conditions working 
yields for each well was created with, 6µg of DNA was diluted into 100 µL of RNAase 
free water.  Separately 10 mg of each of the process output 4 resultant particle systems 
[PLGA50:50-Aspirin, PLGA50:50-Prednisolone, PLGA65:35-Aspirin, PLGA65:35 
Prednisolone] tagged with Rhodamin B was finely crushed and mixed into 20 mL of 
phosphate buffer saline.  To remove residual dye not bound within the particle structure, 
the particle solution was placed into a dialysis membrane submerged in an outer bath of 
PBS at 37.  Prior to well transfection, 10 µg of each nanoparticle solution in 500µL was 
placed in individual aliquots.     
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DNA and Nanoparticle Well Transfection 
On the day before transfection, cells were placed in 12 well plates with each well 
seeded at a density of 500,000 myocytes in 1mL of DMEM (GIBCO) media without 
antibiotics.  The transfection complexes were then prepared: 
Complex 1 – One 6µg of DNA aliquot was diluted into 100µL of media in an individual 
eppendorf vial.  Complex 2- 8µL of Lipofectamine (Invitrogen) was diluted into 100µL of 
media.  Then, complexes 1 and 2 were mixed together and permitted to incubate at 
room temperature for at least 20 minutes.  After 20 minutes the contents of the individual 
eppendorf yields were then transferred into each well.  The plate was gently rocked then 
placed back in the incubator until the first 24 hour imaging time point. 
For the nanoparticle treatment wells as designated, the 500µL filtered sterile solution 
was added via syringe to each well with a 450nm to prevent aggregates from 
transferring.    
Follow up Fluorescent Microscopy 
The first set of images was taken at 24 hours post transfection.  Media was 
removed from each well prior to imaging and replaced prior to returning to the incubator.  
The remaining set of images was taken at the 48 hour time point.   
Fluorescence images were acquired using a Nikon Eclipse TE2000-U fluorescence 
microscope equipped with a Plan Fluor ×20/0.50 objective (Nikon, Tokyo, Japan. 
Microscope controlling and image processing were carried out using Image-Pro Plus 
4.5.1.27 (Media Cybernetics, Bethesda, MD, USA). 
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Statistical Analysis 
All SEM and nanoparticle characterization data was loaded into GraphPrism 
software suite for statistical testing.  Single way ANOVA was utilized to determine 
differences in nanoparticle subtypes.  Individual paired t-tests were used to compare 
across individual groups.  Bonferroni corrections were applied for significance testing. 
8.3  Results 
8.3.1  Process Capability 
 
Over 45 nanoparticle production yields were obtained over the development 
course with the optimal ranges.  The process volumes were held in a fixed ratio, 
featuring water phase #1 at 1mL, the oil phase at 3mL, and the outer water phase #2 at 
15 mLs.  Pilot runs in greater amount adhering to this proportion scale yielded the same 
quality particles.  Briefly, basic guidelines for each process phase: 
Water Phase:  Aspirin 1-3 mg dissolved in PVA 1% or Prednisolone 0.02-1 mg in 10% 
ethanol PVA1%.  It was noted that adding additional solvents to increase drug load in 
this phase resulted in failure to maintain particle integrity and stability.   
Oil Phase:  The process was very flexible in terms of changing the amount of polymer 
added to the system and was stable in the range of 20 – 120 mg of either PLGA type.   
Outer Water Phase:  The PVA in the system acts as a vital stabilizer that can be readily 
increased.  Increases beyond 2% tended to inhibit the amount but not the quality of 
generated nanoparticles.  Thus, a working range of 0.5-2% of PVA stabilizer in the outer 
water phase is suitable for accommodating various drug/polymer complexes with good 
stability. 
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8.3.2  Particle Characterization 
 
The results presented here summarize the characterization for each of the 4 
resultant nanoparticle types acquired from 5 consecutive runs.  Polymer load was fixed 
at 60 mg, aspirin 3 mg and prednisolone at 1mg respectively.  
SEM images from the various runs for each nanoparticle type were loaded into ImageJ 
software for analysis.  The process consistently yields uniform, spherically shaped 
formulations (Figure 8.2AB).  The size distribution was very narrow, of high quality and 
was as follows:  PLGA50:50 Prednisolone [234±9 nm], PLGA65:35 Prednisolone [228±7 
nm], PLGA50:50 Aspirin [323±13 nm] and PLGA65:35 Aspirin [302±7 nm].  ANOVA 
indicated significance between the groups, specifically it was determined that aspirin 
contributed to larger particles as both PLGA50:50 and PLGA 65:35 types were 
significantly larger than their matched prednisolone counterparts. (Figure 8.2C)  This 
difference in size was most likely attributable to both higher aspirin mass content and 
charge of the first water phase in the reaction since size was unaffected by the addition 
of more polymer (data not shown).  
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Yields were very consistent and proportional to polymer mass input in the range 
of 75-80% recovery upon final harvest.  The average yields per polymer/drug type based 
on 60 mg input were:  PLGA50:50 Prednisolone [46±1 mg], PLGA65:35 Prednisolone 
[45±2 mg], PLGA50:50 Aspirin [48±1 mg] and PLGA65:35 Aspirin [47±2 mg].  
Production yields with increased or decreased polymer loading revealed the same 
results (data not shown). 
Loading Efficiency results were uniform for all 4 nanoparticle types, independent 
of drug or polymer and were:  PLGA50:50 Prednisolone [88.9±0.01 %], PLGA65:35 
Figure 8.2.  SEM Characterization Sizing Results.  A.  Narrow size distribution 
and high quality spherical shaped yield example in A at 2µm scaling.  B.  Close 
up 500 nm scaling image indicates narrow size distribution in the 200-350 nm 
range consistently for all manufactured yields.  Nanoparticle average size by 
drug and polymer combination.  C.  Aspirin nanoparticles of either 50:50 or 
65:35 type had greater size (p<0.05) versus prednisolone.    
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Prednisolone [88.2±0.01 %], PLGA50:50 Aspirin [89.0±0.01 %] and PLGA65:35 Aspirin 
[88.8±0.01 %]. 
Stability Analysis 
Positive nanoparticle visualization was realized on the SEM 24 hours after re-
constituting freeze dried product in saline for all 4 polymer configurations.  The particle 
shape and size was retained.  The stability of the nanoparticles in suspension was 
moderate to good in the range of -30 to -53 mV.  A score much less than -30 indicates a 
stability issue with a pharmaceutical dispersion, while any score higher than -60 
indicates maximum.  The potential scores by nanoparticle type shown in (Figure 8.3) 
were as follows: PLGA50:50 Prednisolone [-47±5 mV], PLGA65:35 Prednisolone [-31±1 
mV], PLGA50:50 Aspirin [-45±0.5 mV] and PLGA65:35 Aspirin [-32±0.9 mV].  Statistical 
tests revealed that the PLGA50:50, independent of drug load was superior compared 
with the 65:35 type.   
 
 
 
 
Figure 8.3.  Nanoparticle Zeta Potential Colloidal Stability Testing Results 
indicate that the PLGA50:50 nanoparticles are more stable in solution versus 
the PLGA65:35 types.  
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Controlled Release of the Nanoparticle Formulations 
(Figure 8.4) shows a graphical depiction of the release over the span of 5 days.  It was 
evident that the aspirin released faster overall as compared with prednisolone.  This is 
most likely due to a combination of factors including size, stability and charge.  The 
PLGA50:50 Aspirin type had the fastest release profile. 
 
 
 
 
8.3.4  Process Limitations 
 
The high quality in terms of particle shape uniformity, yield, surface charge and 
release properties were critically limited by a number of key variables. Therefore, 
production with major deviations with the water phase I input (data not shown) resulted 
in lower quality profiles featuring aggregation and wider size ranges.  The first major 
critical variable was the concentration of the loading drug in the first water phase, which 
Figure 8.4.  Controlled release study results demonstrate that aspirin particles 
overall release faster than prednisolone types. 
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was largely limited by the inherent solubility at room temperature.  In the case of aspirin, 
without solvents added, the maximum concentration was 3 mg/mL directly at the 
solubility limit.  Runs at the 5-10 mg/mL range resulted in aggregation and lower quality.  
In the case of prednisolone, it was anticipated that on a per gram basis at least 1 mg/mL 
would be required to achieve high quality in addition to a realistic dosing paradigm for a 
rodent heart with target of 1 gram mass.  This was achieved suitably with 10% Ethanol, 
however concentrations greater than 25% in an attempt to load more drug distorted the 
process (data not shown).  The PLGA and PVA stabilizer system as presented here is 
therefore open to excipient manipulation provided that solubility and other attributes of 
the selected drug are addressed such to prevent deviations in overall quality which may 
or may not be desired depending on the application.  We anticipate this platform would 
be open for further experimentation by professional formulation scientists tailored to 
each specific PLGA/drug selection for the intended direct injection application.    
8.3.5  In-Vitro Myocyte Transfection 
 
All wells were checked for viability and it was determined that none indicated any 
major media discoloration or visual evidence of contamination.  The following 5 groups 
all had positive detection of GFP (green) in at least 2/3 replicate wells at both 24 and 48 
hours, with a greater degree of cells positive as expected at 48 hours.  Figure 5 depicts 
independent uptake of both GFP plasmid and nanoparticle co-signal.  The absorption 
clusters were confirmed in the center of myocytes.  The multiple DNA and nanoparticle 
infection groups yielded nanoparticle presence (red) or both (yellow) at the 24 and 48 
post transfection:  I. Control GFP DNA only (data not shown)  II.  GFP and PLGA65:35 
Aspirin (Figure 8.5A) III.  GFP and PLGA50:50 Aspirin (Figure 8.5B) IV.  GFP and 
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PLGA50:50 Prednisolone (Figure 8.5C)  V.   GFP and PLGA65:35 Prednisolone (Figure 
8.5D). 
 
 
 
 
 
 
Figure 8.5.  In Vitro Fluorescent Imaging at 48 hours post transfection.  All 4 
particle systems exhibited safe and robust uptake in myocytes while not 
interfering with plasmid uptake and subsequent GFP expression.  Yellow 
signal indicates co-existence of GFP and nanoparticle in: A. PLGA65:35 
Aspirin B.  PLGA50:50 Aspirin C.  PLGA50:50 Prednisolone D.  PLGA65:35 
Prednisolone. 
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8.4  Discussion 
 
This study presents two key findings that have broad implications for the 
advancement of cardiac gene therapies.  First a reproducible, simple to use lab scale 
process was developed to generate anti-inflammatory nanoparticles of very high quality 
for co-administration with gene products in a - regulatory friendly - PLGA platform.  
Although only two anti-inflammatory drugs were utilized in this feasibility assessment, it 
is anticipated that any other drug indicated for injection into muscle could be introduced 
by modification of the first drug water phase.  Also the process offers an easy means to 
adjust the polymer content in the oil phase for the desired degradation/release profile, 
along with increasing the amount of stabilizer.   Therefore this system can provide a 
platform to guide future pre-clinical studies to investigate reliable clinical interventions to 
address the role of inflammation on the relative performance of gene products in muscle 
tissue.   
The potential role of inflammation should not be overlooked, particularly in 
myocardial tissue where the most common delivery scenario is in ischemic regions, 
which are characterized by a high degree of inflammation and fibrosis.  The second key 
finding in the final test was that PLGA uptake and release of anti-inflammatory agents  in 
myocytes does not interfere with the absorption and trafficking of the GFP plasmid.  
Muscle tissue has a high risk of developing an adaptive immune response to gene 
products.  Wilson et al described in detail the host response after AAV delivery by route 
of administration and more specifically the role of inflammation. [27] A key finding with 
AAV mediated gene transfer was that the host either induces tolerance or an adaptive 
immune reaction through a series of complex interactions. [28-30]  A prime risk factor in 
these interactions that was found to trigger adaptive immune responses were 
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inflammatory cytokines and signals either already present in tissue or induced at the 
time of delivery. [31] It has been postulated that with attenuation of innate inflammatory 
response signals, the immune system has a much lower risk for mounting maladaptive T 
cell responses.   
Using the example of AAV, once vector capsid antigens are cleared from the 
system, typically 12-16 weeks after delivery, there is a good chance for therapeutic 
tolerance.  The risk is that an adaptive immune response will destroy those cells 
expressing the transgene of interest well before these antigens are cleared. Use of anti-
inflammatory agents to mitigate the innate response to injury is likely to result in 
enhanced long term gene expression.  Intravenous delivery approaches are associated 
with a lower level of induced inflammation but are also very inefficient.  In contrast, the  
IM route in the heart remains attractive because greater cardiac specificity can be 
achieved, especially for angiogenesis or regenerative therapies that require a more local 
delivery profile. Yet IM delivery is associated with a more robust innate immune 
response due to associated tissue injury.      
Direct injection into healthy or ischemic myocardial regions introduces the gene 
product into a highly inflammatory region, which likely explains the poor cardiac gene 
therapy results with IM interventions.  Early studies by Snyder [32] et al reported that 
very little successful transfer occurs in damaged muscle in the inflammatory 
environment.  Numerous examples have validated these observations in gene therapy 
trials.  In hemophilia trials for example it was found that IM injection into skeletal muscle 
resulted in transient therapeutic gene expression and an adaptive CD4+ immune 
response. [33,34]  However, delivery of the same product infused into the liver has 
resulted in better outcomes and limited reactions.  Muscular dystrophy trials have 
encountered similar difficulties and have attempted to utilize immunosuppressant drugs 
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and other agents to limit responses after multiple IM injections compromising patient 
safety. [35] 
8.5 Conclusions and Future Direction  
 
In this proof of concept study, GFP plasmid was utilized to simulate a therapeutic 
construct understanding that naked DNA is likely to be at the lower end in terms of 
transduction efficiency.  For more practical gene therapy applications, it is anticipated 
that viral vectors encoding the gene of interest could readily be combined with particles 
containing potent anti-inflammatory drugs.  The hypothesis offered is that with the right 
formulation, the anti-inflammatory agent would be released at the sufficient level over the 
critical post-delivery inflammatory period to provide an optimal viral vector trafficking 
microenvironment. There would be a predicted increase in transduction efficiency, 
minimize the innate and adaptive immune response to the vector and/or transgene and 
promote long term gene expression in the target tissues..   
This strategy of course would not be without its own limitations and would require 
much more experimentation to determine the best matched drug and release profile for 
co-administration into the heart.  More complex approaches in managing the host 
response following therapy have been applied, however it may turn out that simply 
addressing the innate immune response at the time of delivery may be a meritorious 
approach to advance successful clinical translation.    
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CHAPTER 9 
 
Summary, Limitations and Future Direction for Needleless Liquid Jet Delivery for 
Cardiac Gene Therapy Applications 
 
 
9.1  Summary 
 
Recurrent or a single major acute myocardial infarction (MI) event results in a 
significant decline in cardiac function in the early stages, progressive decline through left 
ventricular remodeling and maladaptive physiology changes in the mid stage, then 
ultimately in end stage heart failure whereby high cost/low reward (i.e. excluding 
transplants) options still fail to extend survival.  The burden this problem presents to the 
healthcare industry as whole does not need more awareness, but more effective 
solutions.  
Cardiac gene therapy applications are expected to meet or exceed growth 
projections and will remain a strong research area in an effort to develop new targets, 
engineered vectors to encode them and finally as argued by this dissertation their 
optimal delivery route for the given dose required.  Demand is the main reason cardiac 
gene therapy will be a stronghold in modern medicine for years to come.  This demand 
is driven by 3 primary factors: (1) The chronic shortage of donor hearts will never meet 
demand for 22 million end stage patients (2) State of the art surgeries and the latest line 
of drugs are palliative and are no longer cost efficient for government and managed care 
payers (3) The incidence of heart disease, specifically from coronary artery disease, is 
expected to increase significantly with aging populations in the United States, Europe, 
Asia and other developing nations whom adopt western habits.                             
Chapter 1 describes the overall advantage of cardiac gene therapies as compared with 
the standard of care.  Regardless of the specific mechanism, the goal is to treat the 
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myocardial disease permanently at its root cause by administering therapeutic molecular 
biologics as the medicine.  These strategies either restore function and or attenuate 
maladaptive cellular regulation with a sustainable encoded fix.  The excitation 
contraction coupling, angiogenesis, and other related survival mechanisms are well 
established.  With the continual growth of computation power, microarrays and 
bioinformatics the number of targets for myocardial dysfunction will also likely increase 
over the next 10-15 years as massive genetic databases are being built [1].  On the 
basic science front, more detail knowledge is being developed with microRNA 
regulation, therefore new strategies to induce cell directed repair/regeneration have 
already found some early success [2].  
In addition to the explosion of new strategies, Chapter 1 also illustrates that viral 
mediated genome transfer can result in safe, long term outcomes as evidenced by a 
longer track record of other AAV gene therapy trials.  The field has simply learned much 
more with a more prudent scientific approach, whereby human trial data and a growing 
network of investigators have blossomed.  Bioproduction engineers and scientists 
therefore will continue to be motivated to develop, safer, more effective transfer vehicles 
engineered for the intended cardiovascular disease now that safety and efficacy can be 
realized with careful administration [3].   
Given the availability of targets and improved transfer vehicles, Chapter 2 introduces the 
key problem of efficient myocardial gene delivery.  This dissertation and a growing body 
of evidence argues that this is the rate limiting problem that must be solved in the clinic 
[4].  Overall, cardiac gene delivery systems have lagged in terms of development as 
compared with targets and vector engineering.  As presented in our detailed 
development of a liquid jet concept, it is clear there are major discrepancies between 
animal model and actual clinical applications.  The first major difference is anatomy, not 
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only in terms of size scale but additional transport barriers that exist in humans such as 
pre-capillary sphincters [6].  The second are co-morbidities common to heart disease 
patients, such as chronic inflammation in the targeted area compounded by diseased 
transport vessels necessary for AAV trafficking into the myocardial compartment.  These 
are never captured in large animal models that claim to resolve the scale issue and must 
be considered. 
Delivery strategies as reviewed in Chapter 2 fall into two major categories: (1) 
Transvascular or those that seek to leverage the capacity of the patient’s cardiac vessels 
for transfer (2) Direct methods which apply physical means of fluid, pressure, electrical 
current etc. to drive AAV directly into beating myocardium.  The primary goal is to 
transfect the highest % of myocytes possible with the least degree of systemic exposure 
that would raise risk profiles.  The majority of gene therapy trials because of safety and 
an established preference with interventional cardiologists, select the percutaneous 
antegrade catheter infusion system. 
As leaders in the cardiovascular gene delivery space for the last 10 years, our 
group has demonstrated that the route of administration is the prime factor that will 
determine outcome, since transfecting a high % of myocytes is an absolute requirement 
for demonstrable efficacy in terms of cardiac rescue with AAV mediated excitation 
contraction coupling genes.  The CUPID Phase II trial results featuring AAV1.SERCA2a 
do not show a statistically significant improvement in echocardiography and other 
improvement metrics are trivial at best [6,7].  Based on analogous large animal and a 
limited number of post mortem clinical specimens, evidence suggests that antegrade 
single pass “slow” intracoronary infusion transduces only 1-3% of myocytes [7,8].  
Moreover, the distribution is limited to the axis of the primary infusion vessel.  Other 
published large animal data with the same construct resulted in a much higher % of liver 
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transfection versus the heart, even with attempts to recapture vector leaving the cardiac 
system with a perfusion circuit (i.e. V-Focus device) [9, 10].  It is important to note that 
these ovine subjects did not have either the transport or disease barrier conditions, 
suggesting that intracoronary infusion without modification may never be a viable route 
despite its safety.   
Given the shortcomings of single pass antegrade, the field has employed 
extensive bioengineering means to develop a variety of catheter modifications such as 
different lumen and or balloon occlusion configurations that have resulted in a slight 
increase in efficacy.   
For upcoming AAV1.SERCA2a trials, a shift has occurred toward favoring 
retrograde systems that leverage more favorable dimensions and less restrictive 
transport barriers on the venous side cardiac anatomy.  Our laboratory designed an ideal 
system leveraging the venous side at the most extreme level, surgically isolating the 
heart in situ with cardiopulmonary bypass, featuring a high pressure retrograde 
recirculation of AAV vector throughout the Molecular Cardiac Surgery with Recirculating 
Delivery (MCARD) system [11].  The MCARD system with AAV1.SERCA2a 
demonstrated the highest reported cardiac specificity (i.e. up to 2000 fold more cardiac 
expression versus liver) and rescued in later stage ovine ischemic cardiomyopathy [12].  
The obvious limitation of MCARD is its relative complexity and available use in a limited 
number of patients already undergoing adjunctive surgical therapy. 
Given the state of cardiac gene delivery systems, it is clear that there is a major 
bias toward transvascular systems and this research sought to contribute to the less 
visited, but increasing important direct injection routes [13].  As described in Chapters 2 
and 3, this bias is primarily due to the poor performance of other direct methods in terms 
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of distribution and resultant induced inflammation, which is known to trigger immune 
responses [14].   
Chapter 3 describes the complete aims in this dissertation to develop a 
translatable direct myocardial injection methodology leveraging liquid jet device 
technology.  The challenge was adapting the DERMOJetTM device for both a rodent and 
ovine application.  The hypothesized advantages of liquid jet delivery were: (1) increase 
myocardial retention (2) limited collateral spillover provided tuned device settings (3) 
wider coverage of myocardial tissue mass per injected unit volume (4) Less 
inflammatory; both in terms of the initial punctures and subsequently generated 
homogenous expression profile and (5) Would potentially provide a solution for 50-60% 
patients excluded from AAV therapy trials due pre-existing antibody titer.  Ideal delivery 
with this proposed route as stated was to project and disperse AAV through myocardium 
in a powerful, yet safe jet stream that would be retained. 
Liquid jet injection technology as discussed in Chapter 4 is not at all novel and 
had previously been utilized in both scientific and basic medical applications including 
vaccination [15].  Within the realm of gene therapy, there was no prior literature 
describing the concept for AAV mediated therapy with contractility transgenes, thus the 
inspiration for this work.   
Preliminary experiments with the DERMOJetTM revealed the need for 
optimization.  As described in Chapter 4, ex vivo muscle and mock demo testing of 
various materials characterizing the jet profile revealed a potent laser like injection track 
with minimal dispersion from close range (i.e. 1-3 inches from the surface).  The nozzle 
velocity was roughly 330 m/s with a 500KPa driving pressure inside the chamber.  These 
factory ratings were tuned for deep skin/muscle penetration, which of course serve 
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vaccination applications well.  It was determined that if this approach would work, 
optimization was required. 
The device settings were altered through working the engineering team of the 
manufacturer to reduce the power rating via actuator spring size reduction. Then, 
through a series of optimization experiments in beating heart non survival models, it was 
determined that 110 m/s velocity and a driving pressure of 100-250KPa would provide 
the proper dispersion.  Another key variable was identifying optimum target distance 
range to achieve safety and maximum myocardial dispersion simultaneously.  This 
range was determined with simple methylene blue studies.  The ideal range was 
between 7.5 to 9 inches from the thoracotomy open heart for the rodent application, and 
2-4 inches for the ex vivo ovine heart application.  Once optimization was achieved, 
several key rodent model experiments were executed in Chapters 5 to both validate the 
system and compare with other delivery approaches. 
Chapter 5 was the heart of this work, essentially validating the liquid jet 
methodology and simultaneously exploring key variables in the new approach against 
others in practice.  As described, important clinical translation aspects were described in 
the experimental series.  The first was retention, whereby needle injection and especially 
transvascular methods were not well characterized from a quantitative basis.  We 
selected a simple fluorescent dye, much smaller than AAV, to assess retention after 10 
minutes post-delivery in an acute model.  The Liquid jet performed well in terms of 
retention with limited uptake in the live and a disperse, homogenous myocardial 
coverage profile.  As expected, the IM group had a very robust retention around the 
injection track, but resulted in inadvertent systemic infusion.  Comparing the left 
ventricular infusion with versus without occlusion, two key points were validated as 
argued previously in this dissertation.  The transvascular systems must increase 
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residence time and driving pressure variables in order to both increase cardiac 
specificity and limiting systemic exposure.  The cost is the level of invasiveness, but the 
concepts were demonstrable.   
The follow up live AAV9.GFP survival model largely revealed the same 
expression profiles as found with the acute retention series.  This permits conclusion that 
the initial delivery event largely determines the expression profile that will be achieved in 
the future.  It was here that a number of key points were determined for the overall aims 
with liquid jet injection for cardiac gene therapy, namely: (1) Liquid jet injection with 
optimized settings can achieve roughly the same, but not as intense, level of the best 
available transvascular approach (2) Limit the degree of systemic exposure (3) Achieve 
more myocardial coverage per injection.  Point #3 is arguably the most important, since 
limiting the number of injections is key for direct myocardial gene delivery.  This topic will 
be expanded upon in the next section discussing the limitations. 
Although the validation experiments revealed positive concept testing results, the 
next series of experiments described in Chapters 6 and 7 tested the methodology’s 
validity in an ischemic myocardial infarction model.  It cannot be underscored that the 
differences between normal and ischemic myocardium are immense.  The induced 
model insult analogous to the clinic has a significant impact on subsequent cardiac 
performance and host responses.  Separately from intervention, the ischemic myocardial 
insult promotes a complex myocardial degeneration process marked by inflammatory 
events, limited repair mechanisms [16].  Due to the limited capacity of cardiac repair, a 
number of compensatory mechanisms locally in the myocardium and neurohormonal 
physiology commence.  These temporal changes from initial insult to chronic failure must 
be considered when optimizing any delivery strategy.  This was a prime challenge for the 
liquid jet injection method, but certainly attainable with careful design.   
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Essentially for Chapter 6, the focus of the liquid jet injection’s applicability was to 
test whether or not it would be efficacious with an AAV therapeutic encoding a bona fide 
transgene within the clinically relevant maladaptive post MI environment.  We selected a 
high cardiotrophic AAV9 vector and arguably the most promising S100A1 transgene, 
which is rapidly approaching clinical trial.  The four groups were 2 Control saline and 2 
single dose 1.2 x 1011 vp ssAAV9.S100A1 treatment.  The head to head delivery 
assessment featured liquid jet against traditional IM injection.  This chapter ultimately did 
not incorporate a comparative infusion group since these results translate poorly to the 
clinical problem as argued in the discussion of Chapter 5.  
The results in Chapter 6 were striking featuring a major discrepancy in outcome 
across delivery groups.  The IM S100A1 group performed considerably worse in terms of 
overall LV function and presented with a degraded LV structure.  The affected infarcted 
area was double, with full blown heart failure in nearly all 8 group subjects.  The Liquid 
Jet group achieved a 4.3 fold higher S100A1 expression profile, greater than control 
(1.0) but slightly less than the IM group at 5.0 overall.  Despite an overall score of 5, the 
proteomic analysis variability in the cross section indicated that some regions likely 
increased this average due to intensity, but the overall degree of expression as in % of 
transfected myocardium may have been lower.  In addition, the results indicated that the 
pattern of expression and the degree of systemic exposure contributed to the major 
declines found in the IM animals.  The host response testing revealed that the IM group 
most likely suffered a deleterious immune response as hypothesized based on much 
higher CD38 tissue marker and systemic inflammatory cytokine profile. 
Following the results of the first major efficacy study, Chapter 7 explored a new 
approach with S100A1 gene therapy with the use of the double stranded DNA or self-
complementary vector scAAV9.S100A1.  Since a vector control group was not utilized, 
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the same dose was selected for this study based on the hypothesis that a selective in 
vivo dose response would be elucidated with higher copy number.  The use of double 
stranded vector is intriguing with several advantages.  The first main advantage is 
conversion efficiency, whereby DNA is ready to drive gene expression just after nuclear 
transfection, whereas with single stranded vector a key conversion step is needed.  The 
second key advantage, as argued by this dissertation, was that in highly focal muscular 
expression patterns the single stranded step might be inflammatory.   
The efficacy results to support these claims and is valid given that the IM 
SCS100A1 performed dramatically better than the single stranded group.  It therefore 
can be concluded within the limits of this study that on a per dose basis self-
complementary vector should be used for direct injection applications since they achieve 
the desired level of therapeutic copy number more efficiently.  A major limitation of the 
efficacy studies presented is the imprecise cause of the adaptive inflammatory immune 
responses in rank order IM S100A1, IM SCS100A1, and Liquid Jet SCS100A1.  The 
host immune response is a complex interaction of induced innate inflammation caused 
by delivery route, biological state of target tissues (i.e. healthy vs. remodeling from acute 
MI), AAV viral vector antigen payload risk, S100A1 expression profile/distribution, and 
collateral organ (i.e. liver) expression.  It is acknowledged that the specific root cause of 
the immunological host response was beyond the limits of this study; however Chapter 8 
explored an often overlooked aspect of these risks, the initial delivery event.                             
Cardiac gene therapy methods, especially direct injection techniques, cause mild 
to moderate levels of inflammation that can increase the risk for the host response.  
Chapter 8 explores the concept of a drug/gene therapy approach, whereby gene therapy 
product would be co-delivered with an anti-inflammatory drug at the time of delivery to: 
(1) Promote a more favorable AAV trafficking environment (2) Reduce stress on cells 
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that need to generate therapeutic expression in the microenvironment (3) Induce 
tolerance by ensuring the host immune response up to 1 week post delivery (i.e. vector 
clearance rate is high by this point) is beyond the window of co-stimulation, which is 
critical for adaptive host responses.  For this theoretical application, a poly lactic glycolic 
acid polymer nanoparticle production process was developed.  The rationale was that a 
nanoformulation would: (1) increase local drug uptake in the myocardium due to size 
advantage (2) Not interfere with vector trafficking and expression mechanisms (3) 
Extended release of anti-inflammatory over the innate immune response period through 
6 days.  Much of the work entailed the anti-inflammatory process development aspects, 
whereby a robust set of operating parameters were identified to engineering 200-300 nm 
particles encapsulating a variety of anti-inflammatory drugs.  Aspirin, prednisolone and 
solumedrol have been tested in the system and the in vitro work illustrated the potential 
for this combination approach.   
The remaining sections discuss the key limitations and future studies for each 
specific aim, followed by on overall conclusion on the body of work. 
9.2  Limitations and Future Direction 
 
9.2.1  Specific Aim#1 - Define and optimize engineering parameters for the liquid 
jet injection device for the cardiac application in an acute rodent model and ex 
vivo large animal setting to define a safe, yet effective operating transfer range. 
 
9.2.1.1  Limitations 
Adapting the liquid jet injection approach for cardiac gene delivery required 
detailed experiments and select modifications of key driving device parameters.  A 
problem is that these same pressure settings that performance well in one given 
myocardial region can also permanently injure another with a more advanced disease 
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stage.  In a controlled, consistent rodent model application however it was possible to 
obtain excellent results due to this level of precision.  This of course would not be in the 
clinic, whereby populations of patients with a diverse set of co-morbidities will have 
different levels of affected areas and geometry.   Therefore settings would need to be 
flexible enough over an acceptable range to remain safe.  Given these findings, the key 
limitation of the current results is that this development process would have to be done 
at a much higher level of sophistication for a clinical application.   
First as presented, the size scale factor is a major problem as it is very unlikely 
that a single pen injector design would be suitable for an AAV mediated therapy.  This is 
especially true for cardiac contractility genes, whereby global myocardial expression 
over roughly 150 – 300 mg of myocardial mass is needed in the left ventricular zone.  
Our rodent model demonstrated efficacy, but the target was only 1 mg reached with 3 
injections.  Therefore, scaling estimates with this primitive system would require at least 
300 injections to reach the same efficacy level, which would not be feasible with a single 
device. 
It is also likely that primate and human host responses are more aggressive than 
the rodent model, therefore inflammatory events would have to managed even more 
carefully with a selective pressure system approach.   
9.2.1.2  Future Direction 
A second generation device configuration would most likely go in two directions: 
(1) A multi array port of injections with selective control over pressure settings featuring 
real time feedback or (2) A hybrid microneedle array concept for direct injection that 
would penetrate then slightly pulse pressurize for maximal distribution.  Concept #1 
would ideally leverage an imaged guidance setup, whether it be echocardiography or 
high fidelity MRI to use structural data to map desired target areas.  The 
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conceptualization is that ischemic areas are typically much thinner than remote healthy 
zones, therefore different injection ports would require the correct programmed 
pressurized settings.  These settings could be optimized with a series of engineering 
modeling and cadaver harvests over a range of cardiac mechanical properties (i.e. 
optimize pressure settings for levels of thickness, disease vs. non-diseased structures).   
Another key concept not explored in this dissertation due to cost was the use of a 
more optimal driving gas.  Many of these liquid jet systems are pressurized by carbon 
dioxide gases instead of room air/oxygen [17].  Although minimal, there is a risk of air 
penetration into the system warranting the use of C02.  The selected gas, may or may 
not alter transfection rates but would be interesting to explore.  For safety reasons, C02 
gas would be the obvious option that is readily available in the clinic.  In the future,, if 
warranted, it is also conceivable that the liquid approach could be adapted to a minimally 
invasive catheter system that would delivery from the endocardial surface. 
Exploring Concept #2 of a microneedle system, these have been tried with different 
transdermal systems with various adjunctive configurations but have not been translated 
into the heart [18].  It is conceivable that the liquid jet concept could be engineered to 
perform more consistently with an image guidance capability but this would be difficult to 
execute.  If engineered correctly however this system would have the advantage of more 
precision in select zones at the cost of complexity.   
9.2.2  Perform a two phase therapeutic delivery study to the beating heart in an 
acute rodent model to evaluate the liquid jet approach against traditional methods 
in practice.  The methods to evaluate against are: A.  Standard IM Injection B.  
Non-selective Intracavitary Infusion C.  Intracoronary Infusion 
 
9.2.2.1 Limitations 
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As concluded in Chapter 5, the sequential validation rodent studies evaluating 
the liquid jet strategy revealed a number of key considerations for myocardial delivery 
overall; with a keen focus on animal model to translational perspectives.  A number of 
key points were highlighted for each delivery class when analyzing model results.  The 
first is scale, and was demonstrated effectively with the Liquid Jet concept.  The targeted 
myocardial LV mass is roughly between 1-2 mg in the healthy condition.  Our results 
demonstrate that with optimal settings, 300 microliters of volume was sufficient to cover 
the entire cross sectional space with Liquid Jet or Infusion with occlusions.   
The ovine (i.e. more resembling the human application) mass target is at least 
150-200 mg, but much less coverage is achieved with a single injection.  This result in 
the demand for 100-350 injections and this reaches the higher risk range for both injury 
and priming for immune responses.  IM delivery on the other hand is worse in that the 
highly focal expression profiles achieved would not promote an overall increase in 
contractility at the larger scale that is needed and surprisingly results in higher systemic 
exposure than expected due to poor retention [19].   
The conclusion with the infusion approaches (e.g. primary infusion with or without 
anatomical occlusions) was that a means to increase the driving pressure and residence 
time of vector in the cardiac anatomy is required to increase expression levels.  This 
concept clearly demonstrates the problem of the endothelial barriers, which prevent viral 
vector trafficking into the interstitial.  Although recognized, implementing this at much 
larger scale is very difficult and requires complex methodology.  Banding the pulmonary 
artery and aorta would never be clinically feasible.  Our laboratory to date has presented 
the only competent means to achieve higher residence time and pressure, which can 
only be done safely under cardiopulmonary bypass conditions [20].   
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The concept of increasing pressure locally around a peripheral artery or vein 
however, is attainable with balloon occlusion catheters.  Despite their success in large 
animal models, the disease vessel integrity breach and other complications that would 
result (i.e. especially on the arterial side) would not be justified with the benefits.  Balloon 
occlusion on the venous side with primary infusion through the greater cardiac vein the 
most applicable strategy.  Groups have shown increased AAV uptake with retrograde 
balloon infusion with various pressure and occlusion settings versus antegrade.  These 
approaches are likely to have a higher translational impact.  This is due to the fact that 
venous side anatomy has both increased dimension and less disease factors [21].    
9.2.2.2  Future Direction 
Marker gene delivery studies featuring multiple approaches most definitely would 
be strengthened by incorporating a wider dose range and using different settings for said 
approaches.  For example altering injection volumes, pressure, occlusion times, device 
design may increase therapeutic AAV transfer.  Elucidating these mechanisms in more 
detail requires multiple level designations for each method, this study only featured one 
dose with one set of delivery parameters for each. 
9.2.3  Perform a chronic ischemic infarction 10 week model study to evaluate 
delivery of a single dose 1.2 x 1011 GC of ssAAV9.S100A1 vector featuring a head 
to head format comparing liquid jet vs. IM injection. 
 
9.2.3.1  Limitations 
Although very striking differences were found between the IM injection and Liquid 
Jet groups versus controls, there were major limitations in this well executed efficacy 
study.  The first was using a single fixed dose and at one time (i.e just after infarct).  
Given the many inherent variability factors that can be different between animal subjects, 
having one or ideally two more dose arms would have complemented the data sets 
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tremendously.  Moreover, analyzing how the transgene rescues at different stage of 
disease would be more clinically relevant.  The analogous clinical situation in this model 
was just after MI, but more than likely AAV.S100A1 therapy would be for advanced 
disease stages.  This is true especially in the context of evaluating why the IM injection 
group performed so poorly which can only be postulated was due to an inflammatory 
response caused by too much collateral expression and or single stranded vector 
conversion signals.  It is anticipated this response might be different after the remodeling 
and after inflammatory courses secondary to MI reach more of a steady state condition 
in the later disease stages.   
Another major limitation in this study beyond its scope was the lack of precision 
with regard to the immunology assays.  Typically, gene therapy studies incorporate the 
use of two key assays that were not used due to cost.  The first is the neutralizing 
antibody titer, which determines the circulating levels of antibody specific to the AAV9 
capsid antigens.  The second is the T cell mediated response precisely determined by 
ELISPOT, whereby a determination can be made on whether responses were generated 
to the capsid antigens or viral mediated S100A1 protein.  The protein encoded in this 
case was human and overexpression of foreign transgenes in different hosts is more 
likely to cause responses than the antigens, although this was not confirmed.  It was 
assumed that the immune reactions would be complex and the focus was more on 
outcome in terms of cardiac function with an associated overall response regardless of 
source.   
Last but not least, the single 10 week timepoint was the most impactful limitation 
in that all conclusions can only be made at 10 weeks.  This concern is twofold given that: 
(1) LV remodeling and cardiac dysfunction changes over greater time periods from initial 
MI (2) Expression profiles, although less likely to change with AAV mediated therapies 
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are still variable (3) Immune response are unpredictable (i.e. the 3 efficacious groups 
might have suffered a response with a reversal in cardiac preservation at 2, 4 or 6 
months later).   
Item #3 is of particular concern since it is backed by findings in many studies that 
show efficacy in the 1-2 month timeframe, then a steep drop off and reversal.  These 
studies would typically show a decrease in gene expression levels accompanied by a 
deleterious CD8 T cell mediated response.  Therefore, the delivery conclusions were 
more valid in this time frame, however long term impact can only be evaluated with 
successive timepoints.  
9.2.3.2  Future Direction 
Multiple dose levels at different points of intervention (i.e. baseline, 3 weeks post 
MI 12 weeks post MI), more precise immune response assays, and longer term 
timepoints (i.e. 3 months, 6 months post MI) would provide a more clear means to 
evaluate aims in greater detail. 
9.2.4 Specific Aim #4 - Two key testing parameters that may significantly alter host 
responses are offered: A.  Using double stranded vector equivalent B.  Co-delivery 
of anti-inflammatory drugs to minimize host response during initial delivery 
phase.   
 
9.2.4.1 Limitations 
Given that the only difference in the follow up pilot study with the self-
complementary double stranded scAAV9.S100A1 vector was molecular, the already 
compiled limitations as stated in 9.2.3.1 hold for part A of this aim as well.   The 
performance of self-complementary vector may or may not be different if applied beyond 
the baseline/Post MI period.  This pilot study only tested whether or not it would perform 
better in terms of transduction and cardiac efficacy.  Despite significant changes in 
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efficacy found in the IM injection group between the two vectors constructs, there was no 
means to determine if these events would be maintained with elevated cytokine profiles. 
With respect to the Part B aim of co-delivery of anti-inflammatories with AAV product, the 
concept was largely limited to a primitive proof of concept in vivo application.  Much 
more detailed in vivo work would have to be performed to determine the correct drug, 
drug and tuned PLGA release profile that would maximize AAV therapy.  The case study 
only featured DNA plasmid in neonatal myocytes which have different properties.  
9.2.4.2  Future Direction 
There are numerous parameters independent of delivery that can alter the host 
response profile in vivo. Follow up studies changing dose levels, promoters in the AAV 
constructs, co-expression of regulatory elements, and changing serotype might yield 
more useful in myocardial muscle in the early to late post MI periods.  AAV1, AAV6 and 
AAV9 all have high functional reported efficacy in cardiac muscle but there have not 
been comparative studies assessing outcome in terms of the host response.  Given that 
the serotype affects efficiency independent of method on a per dose basis, it is 
conceivable that the more efficient vector would be less inflammatory given that dose 
can be lowered to reach the same target expression level.  Counter to that argument, it 
might also be that one set of antigens of the capsid is more responsive versus others, 
this would be measured with ELISPOT assays at a fixed dose with the same construct. 
Despite the best efforts to engineer the AAV delivery vehicle to minimize expression, 
there is no way to stop innate immune activation following direct myocardial delivery 
whether it be with a needle, liquid jet or other physical method.  An anti-inflammatory co-
formulation strategy is novel from the sense of it being locally directed to the 
myocardium rather than systemically.  Numerous gene therapy trials incorporate 
systemic use of steroids and or immunosuppression to knockdown inflammatory host 
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responses.  This dissertation argues that a local blockage may actually be more effective 
and better for the patient’s overall health given the side effects of the current means.  
However, identifying the correct drug with the precise release profile must be determined 
to thoroughly test this strategy in future in vivo rodent study.  
9.3 Conclusions 
 
Improving clinical outcomes in present and future AAV mediated gene therapy 
trials for post myocardial infarction induced heart failure patients will require a systematic 
approach.  Delivery as shown in the study series in this dissertation was proven to be a 
prime factor that can determine outcome along with proper dose, vector and gene 
selection.  Delivery considerations in terms of safety and efficacy may be defined patient 
to patient, whereby the goal is to rescue the sufficient percentage of cells that would 
reach desired expression levels indicative of improved measurable outcomes.  These 
measures must be defined within safety limits that promote host tolerance, or the cardiac 
gene therapy will fail.  Gene therapy as a whole field is a risky enterprise due to this 
risk/reward complex.  In the case studies where therapy fails it is most certain that there 
was not enough therapeutic expression or maladaptive responses mounted negating 
any therapeutic effect. 
The inspiration of this dissertation was to advance the seemingly dead end direct 
delivery arm of cardiac gene delivery technology with a novel concept.  The liquid jet 
concept was reduced to practice in a rodent model, but as stated many more technical 
challenges would need to be surmounted in order for it to become a viable therapeutic 
strategy.   
In terms of market need the liquid jet technology would at minimum be suitable 
as an adjunctive surgical therapy with a controlled device, or perhaps a minimally 
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invasive application where the transgene expression need to be localized (i.e. 
angiogenesis genes).  Therapeutic formulation manipulation with either altering vector 
molecular biology (i.e. as in our case example with double stranded vector) and co-
administration with working pharmacologic compounds to address secondary problems 
offer solutions to manage these risks clinically.  Since the goal is to treat diseased and 
healthy at risk myocardial areas with the least possible dose resulting in an efficacious 
expression profile, it is argued that delivery studies will remain a key research area to 
improve outcomes.    
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